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ABSTRACT
A bstra ct
Survivin is a bifunctional protein that acts as a suppressor of apoptosis 
and plays a central role in cell division. The protein is strongly expressed in 
the most common human neoplasms, has prognostic relevance for some of 
them, and appears to be involved in tumour cell resistance to anticancer 
agents and ionizing radiation. On the basis of these findings, survivin has 
been proposed as an attractive target for new anticancer interventions.
We generated a hammerhead ribozyme (Rz) targeting the CUAno triplet in 
the survivin mRNA and transfected them into the JR8 human melanoma cell 
line. Cells endogenously expressing Rz were characterized by a lower 
survivin protein level than parental cells, and showed an increased caspase- 
9-dependent apoptotic response to treatment with the cytotoxic agents 
cisplatin and topotecan as well as with y-irradiation. Moreover, an increased 
anti-tumour activity of oral topotecan was observed in Rz-expressing cells 
grown as xenograft tumours in athymic nude mice. In addition, we 
constructed a Moloney-based retroviral vector expressing Rz, encoded as a 
chimeric RNA within adenoviral VA1 RNA. Polyclonal cell populations, 
obtained by infection with the retroviral vector, of two androgen-independent 
human prostate cancer cell lines (DU 145 and PC-3) were characterized by a 
significant reduction of survivin expression; the cells became polyploid and 
underwent caspase-9-dependent apoptosis. Survivin inhibition also 
enhanced their susceptibility to cisplatin-induced apoptosis and prevented 
tumour formation when cells were xenografted into athymic nude mice.
Again we used RNAi to specifically repress survivin in DU 145 and PC-3 
cell lines. RNAi-mediated survivin knock-down was able to significantly 
reduce cell proliferation and to enhance the rate of caspase-9-dependent
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apoptosis. Moreover, sequential treatment with survivin-specific siRNA 
followed by the Hsp90 inhibitor 17-allylamino-17-demethoxy-geldanamycin 
produced supra-additive anti-proliferative effects in both cell lines.
Finally, we investigated the effects of the novel cdk inhibitor NU6140, in 
term of ability to potentiate the response to paclitaxel in HeLa cells, in relation 
to its interference with survivin. Sequential administration of cdk inhibitors 
resulted in escape from the mitotic block imposed by paclitaxel and 
significantly increased the apoptotic rate, with inhibition of survivin 
expression/phosphorylation as the potential mechanism.
Overall, such results suggest that strategies aimed at interfering with 
survivin expression/activity can be adopted to improve the chemo/radio- 
sensitivity profile of treatment-refractory human malignancies.
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INTRODUCTION
Chapter 1 Intro du ctio n
1. A po pto sis
Apoptosis and necrosis represent two distinct types of cell death, which 
have been defined morphologically and biochemically [Kiechle & 
Zang, 2002].
Apoptosis, or programmed cell death, first described by Kerr, Wyllie and 
Currie [1972], plays important roles in the elimination of unnecessary, 
damaged or infected cells in multicellular organisms [Cory et al, 2002; 
Opferman & Korsmeyer, 2003]. Deregulation of apoptosis results in 
pathological conditions ranging from cancer [Vaux et al, 1988; Strasser et al, 
2000; Opferman & Korsmeyer, 2003; Danial & Korsmeyer, 2004] to 
autoimmune diseases [Strasser et al, 2000; Franz et al, 2006].
Apoptosis is an active process characterized by morphological changes 
including condensation and fragmentation of the nucleus, shrinkage of the 
cytoplasm, and the formation of apoptotic bodies that contain fragments of 
the nucleus encircled by cytoplasm and cell membrane [Kerr & Kumar, 1998]. 
Apoptotic cells are rapidly eliminated by phagocytic cells including 
macrophages [Fadok et al, 1998]. Because their plasma membrane remains 
intact, apoptotic cells do not trigger an inflammatory response [Levine & Koh, 
1999]. In contrast, necrosis is a passive form of cell death associated with 
inflammation, resulting from a non-specific injury such as blunt trauma, 
exposure to a toxin, or the loss of blood supply [Cohen, 1993; Kerr & Kumar, 
1998; Proskuryakov et al, 2003; Edinger & Thompson, 2004]. Necrosis is 
characterized by cellular and organelle swelling, rupture of the plasma 
membrane and release of cytoplasmic contents, in addition to other events,
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triggering a pronounced inflammatory response [Levine & Koh, 1999; 
Proskuryakov et al, 2003].
Apoptosis can be divided intro three stages [Kroemer et al, 1997]. In the 
first stage, the cell receives an apoptotic signal. A variety of stimuli both 
internal and external to the cell can activate apoptotic pathways. These 
include ligation of a cell surface receptor, removal of essential growth factor, 
exposure to various chemical agents [Au et al, 1997; Edinger & Thompson, 
2004; Fumarola & Guidotti, 2004]. In addition, the exposure of a cell to UV, 
ionising radiation, or heat can also induce apoptosis [Sarin et al, 1996; 
Rehemtulla etal, 1997; Basu & Kolesnick, 1998; Garcia-Bermejo et al, 1998; 
Zundel & Giacca et al, 1998; Edinger & Thompson, 2004; Oancea et al, 
2004; Boehm, 2006]. The cell integrates the various signals and may or may 
not execute the apoptosis. This process involves several signal transduction 
pathways such as the activation (or inactivation) or serine/threonine and 
tyrosine kinases and phosphatases. The final decision to undergo apoptosis 
depends upon several factors including the relative levels of both apoptotic 
and survival factors, as well as the metabolic state of the cell. In the final 
stage of the apoptosis, a degradative pathway is activated [Kroemer 
etal, 1997].
1.1. Features of Apoptosis
The biochemical and morphological changes induced by apoptosis 
influence different aspects of the cell from the plasma membrane to the 
nucleus (Table I).
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Table I. Features of apoptosis.
Structure Alteration
Plasma Exposure of phosphatidylserine
membrane Membrane blebbing
Loss of integrity
Loss of potassium gradient
Cytoplasm Loss of cytoplasmic volume 
Degradation of cytoskeletal proteins
Mitochondria Rupture of outer membrane 
Swelling of matrix 
Release of apoptotic proteins 
Loss of transmembrane gradient
Nucleus Nuclear fragmentation 
Chromatin condensation 
DNA fragmentation
The plasma membrane is composed of a variety of phospholipids 
including both aminophospholipids (phosphatidylserine and 
phosphatidylethanolamine) and choline phospholipids (phosphatidylcholine, 
sphingomyelin) [Schlegel et al, 1996]. In the normal cellular state, the cell 
maintains an asymmetry between the phospholipid content of the inner and 
outer leaflet of the plasma membrane by actively translocating 
phosphatidylserine from the outer to the inner leaflet. In apoptosis, this 
asymmetry is lost as phosphatidylserine equilibrates between the inner and 
outer leaflets [Hampton et al, 1996; Bratton et al, 1997]. Another prominent 
apoptotic change concerning the structure of the plasma membrane is the 
formation of blebs, the small membrane-enclosed pieces of cytoplasm and 
condensed nuclear material [Cohen, 1993].
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Cytoplasmic changes during apoptosis include the loss of cytoplasmic 
volume and degradation of cytoskeletal proteins [Cohen, 1993]. Cytoplasmic 
shrinkage results primarily from two processes: i) the formation of blebs 
results in a loss of volume, and ii) the loss of a potassium gradient that is 
normally maintained by the plasma membrane results in osmotic shrinkage of 
the cytoplasm [Dallaporta et al, 1999]. The degradation of cytoskeletal 
proteins is a consequence of the actions of caspases both directly cleaving 
proteins and activating other degradative enzymes [Krammer, 1999].
The mitochondrion consists of both an inner and outer phospholipid 
membrane. The inner membrane defines the central matrix space with 
mitochondrial DNA and where protein synthesis and respiration occurs 
[Scheffler, 2001]. Mitochondria normally maintain a voltage (Ai|jm) and pH 
gradient across the inner membrane that is used by the Fi/F0-ATPase in the 
formation of ATP [Scheffler, 2001]. During apoptosis this gradient is often 
lost, and is associated with the osmotic swelling of the matrix, the break of 
the outer mitochondrial membrane, and the release of pro-apoptotic proteins 
from the inter-membrane space [Kroemer et al, 2007].
In its normal state, the nucleus is a spherical structure with a relatively 
diffuse staining pattern. This staining pattern reflects different chromatin 
states with darker regions indicating inactive stretches of DNA bundled 
together with histones [Ferri & Kroemer, 2001]. Specific alterations are 
observed as a result of apoptosis and include the condensation of the 
nucleus [Thompson et al, 1999]. The nucleus fragments into several sections 
released from the cell as part of apoptotic bodies [Zamzami & Kroemer, 
1999]. A reduction in the total DNA content of the cell is thus a sign of an
2 2
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apoptotic cell death. On a biochemical level, these nuclear changes are 
associated with the activation of several different endonucleases. The action 
of the DNA degradative enzymes results in the formation of small fragments 
of DNA, often in multiples of 180 base-pairs reflecting basic nucleosome 
structure [Darzynkiewicz etal, 1997; Zamzami & Kroemer, 1999].
1.2. Apoptotic Death Pathways
Two major pathways of apoptosis have been identified in mammalian cells 
(Figure 1). An extrinsic pathway is triggered by the binding of ligands 
[Yuan, 1997] to cell-surface trimeric membrane death receptors and leads to 
caspase-8 activation. An intrinsic pathway involves mitochondria, which 
respond to pro-apoptotic signals by releasing cytochrome c, which in turn 
binds and activates the apoptotic protease activating factor-1 (Apaf-1), 
causing assembly of a multi-protein caspase-activating complex 
(apoptosome) and leading to activation of caspase-9 and initiation of a 
protease cascade [Cryns & Yuan, 1999]. Both pathways can be activated by 
genotoxic and metabolic stress, and result in the activation of effector 
caspases-3, -6 and -7 which cleave a variety of distinct substrates, resulting 
in nuclear fragmentation and cellular disassembly.
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Figure 1. Schematic representation of the two major apoptotic 
pathways in human cells: the "extrinsic" (the death receptor- 
mediated) and "intrinsic" (mitochondrial) programmed cell death.
Apoptosis can be initiated by the death-receptor pathway that acts through 
caspase-8 or mitochondrial pathway that acts through caspase-9. Both 
apoptotic pathways converge to activate the effector caspases. Cell death 
is also regulated by the Bcl-2 and IAP protein families. Bcl-2 proteins are 
thought to regulate the mitochondria permeability transition by inhibiting 
(Bcl-2 and Bcl-xL) or promoting (Bax and Bid) cytochrome c release. IAP 
proteins prevent processing of initiator caspase-9 from the apoptosome and 
inhibit the activity of the effector caspases. Proteins that are released by 
mitochondria during the permeability transition (i.e. cytochrome c and 
SMAC/Diablo) facilitate caspase activation by forming the apoptosome or 
relieving the caspase-inhibitory function of IAP proteins.
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1.2.1. Death Receptor-Mediated Apoptotic Events
The extrinsic pathway is a primary mediator of cellular immunity, but can 
also be activated in response to drug therapy. The death receptor-mediated 
apoptotic events are initiated by binding of death receptors such as 
fibroblast-associated (Fas), tumour necrosis factor receptor (TNF-R), and 
TNF-related apoptosis-inducing ligand receptor (TRAIL-R) to their ligands 
[Trauth et al, 1989] (Figure 2).
TNFR1
DR3
Fas
TRAIL.
R1/2
TRAIL-R3/4
Death
Domains
FADD ? TRADDFADD
Death Effector 
Domains
caspase-8
Caspase-3
Caspase-7 Y  Caspase-6
Figure 2. Signalling pathways triggered by death receptors.
After binding of FASL or AP02L/TRAIL, the death receptors Fas 
assemble the DISC complex: through the adaptor protein FADD, 
they recruit and activate the apoptosis-initiating proteases 
caspase-8. The physical proximity of the recruited enzymes in 
the ligand-induced signalling complex leads to their 
autoactivation by proteolysis, thereby triggering intracellular 
signalling cascades that induce specific cellular responses. After 
binding of TNF, TNF-R1 first recruits TRADD as a platform 
adaptor, and, in turn, assembles a complex which involves FADD 
and caspase-8 and triggers apoptosis in a manner similar to the 
other death receptors. Death receptor DR3 assembles signalling 
complexes that are similar to those of TNF-R1. Death domains 
are indicated in red; death-effector domains in green; caspase 
domains are shown in blue. [Adapted from Gupta et al, 2005]
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This binding initiates ligation of the receptors and transmission of the 
apoptotic signals through motifs called death domains (DDs), death effector 
domains (DED), and caspase recruitment domains (CARD). The DDs are 
found in cytoplasmic proteins including Fas-associated protein with death 
domain (FADD), TNF receptor-associated protein with death domain 
(TRADD), and receptor-interacting protein (RIP) and in transmembrane 
proteins, including Fas, TNF-R1, TRAIL-R1/DR4, and TRAIL-R2/DR5. The 
DED are found in the adaptor molecules and in pro-caspases-8 and -10 and 
play an important role in death receptor-induced apoptosis where the 
interactions between death effector domains of the adaptor molecules and of 
pro-caspases-8 or -10 enable formation of the death-inducing signalling 
complex (DISC) [Lee et al, 2000]. The binding of the DISC (including the 
DED, the DED-containing adaptor molecules and the DED-containing 
cysteine protease caspase-8) to pro-caspase-8 initiates the caspase cascade 
[Weber & Vincenz, 2001]. These events can be regulated by Flip (FADD-like 
interleukin-1-converting enzyme-inhibitory protein), which prevents caspase 
activation [Peter, 2004].
1.2.2. Mitochondria-Mediated Apoptotic Events
In death receptor-mediated apoptosis, the apoptotic pathway is activated 
by the interaction of a relatively small number of structurally-related ligands 
with a relatively small number of structurally-related cell surface receptors. In 
contrast, mitochondrial apoptosis can be induced by a variety of agents
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including chemotherapeutic drugs, reactive oxygen species, kinase and 
phosphatase inhibitors, UV and ionizing irradiation, and environmental 
stresses including growth factor withdrawal, heat, and osmolarity changes 
[Shimizu et al, 1996; Kroemer et al, 1997; Lilly et al, 1999; Galluzzi et al, 
2006; Kroemer et al, 2007].
Cellular response to DNA-damage is a very complex process, involving a 
multitude of proteins that sense the damage, transduce signals into cells and 
execute cellular responses. This network of events includes a protein kinase 
cascade that connects the detection of DNA damage to the activation of 
transcription factors, which in turn regulate the expression of genes 
implicated in specific cellular pathways, including DNA repair mechanisms, 
cell-cycle checkpoints, cellular senescence and apoptosis [Zhou & Elledge, 
2000; Sancar et al, 2004]. In response to the different types of DNA damage, 
the cell cycle checkpoints are activated to delay or arrest cell cycle 
progression, presumably in order to allow time to repair damaged DNA 
[Nyberg et al, 2002]. The blockage of DNA replication leads to collapse of 
replication forks and DNA double-strand breaks (DSBs) formation, which are 
thought to be crucial downstream apoptosis triggering lesions [Roos & Kaina, 
2006]. DSBs are recognised by proteins that exert both kinase and repair 
activity. The most-important ‘sensors’ are ATM (ataxia telangiectasia 
mutated) and ATR (ataxia telangiectasia and Rad3 related) proteins, 
members of the phosphatidylinositol-3-kinase-related family [Durocher & 
Jackson, 2001; Ismail et al, 2005]. Whereas ATM is activated by ionizing 
radiation-induced DSBs, ATR is activated in response to UV light and 
presumably all chemical agents that give rise to stalled DNA replication forks
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[Dart et al, 2004]. Upon activation, ATM phosphorylates various downstream 
substrates such as p53, Nbs1, MDC1, 53BP1, Rad9, Chk1 and Chk2, H2AX 
and BRCA1 [Lavin et al, 2005; Roos & Kaina, 2006]. ATM, and presumably 
also ATR, exerts three crucial functions: regulation and stimulation of DSB 
repair, signaling cell-cycle checkpoints and signaling apoptosis via p53 [Lavin 
et al, 2005]. Once phosphorylated, p53 becomes stabilised and blocks 
proliferation by up-regulation of p21waf1, which triggers Gi/S arrest. It has 
been suggested that at low levels of DSBs only a minor fraction of p53 is 
activated, driving the transcription of the p21 gene and causing cell-cycle 
arrest. By contrast, with high levels of DSBs, p53 becomes metabolically 
stable and transcriptionally activated, and accumulates above a particular 
threshold, inducing the transcriptional activation of pro-apoptotic genes such 
as Bax (Bcl-2-associated X protein), PUMA (p53 up-regulated modulator of 
apoptosis) and FAS receptor [Roos & Kaina, 2006]. p53 activation results 
from post-translational modifications (i.e., phosphorylations, acetylations or 
covalent attachments of small ubiquitin-like proteins), whereas p53 instability 
is due to its ubiquitination and proteosomal degradation. Both these 
processes are transiently suppressed after DNA damage [Bernstein 
et al, 2002].
Most human tumours lose the expression of a functional p53. However, it 
has been demonstrated that crucial DNA damage can activate a p53- 
independent apoptosis via backup systems [Roos & Kaina, 2006]. There are 
several strategies that cells seem to employ to trigger p53-independent DNA 
damage-induced apoptosis. The first one involves the p53 homologs p63 and 
p73 [Roos & Kaina, 2006]. It has been proposed that, upon DNA damage,
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ATM and ATR activate Chk1 and Chk2, which in turn activate E2F1. This in 
turn stimulates transcription of the p73 gene, giving rise to an increased level 
of p73 protein [Urist et al, 2004]. Whereas p53 requires p63 and p73 for 
triggering apoptosis, p73 has a pro-apoptotic activity even in the absence of 
p53 [Flores et al, 2002; Roos & Kaina, 2006]. p73-induced apoptosis was 
shown to be mediated by transcriptional up-regulation of PUMA, NOXA and 
Bax [Melino et al, 2004; Flinterman et al, 2005]. Another factor implicated in 
p53-independent apoptosis is NF-kB (nuclear factor-kB), which is generally 
anti-apoptotic as it transcribes anti-apoptotic genes. However, under some 
circumstances (i.e., topoisomerase inhibitor treatment [Piret et al, 1999], NF- 
kB exhibits pro-damage-signaled apoptosis, by inducing the transcription of a 
growing number of genes related to apoptosis, including Fas ligand [Schmitt 
et al, 2007].
Another trigger of apoptosis upon DNA damage is the inhibition of RNA 
synthesis, which leads to a decline in the level of critical gene products such 
as MKP1 (mitogen-activated protein kinase phosphatase). This causes 
sustained activation of JNK (Jun kinase) and AP-1, which stimulates death- 
receptor activation [Roos & Kaina, 2006].
The mitochondria-mediated apoptotic pathway is mediated by the 
mitochondrial release of cytochrome c [Kiechle & Zang, 2002; Reed, 2000; 
Zimmerman et al, 2002; Kroemer et al, 2007] (Figure 3). Bcl-2 homologous 
protein (including Bax) may oligomerize and form pores in the outer 
mitochondrial membrane, resulting in either a decrease in the inner 
mitochondrial transmembrane potential [Green, 2000] or opening of the 
voltage-dependent anion channel [Shimizu et al, 2001] releasing cytochrome
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c from the space between the inner and outer mitochondrial membranes 
[Goldstein et al, 2000].
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Figure 3. Mitochondrial apoptotic pathway.
Mitochondrial outer membrane permeabilization occurs 
when the pro-apoptotic Bcl-2 family proteins (Bax and/or 
Bak) are activated by BH3-only proteins in response to 
apoptosis-inducing signals. This results in the release of 
proteins of the mitochondrial intermembrane space, 
including cytochrome c and SMAC/Diablo. Cytochrome c 
activates Apaf-1, which oligomerizes to form the 
apoptosome, that in turn recruits and activates caspase-9. 
The activated caspase-9 cleaves and activates executioner 
caspases. lAPs block caspase-9 function and are 
themselves regulated by SMAC/Diablo.
Cytosolic cytochrome c induces the formation of the multi-subunit 
apoptosome composed of Apaf-1, pro-caspase-9 and either ATP or dATP 
[Hengartner, 2000; Cecconi & Gouss, 2001; Auchon et al, 2002; Zimmerman 
et al, 2002] (Figure 3). Activated caspase-9 recruits and activates caspases-3
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and/or -6 and -7. Anti-apoptotic members of the Bcl-2 family, such as Bcl-2 
and B c I-x l, control cytochrome c and SMAC/Diablo release [Thomadaki & 
Scorilas, 2006], whereas activation of caspase-9 and downstream caspases 
is controlled by the family of inhibitor of apoptosis proteins (lAPs) [Vaux & 
Silke, 2003] (Figure 3).
1.2.3. Caspases
The final pathway that leads to execution of the death signal in both 
intrinsic and extrinsic pathways of apoptosis is the activation of a series of 
proteases termed caspases [Thornberry & Lazebnik, 1998; Shi, 2002]. The 
name is derived from the specificity of these cysteine proteases to cleave 
their substrates after an aspartic acid [Thornberry & Lazebnik, 1998]. To 
date, more than 14 caspases have been identified [Kumar, 2007]. Of these, 
caspases-2, -8, -9, and -10 are thought to be initiator caspases, while 
caspases-3, -6 and -7 are considered to be death effectors. Other caspases 
including caspase-1, -4, -5, -11, -13 and -14 have been implicated in the 
inflammatory response [Scott & Saleh, 2007]. Caspase-12, which localizes to 
the endoplasmic reticulum, may play a role in the endoplasmic reticulum 
stress response [Nakagawa et al, 2000]. Generally, the cleavage of caspase 
specific substrates results in the biochemical destruction of the cell and 
phenotypic changes associated with the apoptotic program.
In cells, caspases exist as inactive zymogens that require processing to 
become biologically active. It is generally accepted that this occurs by either 
auto-proteolysis or by the proteolytic actions of other caspases. The
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zymogenic form of the caspase, the pro-caspase, contains an amino terminal 
pro-domain, a large subunit (-20 kDa) containing the active cysteine residue, 
a small subunit (-10 kDa) and a variable length linker region which separates 
the large and small subunits [Nunez & Del Peso, 1998] (Figure 4).
pro-caspase QACXG
Pro-domain Large subunit Small subunit
Aspl Asp!
active caspase
Active site
Figure 4. Schematic representation of caspase structure.
Caspases are cysteine proteases produced in cells as inactive 
precursors (pro-caspase) containing common structural 
elements: a pro-domain, a large and a small subunits and a 
linker region. The active site cysteine is harbored within a 
conserved QACXG motif in the large subunit. The caspase is 
activated by proteolysis that occurs at aspartate residues, 
residing between the pro-domain and the large subunit and 
within the linker region. The active caspase is a tetramer made of 
two large/small subunit heterodimers each with an active site.
Aspartate cleavage sites are found between the pro-domain and the large 
subunit as well as within the inter-domain linker. Caspase activation occurs 
by proteolytic cleavage of the linker region, thus allowing the large and small 
subunits to assemble into a functionally active heterodimer [Wilson et al, 
1994; Nunez & Del Peso, 1998; Wolf & Green, 1999]. Initiator caspases have 
a long pro-domain, which contain either a CARD (caspase-2 and -9) or a
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DED (caspase-8 and -10) domain [Slee et al, 1999]. Interaction of either the 
DED or CARD with corresponding regions in other initiator caspases or 
adaptor proteins facilitates clustering and auto-proteolysis of initiator 
caspases. Once activated, initiator caspases act in a hierarchical manner to 
cleave and activate death effector caspases. Subsequently, activated effector 
caspases can activate remaining initiator caspases. This system of activation 
enables rapid caspase mobilization and cascade amplification 
[Wolf & Green, 1999].
The downstream caspases induce cleavage of protein kinases, 
cytoskeletal proteins, DNA repair proteins, inhibitory subunits of 
endonucleases, and finally, destruction of “housekeeping” cellular functions. 
Caspases also affect cytoskeletal structure, cell cycle regulation, and 
signalling pathways, ultimately leading to the morphologic manifestations of 
apoptosis, such as DNA condensation and fragmentation, and membrane 
blebbing [Thornberry & Lazebnik, 1998; Kumar, 2007].
1.3. Regulators of Apoptosis
At the molecular level, the intrinsic pathway is primarily governed by a 
series of proteins belonging to two distinct groups [Hengartner, 2000]: those 
of the Bcl-2 family and those of the Inhibitors of Apoptosis Proteins (lAPs) 
family.
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1.3.1. Bcl-2 Family Proteins
The bcl-2 gene was first discovered in human B-cell lymphomas where, by 
chromosomal translocations, it was moved into juxtaposition with strong 
enhancer elements in the immunoglobulin heavy-chain locus [Tsujimoto 
etal, 1985]. Bcl-2 gene has been established to be a proto-oncogene that 
prolongs cell survival by inhibiting apoptosis. Subsequent studies have 
demonstrated that Bcl-2 can prevent or delay apoptosis induced by a large 
variety of stimuli in many cell types [Hockenbery et al, 1990; Willis et al, 
2003; Thomadaki & Scorilas, 2006; Zinkel et al, 2006]. However, the exact 
mechanism of its protective action remains unclear. Several hypotheses have 
been proposed to explain the anti-apoptotic function of Bcl-2. Bcl-2 may 
prevent the release of the mitochondria activators of the cytosolic caspases 
[Thomadaki & Scorilas, 2006]. The association of Bcl-2 with the Apaf-1 may 
prevent the cytochrome c release and the activation of the two effector 
caspases, caspase-9 and -3. Also, Bcl-2 might act by modulating the 
collapse of the mitochondrial transmembrane potential that occurs during 
apoptosis [Hockenbery et al, 1990; Kroemer et al, 2007].
Members of the Bcl-2 family are characterized by the presence of distinct 
conserved sequence motifs known as Bcl-2 homology (BH) domains 
designated BH1, BH2, BH3 and BH4, which correspond to a-helical 
segments [Adams & Cory, 2007] (Figure 5). This family members are either 
anti- or pro-apoptotic. Generally, the anti-apoptotic members (such as Bcl-2, 
B cI-X l, Mcl-1, A1, Bcl-W) display sequence homology in all four BH domains 
[Adams & Cory, 2007], whereas the pro-apoptotic members (such as Bax,
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Bak, Bcl-xs, Bok) have homologous BH1-3 domains [Puthalakath & Strasser, 
2002; Adams & Cory, 2007] (Figure 5).
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Figure 5. The Bcl-2 protein family.
Most anti-apoptotic Bcl-2 family members express four 
Bcl-2 homology domains (BH) as well as a putative 
transmembrane domain (TM) responsible for their 
preferred localization at inner membranes. The pro- 
apoptotic Bcl-2 family members can be divided into two 
groups: /', the Bax sub-family (Bax, Bak, Bok) resemble 
Bcl-2 closely in structure and possess three out of four 
BH domains; /'/', the more distantly related ‘BH3-only’ 
proteins only share one BH3 domain with all other Bcl-2 
family members. [Adapted from Ranger et al, 2001]
Pro-apoptotic Bcl-2 family members, upon activation by apoptotic stimuli, 
are capable of forming heterodimers with anti-apoptotic members. Deletion 
and mutagenesis studies show that the BH3 domains among pro-apoptotic 
members are critical for their pro-apoptotic and heterodimerization function 
[Opferman & Korsmeyer, 2003]. Thus, the a-helical BH3 domain serves as a
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critical death domain among pro-apoptotic members. The hypothesis that the 
BH3 domain of pro-apoptotic members may be required and sufficient for 
mediating pro-apoptotic function is supported by the discovery of a third 
subset of the pro-apoptotic members of the Bcl-2 family (such as Bid, Bad, 
Bik, Bim, Bmf, Puma) that have sequence homology only in the BH3 domains 
[Huang & Strasser, 2000] (Figure 5).
Different Bcl-2-like proteins have different cytoplasmic distributions. Both 
Bcl-2 and B c I-x l have a carboxy-terminal membrane insertion sequence, and 
the majority of these proteins are found to be associated with mitochondrial 
membranes, endoplasmic reticulum, and nucleus [Jacobson et al, 1993; 
Wolter et al, 1997; Minn et al, 1998]. In their inactive state, the pro-apoptotic 
members, Bad, Bax and Bid have primarily a cytoplasmic location. However, 
upon activation, they translocate to the mitochondria [Wolter et al, 1997; 
Goping et al, 1998; Khaled et al, 1999; Ruffolo et al, 2000]. Bid and Bik can 
directly induce mitochondria to release cytochrome c, and they may also act 
to inhibit the anti-apoptotic actions of Bcl-2 and Bcl-xL via the formation of 
heterodimers [Shimizu et al, 2000].
Several different cellular mechanisms exist to modulate the activity of both 
the pro- and anti-apoptotic function of Bcl-2 proteins. The dimerization state 
of Bcl-2 family members affects their activity [Korsmeyer, 1999]. One function 
of the anti-apoptotic Bcl-2 and Bcl-xL is to dimerize with pro-apoptotic Bax to 
neutralize its activity. As a heterodimer, Bax is inactive, but once free to 
dimerize with itself, Bax is able to induce apoptosis [Gross et al, 1998; Minn 
et al, 1998]. Altering the expression levels of pro- and anti-apoptotic family 
members can either promote or inhibit apoptosis [Adams & Cory, 2007]. In
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fact, when the amount of Bcl-2 is greater than or equal to the amount Bax, a 
given cell is protected from apoptosis. However, when the amount of Bax 
exceeds the amount Bcl-2, a cell is more prone to undergo apoptosis. 
Moreover, Bcl-2 proteins can be altered by phosphorylation [Ito et al, 1997; 
Maundrell et al, 1997; Thomadaki & Scorilas, 2006]. In its un-phosphorylated 
state, Bad dimerizes with Bcl-2 and Bcl-xL, neutralizing their anti-apoptotic 
activity (and allowing Bax to self-associate) [Yang et al, 1995]. However, 
when Bad is phosphorylated, it is sequestered by a protein, and therefore 
cannot interact with and neutralize Bcl-2 and Bcl-xL [Zha et al, 1998; 
Korsmeyer, 1999]. The function of Bcl-2 family members can be altered by 
cleavage. During Fas-mediated apoptosis, caspases have been shown to 
cleave both Bcl-2 and Bcl-xL [Clem et al, 1998; Fujita et al, 1998]. The 
cleaved products are no longer protective, and in fact become pro-apoptotic 
[Clem et al, 1998; Fujita et al, 1998]. Bid is another Bcl-2 protein that is 
activated by caspase cleavage. While the full-length protein is inactive, after 
caspase-8-mediated cleavage, Bid induces cytochrome c release from the 
mitochondria [Li et al, 1998; Luo et al, 1998; Gross et al, 1999].
Finally, the conformation of Bcl-2 proteins modifies their activity. The best 
evidence for this mechanism comes from studies of Bax [Khaled et al, 1999]. 
In its inactive state, Bax exists in a conformation in which it is resistant to 
protease cleavage. However, upon activation and translocation to 
mitochondria, the amino-terminal region of this protein becomes susceptible 
to protease cleavage, suggesting that a conformational change has occurred 
[Khaled etal, 1999].
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1.3.2. Inhibitor Apoptosis Proteins (lAPs) Family
The Inhibitors of Apoptosis Proteins (lAPs) family are a group of anti- 
apoptotic proteins that are conserved in several species [Deveraux & Reed,
1999]. These proteins characterized by one or more 70-80 amino-acid 
baculoviral IAP repeat (BIR) domains. The BIR domain is a characteristic 
cysteine-and histidine-rich protein folding domain that chelates zinc and 
forms a compact globular structure consisting of four or five a-helices and a 
variable number of antiparallel p-pleated sheets. The core of a BIR domain 
consists of the variable consensus sequence, C(X)2 C(X)6 (X)3 D(X)5 H(X)6 
C, where X is any amino acid [Deveraux & Reed, 1999]. They were first 
discovered in baculoviruses, a group of viruses specific to insects [Birnbaum 
et al, 1994] and proteins containing BIR domains have been identified in a 
wide range of eukaryotic species, including the fission yeast 
Schizosaccharomyces pombe, the budding yeast Saccharomyces cerevisiae, 
the nematode Caenorhabditis elegans, the fly Drosophila melanogaster, and 
several mammalian species including mice, rats, chickens, pigs, and humans 
[Deveraux & Reed, 1999].
The first mammalian IAP homologue to be identified was neuronal 
apoptosis inhibitory protein (NAIP) (Figure 6), which was isolated during a 
positional cloning effort to identify the causative gene for spinal muscular 
atrophy [Roy et al, 1995]. In contrast to the baculoviral lAPs, which possess 
two BIR domains and a carboxy-terminal RING zinc-finger, NAIP encodes 
three BIR domains and a very large and unique carboxy-terminus containing 
a nucleotide-binding oligomerization domain [Koonin & Aravid, 2000].
38
Chapter 1 In t r o d u c t io n
Subsequent to the identification of NAIP, the IAP family expanded with the 
identification of cellular IAP1 (clAP1, hlAP2), clAP2 (hlAP1), and X- 
chromosome-linked IAP (XIAP) (Figure 6), all of which contain three BIR 
domains and a carboxy-terminal RING finger [Rothe et al, 1995; Duckett et 
al, 1996; Liston et al, 1996; Uren et al, 1996]. Finally were identified survivin 
(with a single BIR and the carboxy-terminal coiled-coil domain) [Ambrosini et 
al, 1997], Livin or ML-IAP (with a single BIR and the carboxy-terminal RING 
finger) [Lin et al, 2000; Vucic et al, 2000; Kasof & Gomes, 2001], the testis- 
specific IAP (Ts-IAP, with a single BIR and the carboxy-terminal RING finger) 
[Lagace et al, 2001; Richter et al, 2001], and the Apollon/BRUCE (with a 
single BIR and the carboxy-terminal ubiquitin-conjugating enzyme) 
[Hauser etal, 1998; Verhagen etal, 2001] (Figure 6).
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Figure 6. Schematic structure of the domains of the mammalian IAP family.
The first mammalian IAP homologue, NAIP, encodes three BIR domains and a 
very large and unique carboxy-terminus containing a nucleotide-binding 
oligomerization domain; clAP1, clAP2 and XIAP contain three BIR domains and 
a carboxy-terminal RING finger; survivin contains a single BIR and the carboxy- 
terminal coiled-coil domain; Livin and Ts-IAP encode a single BIR and carboxy- 
terminal RING finger; and BRUCE contains a single BIR and an UBC motif.
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The characterization of IAP proteins suggests that they function as 
suppressor of cell death in a variety of tissue culture systems, including 
triggers of both the endogenous and exogenous pathways of apoptosis 
[LaCasse et al, 1998; Deveraux & Reed, 1999; Wright & Duckett, 2005]. It 
was subsequently shown that the lAPs could directly inhibit the activity of 
several recombinant caspases in vitro [Deveraux et al, 1997; Roy et al, 1997; 
Maier et al, 2002], and structure-function studies of IAP family proteins have 
demonstrated a requirement for at least one BIR domain for suppression of 
apoptosis, although other domains found within some lAPs may also be 
required under certain circumstances. Several of the mammalian, fly, and 
viral lAPs have a RING domain located near their carboxyl termini (Figure 6). 
The necessity for the RING domain for suppression of apoptosis appears to 
depend on cellular context. In fact, some reports have indicated that the 
baculoviral lAPs require both amino-terminal BIR domains and the carboxy- 
terminal RING domain for their anti-apoptotic function in insect cells [Clem & 
Miller, 1994; Harvey et al, 1997]. By contrast, the human proteins clAP1, 
clAP2, and XIAP have been reported to retain anti-apoptotic function in the 
absence of their carboxy-terminal RING domains [Deveraux et al, 1997; Roy 
etal, 1997; Takahashi etal, 1998].
The BIR domains of the lAPs are the most fully characterized functional 
units of the lAPs. Each BIR domain folds into a functionally independent 
structure that chelates a zinc ion and consists of a globular head and an 
unstructured tail derived from the amino-terminal ‘linker’ region located 
upstream of the individual BIR domains. Specific interactions with initiator 
(caspase-9) and effector (caspase-3 and -7) caspases have been mapped to
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individual BIR domains. As a general rule, the lAPs containing multiple BIRs 
employ the third BIR domain to inhibit caspase-9, and the second BIR 
domain functions to inhibit caspase-3 and -7 [Roy et al, 1997; Takahashi et 
al, 1998; Maier et al, 2002], As regards single BIR-containing proteins, Ts- 
IAP inhibits caspase-9 [Richter et al, 2001], while the survivin and livin inhibit 
caspase-3, -7 and -9 [Lin et al, 2000; Vucic et al, 2000; Kasof & Gomes, 
2001; Shin et al, 2001].
Among the mammalian lAPs that are known to be involved in apoptosis, 
X-linked IAP (XIAP) has been characterized extensively (Figure 7).
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Figure 7. Map of XIAP activities and interactions.
XIAP contains three BIR domains and a C-terminal RING motif. 
BIR2 binds to and inhibits active caspase-3 and caspase-7, 
whereas BIR3 potently targets active caspase-9. No specific 
function has been identified for the BIR1 domain. SMAC/Diablo 
peptide, released from mitochondria during apoptosis, binds to a 
highly conserved surface groove on the BIR3 domain of XIAP, and 
re-activates the processed initiator and effector caspases.
This protein contains three BIR domains and a C-terminal RING motif. The 
second BIR domain (BIR2) specifically binds to and inhibits active caspase-3 
and caspase-7, whereas BIR3 potently targets active caspase-9 [Shi, 2002]. 
No specific function has been identified for the BIR1 domain of XIAP. The
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linker segment that immediately precedes the BIR2 domain of XIAP binds to 
the active site of effector caspase-3 and caspase-7, hence, preventing 
substrate binding and subsequent catalysis. By contrast, the BIR3 domain of 
XIAP employs a different method to inhibit the initiator caspase, caspase-9. 
Caspase-9 becomes catalytically active through a conformational change 
when bound by Apaf-1, and thus appears to be unique among the caspases 
in that there is no absolute requirement for proteolytic activation. In addition 
to its ability to proteolytically process caspase-3, caspase-9 can undergo a 
self-cleavage event in the linker region between the p20 and p10 subunits. 
The XIAP BIR3 domain directly binds caspase-9 via this newly exposed 
amino terminus and the interaction is stabilized through additional contacts 
with the enzyme. Using purified caspase-9 and XIAP BIR3, in the absence of 
Apaf-1 and cytochrome c, it was demonstrated that this interaction prevents 
caspase-9 homodimerization and stabilizes the enzyme in an inactive state 
similar to its monomeric form [Shiozaki et al, 2003]. It has been proposed that 
a similar change in caspase-9 morphology occurs within the apoptosome 
complex as a consequence of XIAP binding. Caspase-9 can also undergo 
further cleavage catalysed by caspase-3. This proteolytic event further 
increases the enzymatic activity of caspase-9, and was proposed to remove 
the peptide sequence that binds XIAP [Srinivasula et al, 2001].
In the intrinsic cell death pathway, the key event leading to the activation 
of caspases is the release of several pro-apoptotic proteins from the 
intermembrane space of mitochondria into the cytosol [Wang, 2001]. One 
such protein is SMAC/Diablo [Du et al, 2000; Verhagen et al, 2000]. The 
newly synthesized SMAC/Diablo protein contains 239 amino acids. Its N-
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terminal 55 residues encode the mitochondrial-targeting sequence and are 
proteolytically removed in the mature SMAC/Diablo protein [Du et al, 2000]. 
This cleavage results in the exposure of four hydrophobic amino acids, Ala- 
Val-Pro-lle, at the N-terminus of mature SMAC/Diablo. This tetrapeptide 
represents the founding member of a family of lAP-binding motifs in 
mammals and fruit flies [Shi, 2002]. Structural analysis reveals that this 
tetrapeptide motif binds to a highly conserved surface groove on the BIR3 
domain of XIAP [Liu et al, 2000; Wu et al, 2000] (Figure 7). The interactions 
between SMAC/Diablo and lAPs requires that the N-terminus of the 
tetrapeptide is exposed, which explains why only the mature form of 
SMAC/Diablo is functional in cells. Before apoptosis, accidental activation of 
either caspase-9 or caspase-3 and caspase-7 might not lead to cell death 
because of the inhibitory effect of lAPs. During apoptosis, SMAC/Diablo is 
released from mitochondria and re-activates the processed initiator and 
effector caspases by relieving lAP-mediated inhibition.
1.4. Apoptosis & Cancer
In cancer cells, the growth equilibrium, determined as the ratio between 
the rate of cell proliferation and incidence of apoptosis, is uncontrolled, and 
the increase in abnormal proliferation of cancer cells causes tumour invasion 
and metastatic potential [Olopade etal, 1997].
The goal of most cancer therapies, including radiotherapy, chemotherapy, 
immunotherapy and gene therapy is the reduction or elimination of cancer
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cells. Drug resistance is a major problem that limits the success of the 
treatment. In fact, most tumours are intrinsically resistant to chemotherapy 
prior to treatment. Other tumours, initially sensitive, recur and are resistant 
not only to the initial therapeutic agents, but also to other drugs not used in 
the treatment. Drug resistance, whether intrinsic or acquired, is believed to 
cause treatment failure in over 90% of patients with metastatic cancer, and 
resistant micrometastic tumour cells may also reduce the effectiveness of 
chemotherapy in the adjuvant setting.
Cancer cell resistance to chemotherapy can occur at many levels, 
including increased drug efflux and decreased drug influx, drug inactivation, 
alterations in drug target, processing of drug-induced damage. Apoptosis 
pathways are also extremely related to drug sensitivity and resistance. 
Apoptosis in tumour cells plays a critical role in chemotherapy-induced 
tumour cell killing thus suggesting that blockade of the apoptosis-inducing 
pathway could be another mechanism for multidrug resistance [Kim et al, 
2002]. Several studies have demonstrated that high Bcl-2 expression in 
cancers (particularly lymphomas) correlates with poor response to 
chemotherapy [Campos et al, 1993; Hermine et al, 1996; Bonetti et al, 1998; 
Schmitt et al, 2000; Reed & Pellecchia, 2005; Adams & Cory, 2007]. 
However, other studies have shown either no correlation between Bcl-2 
expression and drug response [Colleoni et al, 1999; Bottini et al, 2000; 
Sjostrom et al, 2002; Adams & Cory, 2007], or an association between Bcl-2 
and good prognosis [Fontanini et al, 1995; Sjostrom et al, 2002; Adams & 
Cory, 2007]. Some clinical studies have also demonstrated a correlation 
between Bax expression and response to chemotherapy [Krajewski et al,
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1995; Kymionis et al, 2001; Adams & Cory, 2007]; however, such an 
correlation was not confirmed in other studies [Campos et al, 1993; Paradiso 
et al, 2001; Adams & Cory, 2007]. It has been also demonstrated that NAIP 
XIAP, clAP1,and clAP2, diminish apoptosis triggered by a number of agents 
including camptothecin and menadione in vitro [Liston et al, 1996]. However, 
it has been found that expression of clAP1, clAP2, and XIAP did not predict 
response to chemotherapy in patients with advanced non-small cell lung 
cancer [Ferreira et al, 2001]. Finally, silencing of Apaf-1 has been reported in 
melanoma cell lines and clinical samples [Soengas et al, 2001]. The Apaf-1- 
deficient melanoma cells exhibited diminished apoptosis in response to 
doxorubicin [Soengas et al, 2001].
Resistance to apoptosis causes a decrease in the sensitivity of cancer 
cells to drugs, resulting in the failure of chemotherapy. Since the induction of 
apoptosis following chemotherapy is associated with the activation of pro- 
apoptotic genes and the suppression of anti-apoptotic genes, attenuation of 
pro-apoptotic genes and increases in anti-apoptotic genes causes resistance 
to apoptosis [Kaufmann & Vaux, 2003]. Thus, targeting apoptosis-related 
genes may lead to new strategies to increase the therapeutic effect of cancer 
chemotherapy. In vitro studies have shown that targeting death receptors 
with recombinant death ligands or agonistic antibodies can induce apoptosis 
and/or enhance chemotherapy-induced apoptosis [Petak et al, 2000; Fan et 
al, 2004; Longley et al, 2004; Wu et al, 2004]. Most pre-clinical studies are 
focused on local administration of rFasL, or the use of FasL-expressing 
vectors as gene therapy [Timmer et al, 2002]. However, it has been 
developed a non-hepatotoxic agonistic Fas antibody [Timmer et al, 2002],
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suggesting that it is possible to develop less toxic Fas antibodies. Apoptosis 
mediated by Fas can be inhibited by cytoplasmic factors, including c-FLIP, 
which binds to the DISC and inhibits caspase-8 activation [Krueger et al,
2001]. Moreover, c-FLIP overexpression has been found to inhibit death 
receptor-mediated apoptosis in a number of in vitro studies [Hu et al, 1997; 
Irmel et al, 1997; Srinivasula et al, 1997]. Small RNA interfering targeting of 
c-FLIP dramatically sensitises a panel of colon cancer cell lines to 5-FU, 
oxaliplatin, and CPT-11 [Galligan et al, 2005], suggesting an important role 
for c-FLIP in regulating colon cancer cell chemosensitivity. A promising 
clinical approach may be to target the TRAIL receptors, as TRAIL has been 
shown to exert marked anticancer activity without systemic toxicity in mice 
[Ashkenazi et al, 2002]. Approaches for targeting TRAIL receptors are 
currently being tested in the clinic.
At mitochondrial level, in vitro studies have demonstrated that down- 
regulation of Bcl-2 and BcI-X l using antisense techniques sensitises cells to 
chemotherapy [Teixeira et al, 1995; Zangemeister-Wittke et al, 2003; 
Hayward et al, 2004; Adams & Cory, 2007], whereas loss of Bax expression 
has been found to decrease chemosensitivity [Zhang et al, 2000; Adams & 
Cory, 2007]. An antisense oligonucleotide against Bcl-2 (oblimersen) has 
been in phase III clinical trials for melanoma, CLL and multiple myeloma, as 
well as in phase II clinical trials for several other cancers [Cummings et al, 
2004; Gleave & Monia, 2005], but the results in the clinic are not very 
promising [Fesik, 2005]. Recently antisense oligonucleotides have been used 
to reduce IAP protein levels in cancer cells. Down-regulation of XIAP protein 
levels induced apoptosis in chemoresistant ovarian cancer cells [Sasaki et al,
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2000] and increased doxorubicin activity in bladder cancer [Bilim et al, 2003], 
An antisense oligonucleotide targeting XIAP are now in phase I clinical trials 
[McManus et al, 2004].
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2. S urvivin
The mammalian IAP survivin is a bifunctional protein that facilitates tumour 
cell evasion from apoptosis and promotes mitotic progression [Altieri & 
Marchisio, 1999].
Survivin was discovered in 1997 by hybridisation screening of a human 
genomic library with the cDNA of the effector cell protease receptor-1 
(EPR-1) [Ambrosini et al, 1997]. Survivin has a particular relationship to 
EPR-1: in fact its sequence is complementary to and in the reverse 
orientation of EPR-1.
2.1. Protein Structure of Survivin
The survivin human gene spans 14.7 kb, and is located on the telomeric 
position of chromosome 17 at band q25 [Ambrosini et al, 1998]. It comprises 
three introns and four exons, a TATA-less proximal promoter, and 
approximately 200 nt GC-rich regions upstream of exon 1 [Ambrosini et al, 
1997]. The gene encodes a 16.5 kDa protein of 142 amino acids. The amino- 
terminal portion of survivin consists of three a helices (residues 14-21, 31-41, 
68-80) and 3 [3-sheets (residues 43-45, 55-58, 61-64), which closely 
resemble the BIR domain that is conserved in the IAP family [Ambrosini et al, 
1997; Chantalat et al, 2000] (Figure 8). Differently from other lAPs, survivin 
contains only one BIR and a carboxy-terminus coiled-coil, but no RING finger 
or other identifiable domain [LaCasse etal, 1998].
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Figure 8. Representation of survivin protein structure.
The amino-terminal portion of survivin consists of three a 
helices (residues 14-21, 31-41, 68-80) and 3 (3-sheets 
(residues 43-45, 55-58, 61-64), which closely resemble the BIR 
domain. Differently from other lAPs, survivin contains only one 
BIR and a carboxy-terminus coiled-coil, but no RING finger or 
other identifiable domain. [Adapted from Verdecia et al, 2000]
Crystal structure analysis of survivin revealed that it exists as a dimer, with 
the two BIR domains forming a “bow-tie-shape” [Chantalat et al, 2000] 
(Figure 9). The carboxy-terminal helix is not involved in the dimerization of 
survivin but extends outward from the entwined BIR structure [Chantalat et 
al, 2000].
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Figure 9. Representation of the survivin dimer.
[Adapted from Verdecia et al, 2000]
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The survivin gene is subjected to alternative splicing (Figure 10). Human 
survivin gene has four dominant (1, 2, 3, and 4) and two hidden (2B and 3B) 
exons. Alternative splicing of its pre-mRNA produces four different mRNAs, 
which encode four distinct proteins, survivin, survivin-2B, survivin-AEx3 
[Mahotka et al, 1999], and survivin-3B [Badran et al, 2004] (Figure 10).
survivin
5’- exon 1 exon 2 exon 3 exon 4 - 3 ’
survivin-2B
5’- exon 1 exon 2 intron _ .2 exon 3 exon 4 - 3 ’
survivin-AEx3
5’- exon 1 exon 2 exon 4 - 3 ’
survivin-3B
5’- exon 1 exon 2 o intron exon 3 3 - 3
survivin-2a
5’- exon 1 exon 2 intron 2 - 3’
Figure 10. Schematic representation of the alternative splicing 
variants of survivin.
Human survivin gene has four dominant (1, 2, 3, and 4) and two hidden 
(2B and 3B) exons. Alternative splicing of its pre-mRNA produces 
different mRNAs, which encode five distinct proteins, survivin, survivin- 
2B, survivin-AEx3, survivin-3B, and survivin 2a.
Survivin (142 aa) is derived from exons 1-4; survivin-2B (167 aa) has an 
additional 23 aa derived from a 69-bp cryptic exon (2B) within intron 2, which 
is spliced into survivin mRNA in frame between exons 2 and 3 (Figure 10);
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survivin-AEx3 (137 aa) is derived from exons 1, 2, and 4, a frameshift read- 
through variant due to exon 3 escape (Figure 10); and the survivin-3B 
(120 aa) consists of the N-terminal 113 aa of survivin (coded by exons 1, 2, 
and 3) plus seven new aa sequences at carboxy-terminal tail encoded by a 
DNA sequence (exon 3B) from intron 3 (Figure 10). Recently, an additional 
splice variant, survivin 2a, has been identified [Caldas et al, 2005]. 
Structurally, the transcript consists of 2 exons: exon 1 and exon 2, as well as 
a 3' 197 bp region of intron 2 (Figure 10). Acquisition of a new in-frame stop 
codon within intron 2 results in an open reading frame of 225 nucleotides, 
predicting a truncated 74 amino acid protein [Caldas et al, 2005a].
Little is known about the differential functions of survivin alternative splice 
forms, which are generally expressed at lower levels than the wild-type 
survivin. However, it has been reported that the expression of survivin-2B is 
predominant in some neuroblastoma with a good prognosis, but it is 
expressed at low levels in most malignant tissues [Islam et al, 2000]. In renal 
cell carcinomas (RCC), while the expression levels of survivin and survivin- 
AEx3 did not show a decrease in late tumour stages in comparison with the 
early and intermediate tumour stages in 57 clinical RCC samples, survivin-2B 
expression was significantly decreased in late tumour stages [Mahotka et al, 
2002a], indicating a possible unfavourable role of these splicing variant in the 
development of this tumour type. In gastric cancer, the expression of 
survivin-AEx3, survivin-2B, and survivin (dominant transcript) was found in 
clinical samples, irrespective of their histological type, grade, or stage [Krieg 
et al, 2002; Meng et al, 2004]. However, survivin-2B expression was 
significantly decreased in later tumour stage in comparison with early stage
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[Krieg et al, 2002; Meng et al, 2004], and inversely correlated with tumour 
differentiation and invasion [Meng et al, 2004]. The expression of survivin 
and survivin-AEx3 remained unchanged in different stages of cancer [Krieg 
et al, 2002], and the expression level of survivin-AEx3 is inversely correlated 
with apoptotic index [Meng et al, 2004]. It was also reported that survivin-2B 
expression was dominant in benign brain tumours in comparison with the 
malignant ones [Yamada et al, 2003], and that survivin-AEx3 expression was 
prominent in comparison with survivin-2B expression in survivin-expressing 
acute lymphocytic leukaemia and chronic lymphocytic leukaemia patient 
bone marrow samples [Nakagawa et al, 2004].
Preliminary data would suggest that heterodimerisation of survivin with 
survivin-AEx3 is essential for the inhibition of mitochondrial-dependent 
apoptosis [Caldas et al, 2005b], further suggesting a possible anti-apoptotic 
role for survivin-AEx3. In addition, the different subcellular localisation of 
survivin-AEx3 (in nucleus) and survivin-2B (in cytoplasm) [Mahotka et al, 
2002b] suggests their potential different functions. These observations 
indicate that survivin-AEx3 and survivin-2B may play an opposing role in 
tumour progression and tumorigenesis. Moreover, it has been demonstrated 
in exogenous expression assays that survivin 2a attenuates the anti- 
apoptotic activity of survivin [Caldas et al, 2005a]. More recently, it was 
reported that despite their ability to interact with wild-type survivin, alternative 
splice isoforms such as survivin-AEx3 and survivin-2B do not play a role in 
mitosis since they do not localize with the chromosomal passenger complex 
in vivo as a consequence of their reduced affinity for the survivin partner 
Borealin [Noton et al, 2006]. Moreover, these splice variants cannot rescue
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cell proliferation inhibited by RNAi-mediated survivin depletion 
[Noton et al, 2006].
Survivin exhibits cell cycle-dependent expression at mitosis. This requires 
canonical CDE/CHR boxes in the proximal survivin promoter [Kobayashi et 
al, 1999; Badie et al, 2000] acting as Gi-repressor elements to shut down 
gene transcription in interphase cells [Kobayashi et al, 1999]. Survivin levels 
are regulated by rapid changes in protein stability. Poly-ubiquitination on 
multiple Lys residues and proteasomal-dependent destruction has been 
proposed as a mechanism to maintain low levels of survivin in interphase 
cells [Zhao et al, 2000], thus further enhancing cell cycle periodicity. In addition, 
mitotic phosphorylation of survivin on Thr34 by p34Gdc2-cyclin B1 has been 
associated with increased survivin stability at metaphase [O’Connor et al, 
2002]. It has been suggested that this pathway is dominant in normal cells 
and constitutes the primary function of survivin in adult tissues [Yang et al, 
2004; Altieri, 2006].
Other non-cell-cycle-dependent mechanisms driving survivin gene 
transcription independent of mitosis have been described, which involve 
tissue patterning circuits (Wnt/(3-catenin) [Kim et al, 2003], cytokine activation 
(STAT3) [Gritsko et al, 2006], costimulatory messages (OX-40) [Song et al,
2005] and pleiotropic signaling mechanisms (AkT, NFkB) [Mitsiades et al,
2002] that are operative during development and generally up-regulated in 
cancer cells [Vogelstein & Kinzler, 2004] and can explain survivin 
overexpression in the large majority of human tumours. It has been recently 
suggested that these non-cell-cycle-dependent pathways are dominant in 
tumours. This hypothesis also relies on the fact that a transgenic mouse
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model expressing the green fluorescent protein reporter gene under the 
control of the minimal survivin promoter demonstrated that expression of 
survivin in development and tumour formation is largely independent of cell- 
cycle-dependent transcription of the survivin gene at mitosis [Xia & Altieri,
2006]. The fraction of survivin produced through these non-cell-cycle- 
dependent mechanisms mediates apoptosis inhibition through intermolecular 
cooperation with cofactors including the hepatitis B virus X interacting protein 
[Marusawa et al, 2003], a target of the oncogenic viral HBX protein, and XIAP 
[Dohi et al, 2004a].
2.2. Survivin & Inhibition of Apoptosis
Survivin plays an important role in the suppression of apoptosis by either 
directly or indirectly inhibiting the activity of caspases (Figure 11).
Survivin Caspases Apoptosis
B
Survivin SMAC ■j XIAP ■ " 1 ^  Apoptosis
Figure 11. The role of survivin in the apoptosis pathways.
Survivin may regulate apoptosis (A) directly inhibiting the caspases responsible 
for induction and execution of apoptosis; (B) indirectly inhibiting caspase 
function by regulating SMAC/Diablo.
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The IAP family members have been shown to suppress apoptosis by 
direct inhibition of caspases [Deveraux & Reed, 1999] via the BIR domains 
[Miller, 1999] (Figure 11A). The structure of survivin has been compared to 
another IAP family member, XIAP (Figure 7). XIAP inhibits caspase-3 and 
caspase-7 via a linker region between the first two BIR domains, and also 
binds to and inhibits caspase-9 through its third BIR (BIR3) domain [Sun et 
al, 1999]. The BIR domain of survivin appears closely related in three- 
dimensional structure to the BIR3 domain of XIAP, suggesting the possibility 
that survivin binds caspase-9 [Shi, 2000]. The interaction between survivin 
and caspase-9, and the functional implications of this interaction, have been 
studied through mutagenesis. Loss of phosphorylation at Thr34 on the T34A 
mutant of survivin results in dissociation of an immunoprecipitable survivin- 
caspase-9 complex on the mitotic apparatus, allowing caspase-9 dependent 
apoptosis [O’Connor et al, 2000].
Survivin may also inhibit caspase activity indirectly (Figure 11B). There is 
evidence of an indirect regulation of caspase activity by survivin in the 
mitochondrial pathway of apoptosis. Haepatocytes of heterozygous survivin 
knockout mice contain low basal levels of activated pro-caspase-8, Bid, pro- 
caspase-9, and pro-caspase-3, and have increased susceptibility to Fas- 
induced apoptosis [Conway et al, 2002]. Fas-induced apoptosis is associated 
with release of cytochrome c and up-regulation of survivin in the mitochondria 
as well as in the nucleus and cytosol [Conway et al, 2002]. Upon Fas 
stimulation in cell culture, survivin has been shown to interact with cdk4, 
which releases p21 from its complex with cdk4 [Suzuki et al, 2000] making it 
possible for p21 to complex with caspase-3, the initial step in inactivating
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caspase-3 in the mitochondria. In addition, overexpression of a second 
mitochondrial- derived activator of caspases, SMAC/Diablo, increases Apo- 
2L/TRAIL-induced caspase-3 activity, and down-regulates the activity of 
survivin and other lAPs such as XIAP and clAP1 [Guo et al, 2002]. 
SMAC/Diablo is released from mitochondria into the cytosol along with 
cytochrome c during execution of the mitochondrial apoptosis pathway. 
SMAC/Diablo can promote apoptosis by binding to and suppressing the 
inhibitory effects of the IAP proteins [Du et al, 2000]. Survivin may possibly 
function to inhibit caspase activity indirectly via binding to and sequestering 
SMAC/Diablo, thus preventing SMAC/Diablo binding to other lAPs [Du et al,
2000] (Figure 11B).
The mechanism of caspase-3 inhibition by survivin remains controversial. 
There are reports indicating that purified survivin directly binds to caspase-3 
and inhibits its activity in vitro [O’Connor et al, 2000; Shin et al, 2001]. 
However, the survivin protein lacks the linker region found in other IAP 
members that is responsible for their interaction with caspase-3 [Sun 
etal, 1999].
Moreover, subcellular compartmentalization of survivin in mitochondria 
seems to play a role in the anti-apoptotic function of the protein. Specifically, 
the existence of a mitochondrial pool of survivin was recently reported, and it 
was found that, in response to cell death stimulation, mitochondrial survivin is 
rapidly discharged and released into the cytosol, where it prevents caspase 
activation and inhibits apoptosis [Dohi et al, 2004b]. In addition, survivin was 
not seen in mitochondria in normal tissues, suggesting that mitochondrial 
survivin is exclusively associated with tumour transformation [Dohi et al,
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2004b]. A very recent study found that survivin has a nuclear export signal 
and that in cancer cells the anti-apoptotic and mitotic roles of survivin can be 
separated through mutation of its NES, which abrogates the cytoprotective 
activity of the protein but still allows mitosis to proceed [Colnaghi et al, 2006].
2.3. Survivin & Cell Division
During the cell cycle, survivin localizes to various components of the 
mitotic apparatus [Vagnarelli & Earnshaw, 2004] (Figure 12).
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Figure 12. The role of survivin in the cell cycle.
Survivin is detected on centromeres at 
prophase/metaphase, in the spindle midzone during 
anaphase/telophase, but is no longer detected by the 
end of telophase. Survivin has been found to be 
localized to kinetochores until metaphase: to the 
spindle midzone in anaphase and in the cleavage 
plane during telophase and cytokinesis.
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Survivin is first detected on centromeres at prophase/metaphase; it is 
present in the spindle midzone during anaphase/telophase, but is no longer 
detected by the end of telophase [Li et al, 1998; Uren et al, 2000]. Moreover, 
survivin is localized to kinetochores until metaphase, then to the spindle 
midzone in anaphase and in the cleavage plane during telophase and 
cytokinesis [Skoufias et al, 2000].
In summary, survivin exists in two immunohistochemically distinct pools, 
with a nuclear pool localised to kinetochores of metaphase chromosomes 
and to the central spindle midzone at anaphase, and a cytosolic pool 
associated with interphase microtubules, centrosomes, spindle poles and 
mitotic spindle microtubules at metaphase and anaphase [Fortugno et al,
2002]. The microtubule-associated pool appears to be quantitatively 
predominant and functionally relevant. These findings, together with the 
phenotype of knockout mice (which is characterised by a catastrophic defect 
of microtubule assembly, with absence of mitotic spindle, formation of 
multinucleated cells and 100% embryonic lethality [Uren et al, 2000]), are 
consistent with a critical role of survivin in mitosis to preserve the mitotic 
apparatus and to allow normal mitotic progression. In fact, it has been 
demonstrated that survivin down-regulation causes pleiotropic cell-division 
defects [Li et al, 1999; Chen et al, 2000]. Moreover, forced expression of 
survivin in HeLa epithelial carcinoma cells profoundly influenced microtubule 
dynamics and also caused stabilization of microtubules against nocodazole- 
induced depolymerization, thus indicating that survivin may facilitate evasion 
from checkpoint mechanisms of growth arrest and, consequently, promote 
resistance to drugs targeting the mitotic spindle [Giodini et al, 2002].
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Additional evidence indicates that survivin also participates in the regulation 
of chromosome segregation [Kallio et al, 2001], and that the protein 
cooperates together with the chromosomal passenger proteins INCENP and 
Aurora-B to perform its mitotic duties [Carvalho et al, 2003].
2.4. Regulation of Survivin Function
A critical requisite for survivin function was identified in the 
phosphorylation on threonine 34 [O’Connor et al, 2000]. The only kinase 
recognized to phosphorylate survivin is p34Gdc2-cyclinB1, a cyclin-dependent 
kinase that is only active during certain points in the cell cycle [O’Connor et 
al, 2000]. The p34cdc2-cyclin B1 was shown, In vivo, to physically associate 
with survivin and to phosphorylate survivin on Thr34 during mitosis. A direct 
link between survivin and p34cdc2-cyclin B1 was independently confirmed 
using array technology in gene-profiling studies of large-cell non-Hodgkin’s 
lymphoma; it was associated with an activated B-cell phenotype and 
unfavourable disease progression [Kuttler et al, 2002]. Mutants of p34cdc2- 
cyclin B1 prevent survivin phosphorylation, and the enzyme can be co- 
immunoprecipitated with survivin in cells that have been synchronized in 
mitosis. Although other members of the cdc2 family of kinases may also 
associate with survivin [Suzuki et al, 2000], they are active only during certain 
cell cycle transitions, and thus the activity of survivin as an apoptosis- 
blocking protein is likely restricted to dividing cells. The p53-dependent 
repression of cdc2 expression has been demonstrated during G2-arrest
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[Passalris et al, 1999], suggesting the hypothesis that p53 loss is associated 
with greater phosphorylation of survivin and thus more complete suppression 
of apoptosis.
Expression of non-phosphorylatable survivin Thr34->Ala prevented 
phosphorylation of endogenous survivin, resulting in apoptosis of various 
cancer cell types [O’Connor et al, 2000], and suppressed cell growth in vivo 
[Grossman et al, 2001; Mesri et al, 2001]. Moreover, inhibitors of cyclin- 
dependent kinases (cdk) such as flavopiridol or the more p34Gdc2-specific 
inhibitor, purvalanol A, were tested in tumour cells arrested at mitosis with 
paclitaxel, which induces hyperphosphorylation of survivin on Thr34 [Zaffaroni 
et al, 2002]. Sequential administration of cdk inhibitors resulted in escape 
from the mitotic block imposed by paclitaxel, marked activation of 
mitochondrial-dependent apoptosis and anticancer activity in vivo [O’Connor 
et a/,2002].
A physical interaction with the molecular chaperone heat shock protein 90 
(Hsp90), which involves the Hsp90 ATPase domain and the survivin BIR 
domain, was shown to be essential for the stability and function of survivin. In 
fact, targeted antibody-mediated disruption of the survivin-Hsp90 complex in 
cancer cells resulted in proteasomal degradation of survivin, mitochondrial- 
dependent apoptosis, and mitotic arrest [Fortugno etal, 2003].
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2.5. Survivin Expression in Normal & Tumour Tissues
One of the most significant features of survivin is its differential expression 
in cancer versus normal tissues. Survivin expression in normal tissues is 
developmentally regulated and the protein was found to be absent or low in 
most terminally differentiated tissues [Ambrosini et al, 1997]. However, recent 
studies tend to attribute a role to survivin in regulating the function of normal 
adult cells [Fukuda et al, 2006] including vascular endothelial cells [Mesri et 
al, 2001], polymorphonuclear cells [Altznauer et al, 2004], T cells [Xing et al, 
2004], erythroid cells [Gurbuxani et al, 2005], and haematopoietic progenitor 
cells [Fukuda & Pelus, 2001]. Moreover, survivin expression was reported in 
adult liver cells [Deguki et al, 2002], gastrointestinal tract mucosa [Chiou et al,
2003] and ovarian granulosa cells [Wang et al, 2004]. However, although 
survivin is expressed in normal tissues characterized by self-renewal and 
proliferation, its expression is significantly lower than in transformed cells. In 
fact, several studies have demonstrated strong survivin expression in most 
human solid tumour types and haematologic malignancies [Altieri, 2003]. 
Expression of survivin has also been detected in a variety of benign and 
preneoplastic lesions including polyps of the colon, breast adenomas, 
Bowen’s disease and hypertrophic actinic keratosis [Altieri, 2003], suggesting 
that re-expression of survivin may occur early during malignant transformation 
or following a disturbance in the balance between cell proliferation and cell 
death. The up-regulation of survivin at the transcriptional level in human 
tumours has been confirmed in genomewide searches, which indicated 
survivin as the fourth top ‘transcriptome’ in cancers of various histology
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[Velculescu et al, 1999]. Moreover, global deregulation of the survivin gene 
mediated by oncogenes such as STAT3 [Gritsko et al, 2006], E2F [Jiang et al,
2004], and activated H-Ras [Sommer et al, 2003; Fukuda & Pelus, 2004], or 
by loss of tumour suppressors like wild type p53 [Hoffman et al, 2002] or the 
adenomatous polyposis coli protein [Zhang et al, 2001], seems to be 
responsible for the enhanced expression of survivin in tumours.
Growing evidence suggests that survivin expression in cancer cells is 
associated with clinicopathologic variables of aggressive disease and may 
represent an important prognostic marker for patient outcome. In fact, several 
studies on different types of solid tumours and haematologic malignancies 
showed that high levels of the protein were predictive of tumour progression in 
terms of either disease-free or overall survival [Altieri, 2003]. In several 
neoplasms the association with tumour progression was corroborated in the 
context of a comprehensive analysis of gene-expression profiling by DNA 
microarray or PCR-based assay. As it is possible to immunohistochemically 
distinguish two intracellular pools of survivin, a nuclear and a cytosolic one, 
the prognostic significance of the protein has been analyzed in some studies 
as a function of its intracellular localization, and inconsistent and sometimes 
contrasting results have been obtained regarding the prognostic value of 
nuclear survivin expression [Fengzhi et al, 2005]. The different prognostic 
value of survivin may reflect differences in methods to detect its expression 
and/or a differential expression of survivin splice variants.
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2.6. Survivin as a Determinant of Treatment Resistance
Considering that apoptosis is the primary mode of cell death induced by 
several classes of chemical and physical agents commonly used in cancer 
therapy, it has been hypothesized that survivin expression/up-regulation 
could be crucial in determining the chemo- and radio-sensitivity profiles of 
tumour cells. This possibility is supported by several experimental evidences 
demonstrating that survivin is able to counteract a broad range of different 
apoptotic stimuli.
Giodini et al [2002] first reported that infection of HeLa cells with an 
adenoviral vector expressing survivin suppressed apoptosis induced by taxol. 
Successively, studies performed on human ovarian carcinoma cell lines and 
clinical specimens clearly indicated that survivin is involved in regulating cell 
sensitivity to taxanes. Specifically, the OAW42 and IGROV-1 human ovarian 
cancer cell lines were transfected with the human survivin cDNA. Stable 
transfection with survivin cDNA was able to protect these cells from the 
cytotoxic effects induced by paclitaxel and taxotere, with IC5o values for the 
survivin-transfectant cell populations 4-6-fold those of the control cells 
[Zaffaroni et al, 2002]. Zhang et al [2005] showed that forced expression of 
wild type survivin in human prostate cancer cell lines increased the 
resistance to taxol in vitro and in vivo. In addition, in the clinical setting, in 
advanced ovarian cancer patients receiving a paclitaxel+platinum-based 
regimen, the overexpression of the anti-apoptotic protein correlated with a 
lower clinical or pathologic complete remission rate (with respect of those
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treated patients where survivin expression was found to be low or absent) 
[Zaffaroni et al, 2002].
It has been reported that taxol-induced microtubule stabilization and 
mitotic arrest increase the expression of survivin, which engenders a cell 
survival pathway to counteract taxol-induced apoptosis [O’Connor et al,
2002]. Interestingly, using a taxol-resistant ovarian cancer cell clone, PTX10, 
with a (3-tubulin mutation at the taxol binding site, Zhou et al [2004] found that 
taxol treatment failed to induce mitotic arrest and survivin expression. 
However, the finding that taxol induced an apoptotic response in these cells 
suggests that mitotic arrest is not strictly required for taxol-induced apoptosis. 
It is also possible that the mitotic survival pathway is not the only one by 
which cancer cells counteract taxol-induced apoptosis. In fact, Ling et al 
[2004] reported that induction of survivin by taxol in MCF-7 cells is an early 
event and is independent of taxol-mediated G2/M arrest, suggesting a role for 
survivin in taxol resistance not only during mitosis but outside of the mitotic 
checkpoint as well. There is evidence that the mTOR pathway, which 
constitutes a sensor network for stress conditions, is involved in resistance to 
paclitaxel by increasing survivin levels [Vaira et al, 2006]. In fact, it has been 
recently reported that IGF-1-mediated mTOR activation in prostate cancer 
cells positively modulated survivin levels by favoring stabilization and 
translation of a survivin mRNA pool, and that mTOR inhibition with 
rapamycin, alone or in combination with paclitaxel, abolished survivin 
increase. Consistent with a critical reduction of the anti- apoptotic threshold 
maintained by survivin, the paclitaxel plus rapamycin combination was more
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effective than either treatment in reducing cell viability of in the presence of 
IGF-1 [Vaira et al, 2006].
An increase in survivin expression has also been reported in prostate 
cancer [Nomura et al, 2005] and thyroid cancer [Tirro et al, 2006] cell lines 
permanently resistant to cisplatin as well as in colorectal cancer cells 
resistant to TRAIL [van Geelen et al, 2004]. Zhang et al [2005] showed that 
survivin mediates resistance to anti-androgen therapy with flutamide in 
prostate cancer cells. Specifically, these authors suggested that up- 
regulation of survivin via insulin-like growth factor-1/AKT signaling during 
androgen blockade may be one of the mechanisms by which prostate cancer 
cells develop resistance to anti-androgens. Paik et al [2004] showed that 
survivin was one of the sixteen genes predictive of recurrence in tamoxifen- 
treated breast cancer patients.
Regarding the role of survivin in determining the response of human 
tumour cells to radiation, Asanuma et al [2000] first reported that survivin acts 
as a constitutive radio-resistance factor in pancreatic cancer cells. 
Specifically, in a panel of established cell lines they found an inverse 
relationship between survivin mRNA expression and in vitro sensitivity to X- 
irradiation. Moreover, they demonstrated that survivin mRNA expression was 
increased by sublethal doses of X-irradiation, which would suggest that the 
protein also acts as an inducible radioresistance factor. Rodel et al [2003] 
also showed an inverse correlation between survivin expression and 
apoptotic response to irradiation in a panel of colorectal carcinoma cell lines. 
More recently, in a translational study of 59 rectal cancer patients treated 
with a combination of radiotherapy and chemotherapy, the same authors
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reported that increased survivin expression was associated with a 
significantly increased risk of local tumour recurrence [Rodel et al, 2005]. It is 
worthy of note that survivin can contribute to radiation resistance also by 
promoting the survival of tumour vascular endothelial cells. In fact, induction 
of vascular endothelial apoptosis was recently shown to be a major 
determinant of overall tumour response to radiotherapy [Garcia-Barros et al,
2003]. Radiation may induce tumour cells to secrete cytokines such as 
vascular endothelial growth factor, which in turn could inhibit radiation- 
induced apoptosis of vascular endothelial cells by up-regulating survivin 
expression, as already demonstrated for drug-induced apoptosis 
[Tran etal, 2002].
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3 . S u r v iv in -D ir e c t e d  C a n c e r  T h e r a p y
In recent years considerable efforts have been made to validate survivin 
as a new target in cancer therapy. In this context, a collection of different 
approaches to counteract survivin in tumour cells, including antisense 
oligonucleotides, ribozymes, small interfering RNAs (siRNAs) and dominant- 
negative mutants, as well as cyclin-dependent kinase inhibitors, have been 
proposed with the dual aim to inhibit tumour growth potential and to enhance 
tumour cell response to apoptosis-inducing anticancer agents (Figure 13).
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Figure 13. Summary of the current strategies for survivin targeting in 
cancer therapy.
A, Molecular antagonists able to target survivin mRNA and inhibit translation;
B, Dominant negative mutants able to inhibit survivin dimerization or survivin 
activation; C, Small molecule antagonists able to inhibit survivin 
phosphorylation on Thr34 residue (CDK inhibitors) or to counteract survivin- 
Hsp90 interaction (Hsp90 inhibitors). In B and C, the wild type protein is 
reported in its dimeric arrangement [Muchmore et al, 2000].
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3.1. Molecular Antagonists
A number of technologies have been used in an attempt to down-regulate 
gene expression. At present, there are three well documented genetic 
approaches being pursued to affect the ablation of defective gene production 
(Figure 14).
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Figure 14. Schematic representation of the most exploited antisense 
approaches.
Antisense oligonucleotides block translation (occupancy mechanism) (1) or 
induce the degradation (RNase H-meduated mechanism) (2) of the mRNA. 
Catalytic nucleic acids (ribozymes and DNA enzyme) lead to mRNA 
degradation through a cleavage mechanism. siRNA, the effectors 
molecules of the RNA interference pathway after being recruited into RISC 
complex induce degradation of the target mRNA [Adapted from Kurreck 
et al, 2003],
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The use of antisense RNA or deoxyoligonucleotides [Milligan et al, 1993; 
Crook & Bennet, 1996; Pan & Clawson, 2006], serve primarily to block gene 
expression by interfering with RNA translation. Ribozyme and DNA enzyme 
are catalytically active oligonucleotides that not only bind, but can also 
cleave, their target RNA in a highly sequence-specific manner [Sun et al, 
1997; Welch et al, 1998; Rossi, 1999]. In recent years, considerable progress 
has been made through the development of novel chemical modifications to 
stabilize oligonucleotides against nucleolytic degradation and enhance their 
target affinity. In addition, RNA interference has been established as a third, 
highly efficient method of suppressing gene expression in mammalian cells 
by the use of 21-23-mer small interfering RNA (siRNA) molecules [Elbashir 
et al, 2001].
3.1.1. Antisense Oligonucleotides
Among the anticancer approaches, antisense-based strategies, first 
developed as a powerful means for target validation, represent a useful tool 
to inhibit specific gene expression for therapeutic purposes [Kurreck, 2003]. 
In fact, several antisense oligonucleotides (AS-ONs) are being tested in 
clinical trials on patients with cancer or other diseases [Dean & Bennet, 2003; 
Kureck, 2003]. Antisense oligomers are nucleic acid-related molecules that 
target a given RNA within cells in a sequence-specific manner, through 
Watson-Crick base pairing. The modality of action of AS-ONs can be 
distinguished in two main mechanisms (Figure 15).
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Figure 15. Mechanisms of action of antisense oligonucleotides.
A, RNase H cleavage induced by antisense oligonucleotides;
B, Translational arrest by blocking the ribosome. [Adapted from
Kurreck et al, 2003].
The modality of action defined as cleavage mechanism leads to 
degradation of the RNA target through the oligomer-mediated recruitment of 
RNase H (a family of ubiquitously expressed enzymes that cleaves the RNA 
strand of an RNA/DNA heteroduplex) or RNase L. Conversely, the modality 
of action, defined as a non-RNA-cleaving mechanism, is based on a steric 
block of RNA transcription/translation mediated by oligonucleotides that do 
not recruit endonucleases, such as peptide nucleic acids (PNAs) and 2’-alkyl 
oligomers (i.e. occupancy mediated mechanism) [Crooke, 1999].
One of the major challenges for antisense approaches is the stabilization 
of oligonucleotides, which as unmodified oligodeoxynucleotides are rapidly 
degraded in biological fluids by nucleases. A vast number of chemically
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modified nucleotides have been used in antisense experiments. In general, 
three types of modifications of ribonucleotides can be distinguished 
(Figure 16): analogs with unnatural bases, modified sugars (especially at the 
2’ position of the ribose) or altered phosphate backbones. A variety of 
heterocyclic modifications have been described, which can be introduced into 
AS-ONs to strengthen base-pairing and thus stabilize the duplex between 
AS-ONs and their target mRNAs.
B -M :  Base
Phosphate _  ^ I ^—►  0 = P  — O
Ribose 
(2’OH group)
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Figure 16. Sites for chemical modifications of ribonucleotides.
Three types of modifications of ribonucleotides can be 
distinguished: analogs with unnatural bases (B), modified sugars or 
altered phosphate backbones. [Adapted from Kurreck et al, 2003].
Phosphorothioate oligodeoxynucleotides (PTO) are the major 
representatives of first generation DNA analogs, which are widely employed 
in clinical trials [Crooke, 1999] (Figure 17). In the PTO molecule, one of the 
nonbridging oxygen atoms of the phosphodiester linkage is replaced by a 
sulfur atom, which enhances resistance to nuclease action. The mechanism 
of action of these oligomers relies on RNase H activation. The major 
disadvantage of PTO is their binding to certain proteins, particularly those 
that interact with polyanions such as heparin-binding proteins [Brown et al,
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1994; Rockwell et al, 1998]. The reason for this nonspecific interaction is not 
yet fully understood, but it may cause cellular toxicity [Levin, 1999] and 
reduce their therapeutic index [Pirollo et al, 2003].
First generation
W
? H 0 =  p —S'
IoV
N
Phosphorothioate
Second generation
H
? ? 
o = P—O' ch 3
I
o
2’-0-methyl RNA
t o 10 o
o =  p - o  0 -C H 3
1o
2’-0-methoxy-ethyl RNA
Third qenetation
D
VU L
Peptide nucleic acid
01
0 = p-0 
1oN
\
Locked nucleic acid
Figure 17. Example of the antisense oligonucleotides chemically modified.
‘B’ denotes one of the base adenine, guanine, cytosine or thymine.
The problems associated with PTO are to some degree solved in second 
generation oligonucleotides containing nucleotides with alkyl modifications at
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the 2’ position of the ribose. 2’-0-methyl and 2’-0-methoxy-ethyl RNA 
(Figure 17) are the most important members of this class. Such oligomers 
are less toxic than PTO and possess enhanced stability and binding affinity 
to the target with respect to their analogous RNA or DNA counterparts. 
However, 2’-0-alkyl oligomers do not activate RNase H to induce the 
cleavage of the target RNA, and their antisense effect is a consequence of 
the occupancy-mediated mechanism [Crooke, 1999; Dean & Bennet, 2003; 
Kureck, 2003] (Figure 15).
In recent years a variety of modified nucleotides have been developed to 
improve properties such as target affinity, nuclease resistance and 
pharmacokinetics. Peptide nucleic acids (PNAs) belong to the third 
generation of antisense oligonucleotides and are the most intensively studied 
DNA analogs [Kurreck, 2003]. In PNAs, the phosphate backbone is replaced 
by a pseudopetide linkage composed of N-(2-aminoethyl) glycine units 
(Figure 17). The uncharged nature of the PNA internucleotide backbone 
increases the stability of the PNA/nucleic acid duplex and affords greater 
resistance to protease and nuclease than unmodified ODNs [Gambari, 2001] 
but does not lead to degradation of the RNA target by recruiting RNase H. 
The Watson-Crick base-pairing rules are strictly observed in hybrids of PNA 
and nucleic acids [Egholm et al, 1993; Smulevitch et al, 1996; Gambari,
2001]. Moreover, PNAs are better at discriminating between base-pair 
mismatches [Egholm et al, 1993; Gambari, 2001] and are less likely to bind 
to proteins through non-sequence-specific interactions than PTOs. The lack 
of electrostatic repulsion between the two strands in a PNA/nucleic acid 
duplex also leaves the melting temperature largely independent of the salt
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concentration. Their favourable properties have led to the use of PNAs for 
different applications in oncology. A number of experiments with 
permeabilised cells, isolated nuclei and also intact cells has demonstrated 
the potential of PNA in antigene or antisense applications to down-regulate 
the transcription or translation of cancer-related genes. PNA invasion of the 
DNA double helix to form a stable PNA-DNA hybrid was found to effectively 
block gene transcription [Ray & Norden, 2000; Knauert & Glazer, 2001; 
Pooga et al, 2001]. The N3’-P5’ phosphoroamidates (NPs) are another 
example of a modified phosphate backbone, in which the 3’-OH group of the 
sugar residue is replaced by a 3’-NH group [Kurreck, 2003] (Figure 17). Such 
a modification confers to the oligonucleotide high binding affinity to the target 
RNA and a greater nuclease resistance. One of the most promising 
candidates of chemically modified nucleotides developed in the last few 
years is locked nucleic acid (LNA), a ribonucleotide containing a methylene 
bridge that connects the 2’-oxygen of the ribose with the 4’-carbon [Braasch 
& Corey, 2001; Vester B & Wengel J, 2004; Karkare S & Bhatnagar, 2006] 
(Figure 17). Introduction of LNA into a DNA oligonucleotide induces a 
conformational change of the DNA/RNA duplex towards the A-type helix 
[Bondensgaard et al, 2000] and therefore prevents RNase H cleavage of the 
target RNA.
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3.1.1.1. Cellular Uptake of Antisense Oligonucleotides
An important hurdle for successful antisense applications is the cellular 
uptake of the molecules. In cultured cells, internalization of naked DNA is 
usually inefficient, due to the charged oligonucleotides having to cross a 
hydrophobic cell membrane. A number of methods have therefore been 
developed for in vitro and in vivo delivery of oligonucleotides [Huges et al, 
2001; Liang et al, 2002]. By far the most commonly and successfully used 
delivery systems are liposomes and charged lipids, which can either 
encapsulate nucleic acids within their aqueous center or form lipid-nucleic 
acid complexes as a result of opposing charges (Figure 18). These 
complexes are usually internalized by endocytosis. For efficient release of 
the ONs from the endosomal compartment, many transfection reagents 
contain helper lipids that disrupt the endosomal membrane and help to set 
the oligonucleotides free. A number of macromolar delivery systems have 
been developed recently that mediate a highly efficient cellular uptake and 
protect the bound oligonucleotides against degradation in biological fluids.
Further polymers for the delivery of AS-ONs consist of amino acids or 
sugars. Evidence has been provided, however, that the structural properties 
of a peptide conjugated to an oligonucleotide do not significantly alter its 
ability to cross mammalian plasma membranes [Oehlke et al, 2002]. 
Therefore, aspects other than improved translocation across the membrane 
are likely to be responsible for enhanced biological activity of peptide- 
oligonucleotide derivatives.
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Another strategy for effective targeting of AS-ONs to specific tissues or 
organs is receptor-mediated endocytosis. For this purpose, oligonucleotides 
are conjugated to antibodies or ligands that are specifically recognized by a 
certain receptor, which mediates their uptake into target cells. For example, 
coupling of a radioactively labelled PNA to a transferrin receptor monoclonal 
antibody made the antisense agent transportable through the blood-brain 
barrier [Shi et al, 2000].
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Figure 18. The method of entry of DNA-polymer complexes.
DNA and polymer are mixed to form complexes that are overlaid onto a monolayer 
of cells. Uptake occurs by endocytosis. The mechanism of release from the 
endosome still remain unclear. Transport to the nucleus occurs by active transport 
through the nuclear pore complex and represents the major barrier for the efficient 
uptake of foreign DNA. [Adapted from Parker et al, 2003]
3.1.1.2. Survivin Inhibition by Antisense Oligonucleotides
The use of antisense to ablate expression of endogenous survivin mRNA 
and protein has consistently shown promising results in several independent 
studies (Figure 13A).
76
Chapter 1 Intro du ctio n
Grossman et al [1999] first demonstrated that transfection of survivin 
antisense triggered spontaneous apoptosis in the absence of other stimuli in 
YUSAC2 and LOX human melanoma cell lines. Successively, several studies 
dealing with the use of survivin antisense oligonucleotides, delivered to the 
cells as chemically synthesized molecules or through the use of expression 
vectors, consistently showed that specific inhibition of survivin mRNA and 
protein could reduce cell proliferation and induce caspase-dependent 
apoptosis in established cell lines of different tumour origins including lung, 
bladder, head and neck, and thyroid cancers, sarcomas and lymphomas 
[Ansell et al, 2004; Cao et al, 2004; Fuessel et al, 2004; Sharma et al, 2005; 
Du etal, 2006]. Moreover, down-regulation of survivin was shown to sensitise 
human tumour cells to cytotoxic drugs such as etoposide and cisplatin 
[Sharma et al, 2005], as well as ionizing radiation [Sah et al, 2006]. 
Antisense-mediated survivin knockdown also caused inhibition of tumour 
growth in xenograft models [Ansell et al, 2004; Cao et al, 2004] and 
sensitised lung cancer xenografts to radiotherapy [Cao et al, 2004]. Kanwar 
et al [2001] demonstrated that survivin inhibition resulted in increased 
sensitivity to immunotherapy in murine EL-4 thymic lymphoma. Specifically, 
tumours injected with plasmids encoding survivin antisense were significantly 
inhibited in their growth. Such growth delay was further enhanced by 
concomitant injection of the T-cell costimulator B7-1.
Supported by a favorable safety profile, the first antisense oligonucleotide, 
LY2181308 (ISIS 23722, Lilly and Co, and ISIS Pharmaceuticals Inc), 
already entered the clinic and is currently undergoing phase I trials in patients 
with advanced cancers.
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3.1.2. Ribozymes & siRNAs
3.1.2.1. Ribozymes
Ribozymes are small RNA molecules that possess specific 
endonucleolytic activity and catalyze the hydrolysis of specific 
phosphodiester bonds, resulting in cleavage of RNA target sequences 
[Puerta-Fernandez et al, 2003]. In nature, existing catalytic RNAs include 
hammerhead, hairpin, hepatitis delta virus (HDV) and Varkud Satellite (VS) 
RNA, group I and group II introns [Khan & Lai, 2003] and the RNA subunit of 
RNase P [Khan & Lai, 2003]. In addition, recent structural and chemical 
analyses strongly suggest that ribosomal RNA is an enzyme [Cech, 2000]. 
Similarly, there is evidence that the RNA component of the spliceosome may 
also have enzymatic properties [Collins & Saville, 1990].
The discovery of ribozymes and fundamental studies on the mechanisms 
of self-splicing have revealed details on the catalytic core and the secondary 
and tertiary structure of RNA folding leading to ribozyme-mediated cleavage 
of RNA. Ribozymes were initially believed to be metalloenzymes requiring 
divalent metal ions for catalysis and it was thought that all ribozymes operate 
through a similar mechanism of action. However, a unique RNA hairpin was 
shown to behave like a ribozyme in the absence of divalent metal ions 
[Earnshaw & Gait, 1998; Murray et al, 1998; Burke, 2002].
The specificity of the cleavage is determined by Watson-Crick base- 
pairing between ribozymes and nucleotides near the cleavage site of the 
target RNA. By altering substrate recognition sequences, several
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intramolecular cis-cleaving ribozymes can be designed to cleave any RNA in 
trans. Theoretically, these trans-cleaving ribozymes can be designed to 
cleave any RNA species in a sequence-specific manner by incorporating the 
flanking sequences complementary to the target. After the cleavage reaction, 
the substrate is accessible to ribonucleases, a step that guarantees its 
permanent inactivation and offers a considerable advantage over the simple 
physical blockage obtained with complementary oligodeoxynucleotides.
Ribozymes are grouped into two classes on the basis of their size: the 
large and the small ribozymes. The large group contains group I and II 
introns, and the RNA subunit of RNase P. Group I and II introns are found in 
bacteria and in the organelles of higher plants, fungi and algae [Lai & Hall, 
1997; Khan et al, 2000; Woodson, 2002]. These introns are spliced out of 
their hnRNA by a two-step mechanism. In the first step of splicing, the 5’- 
spliced site is attacked by the 3’-OH of the external guanosine group 
(group I). Whereas, in group II intron it is attacked by the 2’-OH of the internal 
adenosine residue or by a hydroxide ion. In the second step, the 3’-OH of the 
3’-end of the upstream exon attacks the 3’-spliced site to produce the splicing 
products. RNase P is an endonuclease that generates the mature 5’-ends of 
tRNAs. In bacterial RNase P, the RNA subunit (RNase P ribozyme) has 
catalytic activity and the protein component is thought to act only to facilitate 
the binding of the anionic RNase P ribozyme to its substrate. During the 
cleavage of RNase P ribozyme, a scissile-site phosphate is attacked by a 
hydroxide ion to leave a 3’-oxygen and produce a 5’-phosphate terminus 
[Chen etal, 1994; Kirsebom, 2001].
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The class of small ribozymes comprises hammerhead, HDV (hepatitis 
delta-viroid) hairpin and VS ribozymes. Each of the naturally existing 
ribozymes catalyse the endonucleolytic cleavage of RNA via a mechanism 
that involves nucleophilic attack by a 2’-OH group on the phosphorus of the 
neighbouring phosphodiester bond, generating 5’-OH and 2’,3’-cyclic 
phosphate termini. The cleavage reaction catalysed by these ribozymes 
appears to proceed with the inversion of the configuration at the phosphorus 
atom, suggesting a direct in-link attack with development of a 
pentacoordinate transition or intermediate state [Stage-Zimmermann & 
Uhlenbeck, 1998].
The smallest of the naturally occurring catalytic RNAs that were identified 
to date are the hammerhead ribozymes (Figure 19), which were found in 
several plant virus satellite RNAs, viroids and as transcripts of a nuclear 
satellite DNA (a riboprotein particle of about 12 S in oocytes of Triturus) 
[Foster & Sympson, 1987].
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Figure 19. Structure of a hammerhead ribozyme.
The hammerhead ribozyme consists of a highly conserved 
catalytic core, which cleaves substrate RNA at NHH triplets 3’ 
to the second H, where N is any nucleotide and H is any 
nucleotide but guanidine. [Adapted from Sun et al, 2000]
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A large number of studies have been performed to provide a better 
understanding of the mechanism of ribozyme-mediated catalysis. In general, 
a minimal kinetic description for one turnover of hammerhead ribozyme 
reaction (Figure 20) involves assembly of ribozyme and substrate, cleavage 
of the phosphodiester bond, generating a product with a cyclic phosphate 
terminus and a product with a hydroxyl terminus that remains bound to the 
ribozyme, and release of the products. A Michaelis-Menten mechanism has 
been established by using multiple- and single-turnover conditions for the 
formation of the ribozyme-substrate complex and its subsequent conversion 
to products [Perreault et al, 1990; Hammann C & Lilley, 2002]. Under 
multiple-turnover conditions, the substrate is in excess of the ribozyme so 
that the ribozyme can catalyse the cleavage of several substrate molecules. 
The catalytic rate constant, kcat, is a measure of the rate-limiting step, which 
can be cleavage, conformational transitions of the ribozyme-substrate 
complex, or product release. When a ribozyme with six bases in each arm 
was used in kinetic analysis, kcat and Km were within typical values of 1-2 
min-1 and 20-200 nM, respectively. Extension of the helical arms generally 
results in an increased stability and markedly decreased kcat [Hertel et al, 
1994]. Under single-turnover conditions, the ribozyme is in excess of the 
substrate, and such conditions are normally used for cleavage of long mRNA 
substrate. Cleavage rates are generally several orders of magnitude lower, 
compared with the rates obtained for short substrate [Heidenreich et al, 
1994]. The presence of Mg2+ is essential for the cleavage, and convincing 
evidence suggested that Mg2+ not only assists in RNA folding but also 
participates directly in the cleavage mechanism [Dahm & Uhlenbeck, 1991].
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The hammerhead ribozyme consists of a highly conserved catalytic core, 
which cleaves substrate RNA at NHH triplets 3’ to the second H, where N is 
any nucleotide and H is any nucleotide but guanidine [Kore et al, 1998] 
(Figure 19). One assumption is that the inability to cleave 3’ of G is due to an 
unfavourable interaction with C3 in the core [Baidya & Uhlenbeck, 1997; Blount 
KF & Uhlenbeck, 2005]. NMR studies have confirmed that this base pair exists 
and that it stabilizes the ground state ribozyme-substrate complex [Simmore 
et al, 1998]. However, an additional contribution to the lack of cleavage comes 
from destabilizing the transition state. Various pyrimidine nucleoside analogues 
have been used as H [Baidya et al, 1997]. Although all such modifications had 
no effect on binding of the substrates to the ribozyme, cleavage occurred 
more slowly than when H was cytidine. Comparative studies revealed that the 
reaction rate (kcat) decreases in the following order: AUC, GUC>GUA, AUA, 
CUC>AUU, UUC, UUA>GUU, CUA>UUU, CUU. This indicates that functional 
groups at the cleavage site are important for transition state formation.
In addition to the catalytic core, a particular cleavage site in a target RNA 
can be specifically recognized by creating, in the hammerhead ribozyme 
recognition arms, flanking sequences complementary to specific target RNA 
molecules.
It has been demonstrated the possibility to prepare ribozyme libraries that 
are targeted to multiple mRNA substrates by randomizing the sequences of 
the recognition arms. Such libraries can be used as knock down libraries to 
interfere with the activities of several gene products. Ribozymes can be 
screened and target genes that appear responsible for a particular phenotype 
can be identified by introducing a ribozyme library into cells. Isolation of cells
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with the phenotype of interest allows the rescue of the ribozyme of interest. 
Moreover, the examination of DNA database allows rapid identification of the 
gene responsible for the phenotype of interest using the sequence of the 
rescued ribozyme. Such a methodology has been recently used to identify 
genes involved in cell migration and invasion, two processes that are 
essential features of tumour metastasis [Suyama et al, 2003a; Suyama
et al, 2003b],
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Figure 20. Schematic representation of the catalytic cycle for a hammerhead 
ribozyme.
The ribozyme binds through the flanking arms to its RNA substrate, via Watson-Crick 
interactions (1). Once the ribozyme-substrate complex has formed, the cleavage 
reaction mediated by the catalytic domain of the enzyme leads to cleavage of the 
phosphorodiester linkage located at the 3’ end of a NHH consensus sequence (2). 
Release of the products make the ribozyme available for another cycle of the 
reaction (3). [Adapted from Zaffaroni & Folini, 2004]
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Owing to their ability to efficiently inhibit specific gene expression, 
ribozymes have been used to validate a number of disease-related (mainly 
cancer-related) genes as potential targets for new therapeutic interventions.
3.1.2.2. Small Interfering RNA (siRNAs)
RNA interference (RNAi) is a natural mechanism of sequence-specific, 
post-transcriptional gene silencing. RNAi may play an important role in 
protecting the genome against instability caused by transposons and 
repetitive sequences, and it represents an evolutionary conserved anti-viral 
defense pathway in animals and plants [Elbashir et al, 2002]. Moreover, 
RNAi has emerged as a powerful mechanism for sequence-specific 
modulation of gene expression and seems to provide a higher potency than 
conventional antisense strategies, presumably because it relies on natural 
site-directed cleavage machinery [Elbashir et al, 2002].
In mammalian cells RNAi can be triggered by several double-stranded 
RNAs (dsRNA) or dsRNA domain-containing molecules. Endogenously 
expressed dsRNA domains are converted into the nucleus by specific 
ribonucleases in the form of precursors that are successively processed in 
the cytoplasm to give rise to micro RNAs (miRNAs). The miRNAs are 
believed to bind to sites that have partial sequence complementarity in the 3' 
untranslated region of their target mRNA, causing repression of translation 
and inhibition of protein synthesis [Dykxhoorn et al, 2003; Izquierdo et al,
2005]. By contrast, exogenously-introduced dsRNA (e.g. viral genome) are
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processed in the cytoplasm by the endoribonuclease Dicer into small duplex 
RNAs, the 21-23 nucleotide-long terminal effectors molecule, known as small 
interfering RNAs (siRNA), characterized by a 2-3 nucleotide overhang at the 
3’ terminus [Dykxhoorn et al, 2003; Izquierdo et al, 2005] (Figure 21).
dsRNA
Dicer
Dicer
siRNA 
(21-23 mer)
RISC
RISC-siRNA j 
complex ^
Recycling
mRNA /
mRNA cleavage
Figure 21. Gene silencing by RNAi.
When dsRNA enters the cell, it is recognised by the 
enzyme complex Dicer and cleaved to yield siRNA. 
The siRNAs then bind to a multiprotein complex to 
form the RISC. Activation of the RISC is 
accompanied by the unwinding of the siRNA duplex, 
and one strand of the siRNA then guides RISC to 
cleave the target mRNA.
The resulting siRNAs are then assembled to form an RNA/protein 
complex, referred to as the RNA-induced silencing complex (RISC)
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(Figure 21). The double-stranded siRNA is then unwound, leaving the 
antisense strand to guide RISC to its homologous target mRNA for 
endonucleolytic cleavage. The target mRNA is cleaved in the centre of the 
duplex region arising from the annealing of the antisense strand of siRNA 
and the target mRNA, a process that ultimately results in the target 
degradation.
Different effectors molecules have been identified as inductors of gene 
expression silencing in mammalian cells through the activation of the RNAi 
pathway. Specifically, short hairpin RNAs (shRNAs) are transcribed from 
plasmid- or viral-based vectors as a pre-siRNA in which the sense and 
antisense strands are linked by a short spacer. The pre-siRNA is then 
predicted to form a 19-nucleotide-long stem-loop structure, the terminal 
effectors shRNA. Short hairpin RNAs are usually coded downstream of an 
RNA polymerase III promoter (e.g. U6 small nucleolar RNA or human RNase 
H1 promoters) although the use of inducible or tissue-specific RNA 
polymerase II promoters has been described [Dykxhoorn et al, 2003; 
Izquierdo et al, 2005]. By contrast, pre-synthesized siRNA are RNA duplexes 
formed by two complementary single strands. In this case, a siRNA may be 
obtained by the annealing of two in vitro transcribed 21-nucleotide-long single 
strands leaving two nucleotides unpaired at the 3’ terminus [Dykxhoorn 
et al, 2003; Izquierdo et al, 2005] or as preformed duplexes, usually provided 
by specialized companies.
To date the siRNA technology has been validated in several mammalian 
experimental models but its therapeutic usefulness for human diseases is still 
under intensive investigation. In fact, although the effect of siRNAs on gene
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expression has been demonstrated to be rapid and persistent (days/weeks), 
the main limitation to be overcome before such technology will be exploited in 
the clinical practice is represented by the selectivity for the target RNA, 
delivery and stability inside cells, similarly to ribozyme- and antisense-based 
approaches.
3.1.2.3. Ribozyme & siRNA Delivery Systems
The most challenging aspect of the use of ribozymes and siRNAs for 
therapeutic purposes is delivering these molecules to their site of action, the 
RNA target located within the cytoplasm or nucleus. Delivery requires that 
the oligonucleotide survive local or systemic administration long enough to 
bind to the target cells, cross the cytoplasmic membrane or become released 
from an endosomal/lysosomal vesicle, pass through the nuclear membrane, 
and be able to functionally hybridise to the target RNA.
There are two approaches to deliver ribozymes and siRNAs to cells for the 
successful inhibition of gene expression. One is exogenous delivery where 
the presynthesised molecules are delivered directly to cells. The other is 
endogenous delivery, which provides the gene encoding the ribozyme and 
siRNA, as part of a vector, to the cells where transcription generates the 
ribozyme and siRNA.
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3.1.2.3.1. Exogenous Delivery
Exogenous delivery, at first glance, looks simple, straightforward and attractive. 
Presynthesised ribozymes can be delivered directly to cells or administered to 
an animal. This mode of application is identical to that of the antisense 
oligonucleotides method. Given the amount of accumulated experience, it is not 
surprising that most of the delivery techniques used in the ribozyme field are 
adopted from the AS-ODN strategy. Exogenous delivery requires stabilization of 
oligonucleotides against nuclease degradation. This is particularly true for 
ribozymes, which are rapidly degraded by RNases. AS-ODNs are customarily 
protected by incorporation of phosphorothioates, but ribozymes demand 
modification of the 2-OH group, which the RNases also require for cleavage. 
Stabilization should not compromise catalytic activity of the ribozyme, thus the 
choice of derivative and its placement are crucial. In general, poor uptake is a 
challenge for exogenous delivery of ribozymes to cells in culture. Significant 
improvement can be achieved with the help of carrier such as cationic 
liposomes.
Chemically synthesized or in vitro transcribed siRNAs are probably the 
most easy and direct approach to induce RNA interference in mammalian 
cells. 21-nucelotide RNAs specific to the mRNA target are synthesized and 
annealed in vitro by heating to 90°C followed by slow cooling to 37°C. Such 
RNA duplexes are transfected into cells by generating liposomes incubated 
with cationic lipids, electroporation, covalent binding to hydrophobic carrier 
molecules or covalent coupling to cell penetrating peptides [Wadhwa 
et al, 2004]. The defence interferon system against viruses, however, is very
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sensitive to the presence of double-stranded RNA, and under certain 
conditions, siRNA can activate the interferon system complicating the 
interpretation of the experiments. The removal of the 5’-triphosphate end 
when siRNA is synthesized in vitro using phage T7 RNA polymerase, instead 
of chemical methods, is important to avoid the interferon response in 
mammalian cells [Izquierdo et al, 2005]. High doses should also be avoided 
because they will again induce interferon in vivo and in some instances may 
cause unexpected and divergent changes in the levels of untargeted proteins 
[Izquierdo et al, 2005].
3.1.2.3.2. Endogenous Delivery
The search for ways to introduce genes into cancer cells led to significant 
improvements in viral and nonviral vector development (Table II).
3.1.2.3.2.1. Viral Delivery
A number of viral delivery systems are available for gene delivery of DNA 
or oligonucleotides into mammalian cells, either in vitro or in vivo (Table II). 
The most common vector systems are based on retroviruses, adeno- 
associated virus (AAV), adenovirus, and herpes simplex virus (HSV) [Boulaiz 
et al, 2005; Tan et al, 2006]. Other viral vectors are based on lentiviruses, 
human citomegalovirus (CMV), Epstein-Barr virus (EBV), poxviruses, 
negative-strand RNA viruses (influenza virus), alphaviruses, and herpesvirus
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saimiri [Boulaiz et al, 2005; Tan et al, 2006]. Moreover extremely interesting 
appears the construction of a hybrid adenoviral/retroviral vector, which has 
successfully been used for in vivo gene transduction [Barquiner et al, 2004; 
Ghosh et al, 2004; Warrington & Herzog, 2006].
Table II. Description of the main gene delivery systems.
Vectors Characteristics Disadvantages
V i r a l  D e l i v e r y
Retroviruses Relatively high titers (106-107 
cfu/ml)
Broad cell tropism 
Stable gene expression 
No toxic effect on infected 
cells
Total insert capacity in the 
virion in the range of 10 kb 
Only infection of dividing 
cells
Random insertion of viral 
genome, which may possibly 
result in mutagenesis
Possibility of replication virus 
formation by homologous 
recombination
Lentiviruses Infection of nondividing cells 
Broad cell tropism 
Stable gene expression 
Total insert capacity in the 
virion in the range of 10 kb
Serum conversion to HIV-1
Possible proviral insertional 
mutagenesis in target cells
Adenoviruses Very high titers (1010 pfu/ml) 
Transiently high levels of 
gene expression 
Total insert capacity in the 
vector in the range of 10 kb 
Infection of nondividing cells
Host immune response
Not suitable for long-term 
expression due to the lack of 
integration into host genome
Complicate vector genome
Adeno-associated 
viruses (AAV)
Infection of nondividing cells 
Viral integration specific for 
human chromosome 19 
(only for wild-type AAV)
No toxic effect on infected 
cells
Nonpathogenic for infected 
cells
Difficult to obtain high titers of 
pure viruses
Limited capacity for foreign 
genes (about 4 kb)
Lack of specific integration for 
recombinant AAV vector
N o n v i r a l  D e l i v e r y
Cationic liposomes Not infectious
No limit to the size of DNA
Low degree of toxicity
Non specific targeting 
Low transfection efficiency 
Difficult in vivo application
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Adenovirus, a class of DNA viruses, can successfully deliver genes to the 
nucleus. However, these viruses provide only transient expression of the gene 
and generate a strong antibody response, thus the infected cells are rapidly 
removed and repeated application is not possible [Ali et al, 1994; Relph et al, 
2005; Young et al, 2006]. Adeno-associated virus is an alternative vector for 
ribozyme delivery [Bertrand et al, 1997; Lewin & Hauswirth, 2001]. It is 
appealing for several reasons. It is non-pathogenic and does not require 
dividing cells to integrate the gene into the host genome.
Retroviruses are among the most efficient tools for gene transduction of 
mammalian cells. For this reason, they were successfully used in the early 
gene therapy clinical trials for the treatment of inherited genetic diseases and 
cancer [Young et al, 2006; Rodrigues et al, 2007]. A number of different 
retroviruses are in use as gene delivery vehicles. The most common 
retroviral vector is based on the amphotropic Moloney murine leukaemia 
virus (MoMuLV) [Shinnick et al, 1981]. This system is particularly suitable for 
efficient in vitro cell transduction: the amphotropic MoMuLV has a broad cell 
tropism, it can be produced at relatively high titers (106-107 iu/ml), and allows 
for long-term transgene expression because of the viral integration in the 
host chromosomal DNA. Another important feature of retroviruses is that 
although they do not elicit immune responses in the host, they are 
susceptible to rapid degradation by the complement [Takeuchi et al, 1994]. 
This is a major limitation for in vivo retroviral-mediated gene transfer.
The viral RNA encodes 3 genes called gag, pol and env which encode the 
capsid core proteins (gag), reverse transcriptase, integrase and protease 
(pol) and the envelope antigens (env) (Figure 22). Gag (Group specific
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Antigens) is the precursor to the internal structure of the retrovirus also 
known as the “core”. It gives rise to four different polypeptides. The three 
common to all retroviruses are the capsid (the largest protein composed of 
200-270 amino acids, the matrix (derived from the amino terminus of the 
Gag gene, is a membrane associated protein), and the nucleocapsid (a 60- 
90 amino acid protein that binds the viral RNA). Pol gives rise to three 
polypeptides: the protease, the reverse transcriptase (with RNase H activity) 
and integrase. Finally, Env gives rise to two polypeptides: the
transmembrane “spike” protein (gp41 in HIV) and the knob-like surface 
protein gp120. Together these form the surface antigen gp160 characteristic 
to retroviruses. These proteins are initially inserted into the host cell 
membrane and are acquired by the virus particle at a later stage during 
budding.
u , R us------- (  0 ^ 9  y  p o !  V T  env ')----- R
J V )
LTR LTR
Figure 22. Schematic representation of the genomic 
organisation of a retroviruse.
The retroviral genome is flanked by a long terminal repeat 
sequence (LTR) and encodes 3 genes which encode the 
capsid core proteins (gag), reverse transcriptase, integrase 
and protease (pol) and the envelope antigens (env).
The retroviral genome is flanked by a long terminal repeat sequence (LTR) 
(Figure 22). This region contains all signals necessary for gene expression, 
including the enhancer, promoter, transcription initiation, transcription 
terminator and polyadenylation signal. The size of the LTR varies
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considerably among the different retroviruses. The integrated provirus has 
two LTRs; the 5’ LTR normally acts as an RNA polymerase II promoter 
whereas the 3’ LTR functions as the terminator sequence. An LTR is 
composed of three elements: U3, R and U5 regions. U3 includes most of the 
transcriptional control elements and carries the promoter/enhancer 
sequence. It is the unique, non-coding region of 75-250 nucleotides which is 
in the first part of the genome to be reverse transcribed, forming the 3’ end of 
the provirus genome. R region is usually a short (18-250 nucleotide) 
sequence that provides the sequence homology for strand transfer during 
reverse transcription of the RNA genome. Finally, U5 region carries the poly 
A-site and, together with the R region, determines the poly A addition. It is a 
unique non-coding region of 200-1,200 nucleotides that forms the 5’ end of 
the provirus after reverse transcription. Both U3 and U5 regions contain the 
Att sites required for integration.
The key factor in using a retrovirus as a gene delivery vehicle is biosafety. 
The main goal of the vector design is to ensure that a replication incompetent 
virus is generated. Separation of the packaging function from the genetic 
material to be transferred makes this possible. A basic retroviral vector 
contains the c/'s-acting elements required for replication as a virus, but lacks 
some or all of the viral genes, which are replaced by foreign coding 
sequences. For a retroviral vector to replicate as a virus, it is necessary to 
provide the missing viral gene(s) in trans. Moreover, retroviral particles are 
difficult to concentrate, as they are fragile and can be destroyed during the 
precipitation. This problem can be circumvented by pseudotyping the 
retroviral core with the G glycoprotein of vesicular stomatitis virus (VSV-G).
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This envelope stabilizes the retroviral particles, which can then be easily 
concentrated by ultracentrifugation of the retroviral supernatant [Romano 
et al, 1999]. Engineered cell lines that express the viral genes from 
heterologous promoters are used to produce vector virus. These genetically- 
engineered cell lines are called packaging or helper cells. There are various 
packaging cell lines that can be used to generate retroviruses; the choice of 
packaging cells depends on the host range or tropism of the desired virus 
(Figure 23).
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Figure 23. Production of an infectious retroviral particle and 
infection of a target cell.
A replication-incompetent vector encoding a gene of interest (x) is 
introduced into a pakaging line (1). This cell line encodes the proteins 
necessary for production of viral particles. The viral transcript is 
pakaged into viral particles, which are thus budded from the pakaging 
cell. The replication-incompetent retroviral vector interacts with a host­
cell receptor and enters into the target cell (2), where the virus reverse 
transcribes its RNA genome and integrates it into the host genome.
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3.1.2.3.2.2. Nonviral Delivery
As an alternative to viral vectors, several DNA-based plasmid vectors for 
transient and stable expression of ribozymes and siRNA have been 
developed [Brummelkamp et al, 2002; Sui et al, 2002].
Nonviral gene delivery makes use of lipo/polyfection reagents such as 
liposomes, cationic lipids, or cationic polymers complexed with the foreign 
DNA for transfection [Azzam & Domb, 2004; Tiera, 2006] (Figure 18), or 
physical methods such as microinjection, gene gun delivery, or the use of 
uncomplexed, “naked” plasmid DNA. All these methods are less efficient than 
viral transduction and there are viability complications due to toxicity as well 
as evidence that unmethylated plasmid DNA amplified in bacteria is 
immunogenic [Deng et al, 1999; Loisel et al, 2001]. However, there are few 
restrictions on the size of the gene of interest.
Briefly, the plasmid carries the genetic information required to express a 
foreign protein or ribozyme or siRNA: all the necessary sequences for 
subcloning the gene of interest, elements needed for bacterial propagation 
and amplification of the plasmid as well as eukaryotic promoters, poly(A) 
signals and antibiotic resistance genes for selection of stable cell lines. 
Newer features of plasmids allow for a choice of episomal or extra- 
chromosomal maintenance, integration, site-specific integration, and the 
ability to turn gene expression on or off. DNA-polymer complexes enter cells 
either by charge-mediated interactions with proteoglycans or by receptor- 
mediated endocytosis. Either method results in delivery to lysosomes 
followed by release and transport to the nucleus. DNA transport across the
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nuclear membrane through the nuclear pores requires active transport, is 
limited to particles 100 nm in size, and is the major barrier to overcome in 
nonviral gene delivery [Tachibana et al, 2001].
The key principles for nonviral delivery systems are to avoid undesirable 
interactions with surface proteins and the extracellular matrix, and to avoid 
self-aggregation. Thus, the DNA and reagent must complex, preferably in a 
predictable ratio, and the DNA must condense or the particle will be too large 
to pass through the nuclear pore. Furthermore, the complex should allow 
endolysosomal release, but not inhibit downstream cellular processes, that is, 
transcription and translation.
3.1.3. Survivin Inhibition by Ribozymes & siRNAs
As an alternative antisense strategy for survivin inhibition (Figure 13A), 
Choi et al [2003] developed two hammerhead ribozymes able to cleave the 
human survivin mRNA at nucleotide position +279 and +28 and cloned them 
into a replication-deficient adenoviral vector. These authors showed that 
survivin down-regulation increased the apoptotic response to etoposide in 
transduced MCF-7 breast cancer cells.
Several studies on experimental human tumour models have 
demonstrated the feasibility of the use of the small interfering RNAs 
approach for the inhibition of cancer-related genes including survivin 
(Figure 13A).
96
Chapter 1 In tro du ctio n
Carvalho et al [2003] first used RNAi to specifically repress survivin in 
HeLa cells. These authors showed that survivin was no longer detectable in 
cultures 60 hours after transfection with specific siRNAs and that survivin- 
depleted cells were delayed in mitosis and accumulated in prometaphase 
with misaligned chromosomes. Several studies dealing with the use of 
chemically synthesized siRNAs or plasmid/viral vectors encoding short 
hairpin RNAs showed that RNAi-mediated survivin knockdown was able to 
reduce tumour cell proliferative potential and induce caspase-dependent 
apoptosis in a variety of human tumour cell models [Lens et al, 2003; 
Beltrami et al, 2004;Yang et al, 2004; Ai et al, 2006; Nakao et al, 2006; Jiang 
et al, 2006], as well as to decrease the formation of new tumours and the 
growth of already established lesions in nude mice [Jiang et al, 2006; Li et 
al, 2006]. Survivin down-regulation also induced an enhanced apoptotic 
response of tumour cells of different histologic origin to several stimuli, 
including treatment with vincristine [Jiang et al, 2006], doxorubicin [Li et al, 
2006; Yonesaka et al, 2006], TNF-alpha [Li et al, 2006] and AP02L/TRAIL 
[Nakao et al, 2006], and caused radio-sensitisation of a sarcoma cell line 
expressing wild-type p53 [Kappler et al, 2005]. Finally, Coma et al [2004] 
demonstrated that transfection of endothelial cells with survivin-specific 
siRNAs induced a marked increase in the rate of apoptosis, a dose- 
dependent inhibition of their migration on vitronectin, and a decrease in 
capillary formation.
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3.2. Gene Therapy
Two main gene therapy approaches targeting survivin have been 
successfully developed. One is based on the use of plasmids or viral vectors 
to deliver dominant-negative survivin mutants to tumour cells (Figure 13B) 
and the second involves the use of the survivin gene promoter to drive the 
expression of cytotoxic genes in tumour cells [Lo et al, 2005].
3.2.1. Dominant Negative Mutants
Two mutations in survivin have been characterized for what appears to be 
a dominant negative effect on the function of the endogenous molecule 
(Figure 13B).
Grossman et al [1999] first demonstrated that transfection of YUSAC2 and 
LOX melanoma cell lines with a mutant carrying a cysteine 84->alanine 
(Cys84Ala) mutation in the survivin BIR domain increased the apoptotic index 
and enhanced the sub-Gi apoptotic cell fraction in both tumour models. More 
recently, Tu et al [2005] showed that adeno-associated viral vector-mediated 
transfer of the survivin mutant Cys84Ala induced apoptosis and mitotic 
catastrophe in colon cancer cells, inhibited angiogenesis and tumour growth 
in a colon cancer xenograft model in vivo, and strongly enhanced the 
antitumour activity of 5-fluorouracil. By using a phosphorylation-defective 
survivin threonine 34->alanine (Thr34->Ala) mutant, Grossman et al [2001] 
demonstrated the induction of spontaneous apoptosis in different melanoma
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cell lines as well as an increased apoptotic response following cisplatin 
treatment. Conditional expression of Thr34->Ala in these cells prevented 
tumour formation upon subcutaneous injection in 13 of 15 CB.17 severely 
combined immunodeficient (SCID) mice. Such treatment also caused a 
significant reduction (60-70%) in the growth rate of already established 
tumours and enhancement of apoptosis [Grossman et al, 2001]. Mesri et al 
[2001] investigated the effect of a replication-deficient adenovirus encoding 
the survivin Thr34->Ala dominant-negative mutant (pAd-T34A) in human 
tumour cells of various origin in vitro and in vivo. They showed that infection 
with pAd-T34A caused enhanced spontaneous and paclitaxel-induced 
apoptosis in cell lines of different tumour origin while not affecting the growth 
of proliferating normal human cells not expressing survivin. In vivo 
experiments on the MCF-7 human breast cancer xenograft model 
demonstrated that pAd-T34A was able to suppress de novo tumour 
formation, inhibit the growth of already established tumours by approximately 
40%, and reduce intraperitoneal tumour dissemination. Moreover, tumours 
infected with pAd-T34A showed massive apoptosis and loss of proliferating 
cells. Very recently, using a recombinant fusion protein containing the TAT 
transduction domain and the Thr34->Ala dominant-negative mutant (TAT- 
Surv-T34A), Yan et al [2006] observed an induction of caspase-dependent 
apoptosis in melanoma cells. Moreover, repeated intraperitoneal injection of 
TAT-Surv-T34A resulted in a marked reduction of the growth and mass of 
established subcutaneous tumours in mice.
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3.2.2. The Survivin Gene Promoter
The second gene therapy approach involves the use of the survivin gene 
promoter to drive the expression of cytotoxic genes in tumour cells 
[Lo etal, 2005]. It was shown that when coupled to the pro-apoptotic protein 
Bik, administration of the suicidal construct as a DNA-liposome formulation 
suppressed the growth of human lung cancer in vitro and in vivo [Chen et 
al, 2004]. Van Houdt et al [2006] showed recently that survivin promoter- 
based conditionally replicative adenoviruses (CRAds), composed of survivin 
promoter-regulated E1 gene expression and an RGD-4C capsid modification, 
efficiently replicated within and killed a variety of established glioma cell lines 
but were inactive in a normal liver culture. Moreover, survivin promoter-based 
CRAds significantly inhibited the growth of glioma xenografts in vivo.
3.3. Small Molecule Antagonists
3.3.1. Cyclin-Dependent Kinase (CDK) Inhibitors
If survivin phosphorylation on Thr by p34cdc2 is required for cancer cell 
viability, it should be possible to target this step with a more generally 
applicable pharmacological approach (Figure 13C). Indeed, kinase inhibitors 
and in particular antagonists of cdk have emerged as promising anticancer 
drugs for their ability to disrupt a number of cell proliferation and cell survival 
pathways [Davies et al, 2002]. In particular, the flavone cdk inhibitor of
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p34cdc2, flavopiridol, is has been explored in the clinic for its ability to induce 
apoptosis in various tumour cell types [Senderowicz, 2003].
Flavopiridol (NSC 649890, L86-8275 or HMR 1275) is a semisynthetic 
small molecular derivative of rohitukine, an alkaloid isolated from Dysoxylum 
binectariferum (Figure 24). Initially, flavopiridol demonstrated potent effects 
on cell proliferation (IC50=66 nM) in 60 National Cancer Institute human 
tumour cell lines, with no obvious tumour-type selectivity [Day & Grant, 
2003]. Antitumour effect has also been observed in xenograft models of 
various tumour-types treated with this compound [Day & Grant, 2003]. 
Flavopiridol is a potent small molecule inhibitor of multiple cdks, including 
cdkl (cdc2), cdk2, cdk4, cdk6, and cdk7 [Senderowicz & Sausville, 2000]. It 
inhibits cdks by binding to their ATP-binding pocket [Senderowicz & 
Sausville, 2000]. Flavopiridol also causes transcriptional repression of cyclin 
D1 [Senderowicz & Sausville, 2000]. By inhibiting cyclin H-cdk7, it inhibits the 
phosphorylation of cdks at threonine 160/161 [Senderowicz & Sausville, 
2000]. These activities result in the arrest of the cell cycle in the Gi/S or G2/M 
and mediate the anti-proliferative effect of flavopiridol in tumour cells. 
Flavopiridol has also been shown to induce apoptosis, to inhibit transcription 
and to have anti-angiogenic activity [Day & Grant, 2003].
As a member of the first generation of cdk inhibitors, flavopiridol is not 
particularly selective for a specific cdk. However, more selective cdk 
inhibitors have since been developed. Several of these compounds are being 
evaluated for antitumour activity in preclinical model systems. Purine-based 
cdk inhibitors display greater selectivity for cdks 1, 2 and probably 5, but 
exhibit no inhibitory activity toward cdks 4 and 6. Some of these inhibitors
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have been reported to exert potent antitumour activity, including olomucine, 
roscovitine, and purvalanols.
Purvalanol A and B, are olomucine derivatives (Figure 24) which exhibit 
potent and selective inhibition of cdks 1 and 2. In vitro studies demonstrated 
that purvalanol inhibits cell growth (IC5o=2.5 pM) and induces G2/M arrest. 
These effects are linked to inhibition of cdkl and p42/p44 mitogen-activated 
protein kinase, both of which have been identified as intracellular targets of 
purvalanol [Day & Grant, 2003]. Administration of purvalanol did not appear 
to trigger extensive activation of caspases; however, induction of apoptosis 
might be highly dependent upon the concentration of cdk inhibitors [Day & 
Grant, 2003].
HN‘
HO.
OH
Purvalanol A (R=H) 
Purvalanol B (R=C02H)
Flavopiridol
Figure 24. Structure of small-molecule direct cdk modulators.
In the context of a strategy focused on pharmacologic inhibition of mitotic 
phosphorylation of survivin on Thr34 to accelerate protein destruction and 
counteract its function [O’Connor et al, 2002], cdk inhibitors such as 
flavopiridol or the more p34Gdc2-specific inhibitor, purvalanol A, were tested in 
tumour cells arrested at mitosis with paclitaxel, which induces
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hyperphosphorylation of survivin on Thr34 [Zaffaroni et al, 2002]. Sequential 
administration of cdk inhibitors resulted in escape from the mitotic block 
imposed by paclitaxel, marked activation of mitochondrial-dependent 
apoptosis, and anticancer activity in vivo [O’Connor et al, 2002].
3.3.2. Hsp90 Inhibitors
A structure-based rational screening for antagonists of the survivin-Hsp90 
complex identified a cell-permeable peptidomimetic derived from the survivin 
sequence Lys79-Leu87, shepherdin [Plescia et al, 2005]. In addition to 
counteracting survivin-Hsp90 interaction, the molecule inhibited Hsp90 
chaperone function by competing with ATP binding. Specifically, shepherdin 
was able to destabilize several Hsp90 client proteins (including Akt, cdk6 and 
telomerase) and to induce cell death via apoptotic and non-apoptotic 
mechanisms in cell lines of different tumour types. The cytotoxicity of 
shepherdin was seen to be independent of the proliferative activity of the cell 
model, concomitant overexpression of other cytoprotective factors such as 
Bcl-2, and p53 status. Moreover, shepherdin appeared to be selective in its 
antitumour activity since it did not affect viability of normal cells or tissues, 
including haematopoietic progenitors. Systemic administration of shepherdin 
in vivo was safe and well tolerated and inhibited the growth of already 
established prostate and breast cancers without inducing systemic or organ 
toxicity. Moreover, immunohistochemical analysis of Hsp90 client proteins 
carried out in tumours samples at the end of shepherdin treatment showed a
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nearly complete loss of Akt levels and severely attenuated survivin 
expression [Plescia et al, 2005]. The clinical development of shepherdin with 
respect to its optimal formulation and pharmacokinetic profile is currently 
under way through the National Cancer Institute (NCI) Rapid Access to 
Intervention Development (RAID) program.
Since the shepherdin residues between Lys79 and Gly83 were shown to be 
essential for Hsp90 binding, a new five-residue peptide containing the Lys79- 
Gly83 sequence (called shepherdin[79-83]) was successively synthesized 
[Gyurkocza et al, 2006]. The oligopeptide inhibited the formation of the 
survivin-Hsp90 complex and competed with ATP binding to Hsp90. Cell- 
permeable shepherdin[79-83] induced rapid killing in different types of human 
acute myeloid leukaemia cell lines and in patient-derived AML peripheral 
blasts but not in normal mononuclear cells. Moreover, when systemically 
delivered, shepherdin[79-83] abolished the growth of AML xenograft tumours 
without systemic or organ toxicity [Gyurkocza et al, 2006]. We have recently 
used shepherdin as a scaffold to rationally identify low-molecular-weight 
compounds that may act as structurally novel Hsp90 inhibitors. Through a 
combined structure- and dynamics-based computational design strategy, the 
nonpeptidic small molecule 5-aminoimidazole-4-carboxamide-1-p-D- 
ribofuranoside (AICAR) was selected to bind the Hsp90 N-terminal domain, 
mimicking the chemical and conformational properties of shepherdin. AICAR 
was shown to destabilize several Hsp90 client proteins in vivo, including 
survivin, and to exhibit anti-proliferative and pro-apoptotic activity in multiple 
tumour cell lines, while not affecting proliferation of normal human fibroblasts 
[Meli et a/,2006].
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3.3.3. Other Small Molecules
Additional small molecules that target survivin have been developed and 
some of them are currently being evaluated in clinical trials. One of those that 
directly affect survivin expression, tetra-O-methyl nordihydroguaiaretic acid 
(M(4)N), was shown to suppress Sp1-dependent survivin gene transcription 
and activate the mitochondrial apoptotic pathway in transformed cells [Chang 
et al, 2004]. Moreover, M(4)N suppressed the growth of human xenograft 
tumours following systemic treatment [Park et al, 2005]. However, 
considering that the compound is a global transcription inhibitor, both 
survivin-dependent and survivin-independent pathways are thought to be 
responsible for drug-induced cell death in tumours [Huang et al, 2006].
YM155 is a small molecule that selectively inhibits survivin gene 
transcription and protein expression in several tumour cell lines. It showed 
marked anti-proliferative activity (in the nanomolar range) in a broad 
spectrum of human tumour cell lines and induced tumour regression in 
lymphoma, prostate cancer and non-small cell lung cancer xenografts [Mita 
et al, 2006]. Moreover, preliminary evidence of the clinical activity of the 
compound was derived from a phase I open-label study in which 41 patients 
with different tumour types were treated with 7-day continuous intravenous 
infusion of YM155 and objective responses were observed in 3 patients with 
non-Hodgkin’s lymphoma [Mita et al, 2006]. The compound is currently being 
evaluated in a phase II study for patients with stage III and stage IV 
melanoma.
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Other small molecules currently in the clinic were shown to indirectly affect 
survivin expression. Some of them, including STAT3 [Turkson, 2004] and T- 
cell factor [Emami et al, 2004] antagonists, caused the suppression of 
survivin gene transcription, whereas others, such as the ErbB2 antagonist 
lapatinib [Xia et al, 2006], markedly inhibited survivin expression by acting at 
the post-translational level through the promotion of the ubiquitin- 
proteasome-mediated degradation of the protein [Xia et al, 2006].
Overall, these data clearly validate survivin as a good target for cancer 
therapy thus indicating that interfering with survivin expression/activity by 
means of novel strategies may provide a viable approach to kill cancer cells 
selectively. Moreover, the notion that this factor plays a crucial role also in 
tumour angiogenesis would suggest that its targeting can increase the overall 
tumours treatment response not only through direct interference with the 
apoptotic pathways in cancer cells but also by favouring the apoptotic 
involution of newly formed tumour vasculature.
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Apoptosis is a physiological process by which unwanted or useless cells 
are eliminated during development and other normal biological processes. 
Resistance to apoptotic stimuli is a hallmark feature of various malignancies 
including cancer. One of the mechanisms through which tumour cells acquire 
resistance to apoptosis is by overexpression of Inhibitor of Apoptosis 
Proteins (lAPs), a group of anti-apoptotic proteins that interact with and 
inhibit the enzymatic activity of caspases. Survivin is a structurally unique 
member of the IAP family, which is involved in control of cell division and 
inhibition of apoptosis. This protein is undetectable in most terminally 
differentiated normal tissues but is selectively expressed in the most common 
human neoplasms and associated with clinical tumour progression. Survivin 
also appears to be involved in tumour cell resistance to some anticancer 
agents as well as ionising radiation. It has been reported that survivin 
inhibition by use of the oligonucleotide antisense, mutant dominant negative, 
ribozyme and small interfering RNA, renders tumour cells more susceptible 
to treatment with chemotherapeutic agents and ionising radiation. On the 
basis of these findings, survivin has been proposed as a promising 
therapeutic target for novel anticancer therapies.
The present study is aimed to develop different approaches to induce a 
specific inhibition of survivin expression/activity in human cancer cells 
with the final aim to sensitise tumour cells to the effects of apoptosis- 
inducing anticancer agents.
108
Chapter 2 A im s  of t h e  study
Specifically, we proposed to inhibit:
s  survivin expression through the use of hammerhead ribozymes and 
small interfering RNA targeting different portions of survivin mRNA;
S survivin activity through the use of specific cdk inhibitors.
The knock down phenotype arising from the exposure of tumour cells to 
different inhibitors was evaluated in terms of cell proliferative and tumorigenic 
potential, susceptibility to activate programmed cell death and 
chemosensitivity profile.
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1. G en era l  P r o c ed u res
1.1. Drugs
Cisplatin was obtained from Pharmacia-Upjohn (Milan, Italy). Topotecan 
was purchased from Smith-Kline Beecham Pharmaceuticals (King of Prussia, 
PA, USA). Temozolomide was obtained from Schering Plough Inc (Madison, 
NJ, USA). Paclitaxel was purchased from Sigma (Milan, Italy). The 17- 
allylamino-17-demethoxy-geldanamycin (17-AAG) was kindly provided by 
Dr E. Sausville (NCI, Bethesda, MA, USA). Purvalanol A was purchased from 
Tocris (Bristol, United Kingdom). NU6140 was kindly provided by Prof D.R. 
Newell (University of Newcastle, Newcastle upon Tyne, United Kingdom).
1.1.1. Cisplatin Preparation
To obtain a 1 mg/ml cisplatin stock solution, 10 ml of PBS were added to 
cisplatin powdered stock and the drug was completely dissolved by vigorous 
vortexing immediately before use.
1.1.2. Topotecan Preparation
To obtain a 1 mg/ml topotecan stock solution, 10 ml of sterile water were 
added to topotecan powdered stock and the drug was completely dissolved,
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stored at -20°C and diluted in complete culture medium immediately before 
use.
1.1.3. Temozolomide Preparation
To obtain a 1 mg/ml temozolomide stock solution, 10 ml of DMSO were 
added to temozolomide powdered stock and the drug was completely 
dissolved, stored at -20°C and diluted in complete culture medium 
immediately before use.
1.1.4. Paclitaxel Preparation
To obtain a 1 mg/ml paclitaxel stock solution, 10 ml of DMSO were added 
to paclitaxel powdered stock and the drug was completely dissolved, stored 
at -20°C and diluted in complete culture medium immediately before use.
1.1.5. 17-AAG Preparation
To obtain a 1 mg/ml 17-AAG solution, 10 ml of DMSO were added to the 
powder stock and the drug was completely dissolved, stored at -20°C and 
diluted in complete culture medium immediately before use.
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1.1.6. Purvalanol A Preparation
To obtain a 1 mg/ml purvalanol A stock solution, 10 ml of DMSO were 
added to purvalanol A powdered stock and the drug was completely 
dissolved, stored at -20°C and diluted in complete culture medium 
immediately before use.
1.1.7. NU6140 Preparation
To obtain a 1 mg/ml NU6140 stock solution, 10 ml of DMSO were added 
to NU6140 powdered stock and the drug was completely dissolved, stored 
at -20°C and diluted in complete culture medium immediately before use.
1.2. Human Tumour Cell Lines
The melanoma cell line (JR8) was kindly supplied by Dr. Zupi 
(Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, 
Rome, Italy). The cell lines derived from untreated patients with prostate 
carcinoma (DU 145 and PC-3) and uterine cervix carcinoma (HeLa), were 
purchased from American Type Culture Collection (ATCC, Rockville, MD, 
USA). The ovarian cancer cell lines, OAW42/e and OAW42/Surv were 
previously obtained after transfection of the OAW42 parental cell line 
(purchased from ATCC) with the empty pCI-neo vector and the pCI-neo
113
Chapter 3 M a t e r ia l  & M etho ds
expression vector carrying the full-length human survivin cDNA (pCI-surv) 
[Zaffaroni et al, 2002].
1.2.1. Human Tumour Cell Lines Growth Conditions
All cell lines were maintained as monolayers in 25-cm2 flasks (Corning- 
Costar Italia, Milan, Italy) at 37°C in a 5% CO2 humidified atmosphere in an 
air incubator (Heraeus Sepatech, Milan, Italy).
JR8, DU145 and PC-3 were maintained in RPMI-1640 medium (Cambrex 
Italia, Milan, Italy), supplemented with 10% (v/v) FBS, 2 mM L-glutamine, and 
0.1% (v/v) gentamycin, at a density of 0.6 x 105 cells per 25-cm2 flask. HeLa 
cells were cultured using D-MEM/F12 medium (Cambrex), supplemented 
with 10% (v/v) FBS, 2 mM L-glutamine and 0.1% (v/v) gentamycin, at a 
density of 0.8 x 105 cells per 25-cm2 flask. OAW42/e and OAW42/Surv were 
maintained D-MEM/F12 medium (Cambrex), supplemented with 10% (v/v) 
FBS, 2 mM L-glutamine, 0.25 units/ml insulin, 0.1% (v/v) gentamycin, 
1 mg/ml G418, at a density of 1 x 105 cells per 25-cm2 flask.
All tumour cells were cultured as follow: at set time points, specific growth 
medium was removed from the 25-cm2 flask and the cell monolayer was 
washed twice with 5 ml 37°C-heated PBS. One ml of a Trypsin-EDTA 
solution (Cambrex) was then added to each flask. After a 5 minutes- 
incubation at 37°C with gentle shaking, cell detachment was checked under 
the microscope (Nikon TMS, Folabo, Buccinasco, Italy) and trypsin activity 
was blocked by addition of 5 ml of complete medium. Five ml-suspension
114
Chapter 3 M ater ia l  & M etho ds
containing detached cells was transferred in a sterile 15 ml conical tube 
(Falcon-Becton Dickinson Italia, Milan, Italy) and centrifuged at 1,500 rpm for 
5 minutes at room temperature in a Varifuge 3.0R centrifuge (Heraeus 
Sepatech). Cell pellet was then carefully resuspended in 5 ml of growth 
medium and a small aliquot (100 pi) was transferred in a plastic 20 ml-vial 
(Falcon-Becton Dickinson) containing 10 ml of the isoton solution (azide-free 
balanced electrolyte solution; Coulter Scientific, Luton, United Kingdom). 
Single-cell suspension was checked under the microscope in a Burker 
camera, and the number of detached cells was calculated by counting in a 
particle counter (Coulter Counter, Coulter Scientific).
Frozen stocks of human tumour cell lines were prepared as follows. Cells 
in logarithmic growth phase were detached from the flasks and counted as 
previously described. The percentage of viable cells was also determined by 
Trypan blue dye exclusion test by mixing, in a 0.5 ml clean conical tube 
(Eppendorf Italia, Milan, Italy) 5 pi of detached cells suspension, 45 pi of PBS 
and 50 pi of Trypan blue dye (Sigma). Five pi of Trypan blue dye-stained cell 
suspension were placed onto a Burker camera and checked under the 
microscope. The number of viable cells generally exceeded 95%. After 
counting, the cell suspension was centrifuged at 1,500 rpm for 5 minutes 
at4°C. The supernatant was removed and the cell pellet was carefully 
resuspended in 4°C-cold freezing medium [D-MEM/F12 medium 
supplemented with 40% (v/v) FBS] at a density of 5 x 106 viable cells/ml. One 
ml of such a cell suspension was then transferred in a 2 ml sterile Nalgene 
tube (Nalgene Company, Rochester, NY, USA) and placed on ice. One ml of 
cryoprotective medium [basal EAGLE’S medium with HANKS’ BBSS and
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15% (v/v) dimethylsulfoxide (DMSO)] (Cambrex) was added to each tube and 
after a gentle resuspension, the tube was placed onto a Cryo 1°C Freezing 
Container (Nalgene) and stored at -80°C for the initial freezing step. After 
16-24 hours, frozen cells were removed from the freezing container and 
stored under liquid nitrogen vapours in the Barnstead/Thermolyne containers 
(Barnstead/Thermolyne, Dubuque, IO, USA).
For cell thawing, frozen cells were incubated in a 37°C water bath (PBI 
International Italia, Milan, Italy), transferred into a sterile 15 ml conical tube 
containing 10 ml of complete growth medium and centrifuged at 1,500 rpm 
for 5 minutes at room temperature. The cell pellet was then resuspended in 
15 ml of growth medium and cells were seeded in a 25-cm2 flask.
1.3. Nucleic Acids Quantification
Concentration and quality of solutions containing DNA, RNA or 
oligonucleotides were determined by spectrophotometric analysis as follows. 
In two clean 1.5 ml tube (Eppendorf), a suitable volume of nucleic acid- 
containing solution (generally, 5 and 10 pi) was gently mixed with RNase- or 
DNase-free distilled water to a final volume of 200 pi to obtain a 1:40 and 
1:20 dilutions. As the blank sample, a third clean tube containing 200 pi of 
RNase- or DNase-free distilled water was also prepared. The content of each 
tube was transferred into quartz cuvettes (Perkin-Elmer Italia, Monza, Italy), 
the cuvettes were then placed onto a Lambda 11/Bio spectrophotometer 
(Perkin-Elmer) and absorbance values at 260 nm (A260nm) and 280 nm
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(A2 8 0nm) of wave length were measured. The A2 6 0nm and A2 8 0nm values 
obtained with the blank sample were subtracted from the absorbance values 
obtained with the nucleic acid-containing samples, and DNA, RNA or 
oligonucleotide concentration was then calculated using these formulae:
pg/ml of DNA = ( A 2 6 0 n m ) x  (d ilu t io n  f a c t o r )  x  (50 pg/ml) 
pg/ml of RNA = ( A 2 6 0 n m ) x  (d ilu t io n  f a c t o r )  x  (40 pg/ml) 
pg/ml of oligonucleotide = ( A 2 6 o n m ) x  (d ilu tio n  f a c t o r )  x  (30 pg/ml)
The nucleic acid concentration was expressed as the mean of the values 
(pg/ml) obtained in the two independently-prepared and -measured dilutions.
The quality of nucleic acid solutions was evaluated by calculating the 
A2 6 0nm/A2 8 0nm ratio. It is well known that for both DNA and oligonucleotide, a 
ratio of 1.8-2 was indicative of a good-quality preparation, whereas high 
quality RNA solutions are characterised by a A2 6onm/A2 8 0nm ratio of 2.
1.4. Protein Concentration Determination
Protein concentration was determined according to Bradford [1976].
1.4.1. Calibration Curve Preparation
Solutions of bovine serum albumin (BSA) (0.001 pg/pl, 0.0025 pg/pl, 
0.005 pg/pl, 0.01 pg/pl, 0.025 pg/pl and 0.05 pg/pl) were prepared by 
dissolving powdered BSA (Sigma) in distilled water. In a 1.5 ml tube, 250 pi
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of each BSA solution were mixed with 150 pi of distilled water and 100 pi of 
Biorad Protein assay dye (Biorad, Milan, Italy). In the blank sample, 400 pi of 
distilled water were mixed with 100 pi of Biorad Protein assay dye. Samples 
were rapidly transferred into disposable 96 well plate (Corning-Costar) and 
the absorbance at 595 nm wave length of each calibration point was 
measured using a microtiter plate reader (PBI International). The absorbance 
value corresponding the blank sample was then subtracted from the values 
obtained in the BSA-containing samples. Each calibration sample was run in 
triplicate.
1.4.2. Protein Concentration Quantification
Concentration of extracted proteins was determined by mixing in a 1.5 ml 
tube 5 pi of protein extracts with 95 pi of Biorad Protein assay dye and 
distilled water to a final volume of 500 pi. Samples were rapidly transferred 
into 96 well plate and the absorbance at 595 nm wave length was measured 
in the spectrophotometer plate reader. From the calibration curve, it was 
possible to determine the protein concentration of each sample. Also in this 
case, each sample was run in triplicate.
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1.5. Agarose Gel Preparation
All agarose gel electrophoresis experiments were carried out using Hoefer 
horizontal electrophoresis units (Amersham-Pharmacia Biotech Italia, 
Cologno Monzese, Italy).
Gels of different sizes and percentages (w/v = grams of powdered agarose 
per 100 ml of running buffer) were prepared in clean glass bottles by mixing 
suitable amounts of powdered agarose (Sigma) in 1x TAE [0.04 M Tris- 
Acetate (Sigma), 0.001 M EDTA (Sigma)] or 1x TBE [0.09 M Tris-Borate 
(Sigma), 0.002 M EDTA] running buffers. Agarose was dissolved by heating 
in a microwave, cooled to about 50°C, transferred onto the casting tray and, 
after the insertion of a clean comb, left to polymerise at room temperature. 
When polymerisation was completed, the comb was removed and solidified 
agarose gel was transferred into the running tray and submerged with 
running buffer.
1.6. SDS-Polyacrylamide Gel Preparation
All SDS-polyacrylamide gels used for protein separation (8 centimetres 
high/ 10 centimetres length/1 millimetres thick) were prepared as described 
by Laemmli [1970] and run in a Hoefer SE 600 vertical electrophoresis slab 
unit (Amersham). Resolving gel (10 ml) was prepared in a 15 ml conical tube 
(Falcon-Becton Dickinson) by mixing a suitable volume of 40% (w/v) 
polyacrylamide stock solution (acrylamide:N,N'-methylenebisacrylamide
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molar ratio = 29:1) (Sigma) with 0.1 ml of 10% (w/v) SDS solution (Sigma) 
[final concentration = 0.1% (w/v)], 2.5 ml of 1.5 M Tris-HCI pH 8.8 solution 
(Sigma) (final concentration = 375 mM), 100 pi of 10% (w/v) APS (Sigma) 
[final concentration = 0.1% (w/v)] and 6 pi of TEMED (Sigma) [final 
concentration = 0.06% (v/v)], and subsequently poured into the gap between 
glass plates (previously washed with absolute ethanol) leaving sufficient 
space for the stacking gel. The poured resolving polyacrylamide gel solution 
was immediately and carefully overlaid with 0.1% (w/v) SDS solution (the 
overlay prevents oxygen from diffusing into the gel and inhibiting 
polymerisation) and the gel was placed in a vertical position at room 
temperature to polymerise. When polymerisation was complete (within 20-40 
minutes), the overlay was poured off and the top of the gel was carefully 
washed several times with distilled water to remove any unpolymerised 
acrylamide. The stacking gel (2 ml) containing 5% (w/v) polyacrylamide 
(acrylamide:N,N'-methylenebisacrylamide molar ratio = 29:1), 0.1% (w/v) 
SDS, 125 mM Tris-HCI pH 6.8, 0.1% (w/v) APS and 0.1% (v/v) TEMED was 
prepared in a 15 ml conical tube and poured directly onto the surface of the 
polymerised resolving gel. A clean comb was immediately inserted into the 
stacking gel solution and the gel was placed in vertical position to polymerise. 
When polymerisation was complete, the comb was removed, the wells were 
washed with distilled water to remove any unpolymerised acrylamide and the 
gel was mounted in the electrophoresis apparatus containing TGS running 
buffer [25 mM Tris base, 250 mM Glycine (Sigma), 0.1% (w/v) SDS, pH 8.3] 
in both upper and lower buffer reservoirs.
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1.7. Non-Denaturating Polyacrylamide Gel Preparation
Non-denaturing polyacrylamide gels (16 centimetres high/16 centimetres 
length/1.5 millimetres thick) were prepared and run in a Hoefer SE 600 
vertical electrophoresis slab unit (Amersham).
Polyacrylamide gel solution (30 ml) containing 10% (w/v) polyacrylamide 
(acrylamide : N.N'-methylenebisacrylamide molar ratio = 19:1), 0.5x TBE 
buffer, 0.07% (w/v) APS and 0.035% (v/v) TEMED, was prepared in a 50 ml 
conical tube and subsequently poured into the gap between glass plates 
(previously washed with absolute ethanol). A clean comb was immediately 
inserted and the gel was placed in vertical position to polymerise. When 
polymerisation was completed, the comb was removed, the wells were 
washed with 0.5x TBE buffer to remove any unpolymerised acrylamide and 
the gel was mounted in the electrophoresis apparatus containing 0.5x TBE 
running buffer in both upper and lower reservoirs.
1.8. Preparation of the Plasmid Vectors
To obtain a permanent and stable source of pRc/CMV (Invitrogen, San 
Diego, CA, USA), pCI-neo (Promega Italia, Milan, Italy) and pCLXSN 
(Imgenex, San Diego, CA, USA) vectors carrying ribozyme and survivin 
sequences, the following procedures were performed.
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1.8.1. Preparation of Competent JM109 E. Coli Cells for Transformation
Fifty pi of sterile JM109 E. coli cellular suspension (Promega) were mixed, 
in a sterile 50 ml conical tube, with 10 ml of sterile LB medium [1% (w/v) 
Bacto-Tryptone (Invitrogen), 0.5% (w/v) Bacto-Yeast extract (Invitrogen), 1% 
(w/v) NaCI (Sigma), pH 7.0] and allowed to grow in a 37°C-heated shaking 
incubator (GFL3031; Folabo) at 225 rpm over night. One ml of such liquid 
bacterial culture was then transferred into a sterile 500 ml bottle containing 
100 ml of sterile LB medium and the bottle was placed into the 37°C-heated 
shaking incubator at 225 rpm.
To harvest bacterial cells in logarithmic growth phase, 2 hours later, 1 ml 
of liquid culture was transferred, under a laminar flow, in a disposable cuvette 
and the absorbance at 600 nm of wave length was read on the 
spectrophotometer. E. coli concentration in the liquid culture was calculated 
by considering that 1 A 6oonm unit corresponds to about 8 x 106 bacterial 
cells/ml. When A 6oonm of the liquid culture reached 0.3 units (corresponding to 
240 x 106 cells/ml; 24 x 109 cells in 100 ml) the bacterial suspension was 
transferred, under a laminar flow, in two ice-cold sterile 50 ml conical tubes 
and the cell growth was stopped by placing the tubes on ice for 15 minutes. 
E. coli cells were pelleted by a 3,000 rpm centrifugation at 4°C for 10 minutes 
and, after the removal of LB medium, cell pellets were pooled in the same 
tube by gentle resuspension in 10 ml of ice-cold sterile 0.1 M CaCI2 solution 
(Sigma). After addition of 40 ml of ice-cold sterile 0.1 M CaCI2 solution, 
bacterial suspension was incubated on ice for 30 minutes and subsequently 
centrifuged at 3,000 rpm for 10 minutes at 4°C. The supernatant was then
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removed and the cell pellet was carefully resuspended in 5 ml of an ice-cold 
sterile 0.1 M CaCl2-15% (v/v) glycerol (Sigma) solution. Such a bacterial 
suspension was incubated on ice for 24 hours. At the end of incubation, the 
bacterial suspension was mixed by gentle pipetting, divided in 500 pl-aliquots 
(4.8 x 109 cells/ml; 2.4 x 109 cells in each 500 pl-aliquot) in sterile 0.5 ml 
Nalgene tubes, frozen by snap freezing in liquid nitrogen and stored at -80°C.
Fifty pi (240 x 106 cells) of freshly-prepared competent cells were 
transformed with 50 ng of a DNA vector able to confer ampicillin resistance 
and 1/100,000 (dilution factor, 105) of the bacterial suspension was plated as 
described in the 2.1.9.2 section. Transformation efficiency, calculated on the 
basis of the formula
(NUMBER OF COLONIES) X (103) X (DILUTION FACTOR) I 50 ng
was expressed as the number of colony forming units (CFU) per pg of 
plasmid DNA. Generally, 106-108 CFU per pg of plasmid DNA were indicative 
of a good preparation of competent bacterial cells.
1.8.2. Transformation of Bacteria
In an ice-cold 10 ml Falcon 2059 tube (Falcon-Becton Dickinson), 
240 x 106 of competent bacterial cells (50 pi; section 2.9.1) were diluted to a 
final volume of 100 pi with 0.1 M CaCb and 50 ng (5 pi) of purified vector 
were then added. The mixture was gently mixed by tapping and the tube was 
chilled on ice for 30 minutes, incubated for 90 seconds at 42°C in a water
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bath and for 2 minutes on ice. After a 5-minute incubation at room 
temperature, 900 pi of LB medium were added and tube was placed into a 
37°C-heated shaking incubator at 225 rpm for 2 hours. The tube was then 
centrifuged at 3,000 rpm for 5 minutes at room temperature, 950 pi of 
supernatant LB were removed and bacterial cell pellet was resuspended in 
the remaining 50 pi, plated onto 90-mm dish (Corning-Costar) containing 
selective solid LB medium [liquid LB medium, 1.5% (w/v) agar (Invitrogen), 
50 pg/ml ampicillin (Mead-Johnson, Rome, Italy)] and incubated over night at 
37°C. Each colony, representing ampicillin-resistant/transformed growing 
bacterial cells, was picked-up with a sterile disposable loop, dissolved in a 
50 ml conical tube containing 10 ml of liquid LB medium supplemented with 
ampicillin (50 pg/ml final concentration) and allowed to grow over night 
at 37°C with 225 rpm shaking.
1.8.3. Small Scale Preparation of Plasmid DNA (“miniprep”)
To confirm the presence of plasmids in ampicillin-resistant liquid culture, 
8 ml of the bacterial suspension were used for “miniprep” by using Qiagen 
Plasmid Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's 
instructions. Plasmid DNA concentration was determined 
spectrophotometrically as described in the section 1.3.
Electrophoretic analysis was performed on 1% (w/v) agarose mini gel 
prepared and run in 1x TAE buffer. About 500 ng of extracted and original 
DNA vectors were loaded and separated at 90 volt (SE300 power supply;
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Amersham) at room temperature for 1 hour in the presence of 500 ng of A- 
Bstell molecular weight marker (Sigma). DNA fragments were visualised by 
placing the gel onto the UV-transilluminator (260 nm wave length) (Biorad) 
after a 30-minutes staining with 1 pg/ml ethidium bromide (Invitrogen)-lx 
TAE buffer staining and a 30-minute 1x TAE buffer destaining.
1.8.4. Storage of Vector-Transformed Bacteria
In a 2 ml sterile Nalgene tube, 1.6 ml of ampicillin-resistant liquid bacterial 
culture and 0.4 ml of sterile pure glycerol (final concentration (v/v) = 20%) 
were mixed by a vortex mixer and frozen by snap freezing in liquid nitrogen 
and stored at -80°C.
1.8.5. Large Scale Preparation of Plasmid DNA (“maxiprep”)
By means of a sterile spatula, frozen bacterial cells were scraped from the 
2 ml sterile Nalgene tube and dissolved in 10 ml of 50 pg/ml ampicillin 
containing-LB medium (contained in a 50 ml conical tube) and allowed to 
grow at 37°C in a shaking incubator at 225 rpm. After 8 hours, 10 ml liquid 
culture was mixed with 100 ml of fresh 50 pg/ml ampicillin containing-LB 
medium into a 500 ml glass bottle and cells were left to grow over night at 
37°C and 225 rpm.
Bacterial cells were pelleted by a 30-minute centrifugation at 4,000 rpm at 
4°C and, after removal of LB medium, plasmid DNA was purified with the
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Qiagen Plasmid Maxi Kit (Qiagen) according to the manufacturer's 
instructions.
Concentration and quality of the plasmid DNA were evaluated as 
described in the section 1.3.
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2. S pec ific  P r o c ed ures
2.1. Design and Synthesis of Ribozymes Targeting Survivin mRNA
The ribozyme design was performed by an in siiico approach using the 
already described, home-developed computing method [Mercatanti et al, 
2002], which predicts the regions of the survivin mRNA (GeneBank 
Accession N. NM_001168.1) endowed with the most probable conformational 
accessibility. Many NHH consensus cleavage triplets (N= any nucleotide, H= 
A, C, U) lie within these accessible regions, therefore they were recognized 
to be suitable targets for hammerhead ribozymes. A series of catalytic 
ribozyme sequences were correspondingly deduced. The final analysis 
accounting for the correct structure-activity relationship enabled us to select 
the hammerhead ribozyme addressed to the CUAno triplet located on the 
survivin mRNA. The ribozyme sequence, Rz (Figure 25), was synthesized by 
in vitro transcription. A mutant ribozyme (mutRz) obtained by deleting the G12  
from the catalytic core (as indicated by the circled letter in Figure 25) and an 
irrelevant ribozyme (CTR) directed against the FIV primer bonding site, were 
designed and synthesized to obtain the negative controls. Single-stranded 
synthetic DNA oligonucleotides encoding active and control ribozymes were 
obtained from MWG Biotech (Ebersberg, Germany). The oligonucleotide 
sequences were the following:
Rz+ 5’-AGCTT CTT GAATGCT GAT GAGGCCGAAAGGCCGAAAG AGAT GT-3’
Rz- 5’-CTAGACATCTCTTTCGGCCTTTCGGCCTCATCAGCATTCAAGA-3’ 
mutRz+ 5’-AGCTT CTT GAATGCT GAT G AGGCCG AAAG GCC AAAG AG AT GT -3’ 
mutRz- 5’-CTAGACATCTCTTTGGCCTTTCGGCCTCATCAGCATTCAAGA-3’
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Figure 25. Ribozyme structure.
Schematic representation of base pairing of the Rz ribozyme with 
its RNA target site obtained from survivin mRNA. The cleavage site 
is indicated by an arrow. The mutant ribozyme mutRz, which was 
used as control throughout the study, was obtained by deleting the 
G12 from the catalytic core of the active ribozyme.
2.1.1. Annealing of Complementary Pairs of Oligonucleotides
In a microcentrifuge tube, the complementary oligonucleotides were mixed 
together at a 1:1 molar ratio. The oligonucleotide mixture was then diluted to 
a final concentration of 1 pmol/pl with a phosphate buffer containing salt 
[10 mM Tris, 1 mM EDTA, 50 mM NaCI (pH 8.0) or 100 mM sodium 
phosphate, 150 mM NaCI, 1 mM EDTA (pH 7.5)]. The oligonucleotides were 
incubated at 95°C for 5 minutes, and then the heat was gradually reduce until 
the oligonucleotides have reached room temperature. The double-stranded 
DNA probe was stored at -20°C. Annealing of the complementary
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oligonucleotides produced two fragments with Hindlll and Xbal protruding 
ends.
2.1.2. Synthesis of Ribozyme-Expressing Plasmid Vectors
2.1.2.1. Digestion of the pRC/CMV Plasmid Vector
In a 1.5 ml tube, an aliquot containing 30 pg of pRC/CMV plasmid was 
mixed with 60 units of Hindlll and Xbal restriction enzymes (Promega), 1x 
digestion buffer specific for both enzymes (Buffer E) (Promega) and distilled 
water to a final volume of 100 pi. The mixture was then incubated at 37°C in 
a water bath. After 1 hour, the reaction was stopped by addition of 5 pi of 0.5 
M EDTA, pH 8. The digestion of the vector template was verified as 
described in the 1.8.3. section by loading about 200 ng of digested vector 
with the same amount of undigested plasmid DNA and 500 ng of K-BstEII 
molecular weight marker.
2.1.2.2. Purification of Hindlll/Xbal-Dlqested pRC/CMV Vector
Digestion mixture was diluted to a final volume of 400 pi with distilled 
water. An equal volume of phenol (Sigma)/chloroform/isoamilic alcohol (Carlo 
Erba Reagenti, Milan, Italy) solution [25:24:1, (v/v/v)] was then added. The 
tube was extensively mixed by tapping and centrifuged at 12,000 rpm at 4°C 
for 5 minutes, then the aqueous upper phase, containing plasmid DNA, was 
recovered and placed in a clean 1.5 ml tube and an equal volume of
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chloroform/isoamilic alcohol solution [24:1, (v/v)] was added. After mixing, the 
tube was centrifuged and the aqueous upper phase was recovered and 
placed in a clean 1.5 ml conical tube. To precipitate plasmid DNA, the 
aqueous phase was mixed with sodium acetate, pH 5.2 (Sigma), (0.3 M final 
concentration) then, after addition of 2 volumes of -20°C-cold 100% ethanol, 
the solution was mixed for a few seconds using the vortex and placed for 
1 hour at -80°C. The sample was then centrifuged at 12,000 rpm at 4°C for 
30 minutes, and, after ethanol removal, pelleted DNA was washed twice with 
70% (v/v) ethanol and dried for 3 minutes with a speed-vacuum centrifuge 
(Heraeus). Dried plasmid vector was then dissolved in distilled water and 
quantified spectrophotometrically.
2.1.2.3. Cloning of the Ribozyme Sequences into the pRC/CMV Vector
In a 1.5 ml tube, 10 pi of each fragment was mixed with 3 pi digested 
plasmid, 4 pi 5x ligation buffer, 1 pi T4 DNA ligase, and sterile distilled water 
to a final volume of 20 pi. Tubes were incubated overnight at 16°C. The 
resulting plasmids were named pRc/Rz and pRc/mutRz. A permanent and 
stable source of the plasmids were obtained as described in 1.8.2. and 1.8.4. 
sections.
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2.1.3. Synthesis of VA1-Fusion Ribozymes
2.1.3.1. Digestion of the pBS-VA1 Plasmid Vector
In a 1.5 ml tube, 30 pg of pBS-VA1 plasmid [Prislei et al, 1997] was mixed 
with 60 units of Hindlll and Xbal restriction enzymes (Promega), 1x digestion 
buffer specific for both enzymes (Buffer E) (Promega) and distilled water to a 
final volume of 100 pi. The mixture was then incubated at 37°C in a water 
bath. After 1 hour, the reaction was stopped by addition of 5 pi of 0.5 M 
EDTA, pH 8. The digestion of the vector template was verified as described 
in the 1.8.3 section by loading about 200 ng of digested vector with the same 
amount of undigested plasmid DNA and 500 ng of K-BstEII molecular weight 
marker. The mixture was then purified and quantified as described in the
2.1.2.2. section.
2.1.3.2. Cloning of the Ribozyme Sequences into the pBS-VA1 Vector
In a 1.5 ml tube, 10 pi of each fragment was mixed with 3 pi digested 
plasmid, 4 pi 5x ligation buffer, 1 pi T4 DNA ligase, and sterile distilled water 
to a final volume of 20 pi. Tubes were incubated overnight at 16°C.
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2.1.3.3. Digestion of the VA1 -Ribozyme Cassette
In a 1.5 ml tube, 30 pg of VA1-ribozyme cassette was mixed with 60 units 
of EcoRI and Hindlll restriction enzymes (Promega), 1x digestion buffer 
specific for both enzymes (Buffer H) (Promega) and distilled water to a final 
volume of 100 pi. The mixture was then incubated at 37°C in a water bath. 
After 1 hour, the reaction was stopped by addition of 5 pi of 0.5 M EDTA, 
pH 8. The digestion of the template was verified as described in the 1.8.3 
section by loading about 200 ng of digested vector with the same amount of 
undigested plasmid DNA and 500 ng of K-BstEII molecular weight marker.
2.1.3.4. Blunting of the VA1 -Ribozyme Cassette
In a 1.5 ml tube, 0.1 pmol of VA1-ribozyme cassette was mixed with 1 pi of 
T4 DNA polymerase (Promega), 1x of reaction buffer (Promega) and distilled 
water to a final volume of 10 pi. The mixture was then incubated 5 minutes at 
70°C followed by 5 minutes at 37°C. The reaction was stopped by addition of 
DNA dilution buffer to bring the DNA concentration to 1 pg/50 pi. The mixture 
was then purified and quantified as described in the 2.1.2.2. section.
2.1.3.5. Digestion of the pCLXSN Plasmid Vector
In a 1.5 ml tube, 30 pg of pCLXSN plasmid was mixed with 60 units of 
Nhel restriction enzyme (Promega), 1x digestion buffer specific for both
132
Chapter 3 M a ter ia l  & M ethods
enzymes (Buffer H) (Promega) and distilled water to a final volume of 100 pi. 
The mixture was then incubated at 37°C in a water bath. After 1 hour, the 
reaction was stopped by addition of 5 pi 0.5 M EDTA, pH 8. The digestion of 
the vector template was verified as described in the 1.8.3 section by loading 
about 200 ng of digested vector with the same amount of undigested plasmid 
DNA and 500 ng of K-BstEII molecular weight marker. The mixture was then 
purified and quantified as described in the 2.1.2.2. section.
2.1.3.6. Cloning of the VA1 -Ribozyme Cassette into the pCLXSN Vector
In a 1.5 ml tube, 10 pi of each VA1-ribozyme cassette was mixed with 3 pi 
digested plasmid, 4 pi 5x ligation buffer, 1 pi T4 DNA ligase, and sterile 
distilled water to a final volume of 20 pi. Tubes were incubated overnight at 
16°C. The resulting plasmids were named pCLXSN/Rz and pCLXSN/CTR. A 
permanent and stable source of the plasmids were obtained as described in
1.8.2. and 1.8.4. sections.
2.2. In Vitro Catalytic Activity
2.2.1. In Vitro Ribozyme Transcription
2.2.1.1. Linearization of the pRc/Rz and pRc/mutRz Plasmids
In a 1.5 ml tube, 30 pg of pRc/Rz and pRc/mutRz plasmids were mixed 
with 60 units of Xbal restriction enzyme (Promega), 1x specific digestion
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buffer (Buffer E) (Promega) and distilled water to a final volume of 100 pi. 
The mixture was then incubated at 37°C in a water bath. After 1 hour, the 
reaction was stopped by addition of 5 pi 0.5 M EDTA, pH 8. The linearization 
of the vector template was verified as described in the 1.8.3. section by 
loading about 200 ng of digested vector with the same amount of undigested 
plasmid DNA and 500 ng of A-BstEII molecular weight marker. The mixtures 
were then purified and quantified as described in the 2.1.2.2. section.
2.2.1.2. In Vitro Transcription of Ribozymes
In a 0.5 ml tube, 20 pg of the resulting linear templates were in vitro 
transcribed in 0.2 ml of a reaction mixture composed of 260 units 
recombinant RNAsin ribonuclease inhibitor (Promega), 0.25 mM each of 
ribonucleotide triphosphates, 5 mM DTT, 1x transcription buffer (40 mM Tris- 
HCI, pH 8, 8 mM MgCI2, 2 mM spermidine), and 200 units T7 RNA 
polymerase (Takara, Shuzo Co., Otsu Shiga, Japan). The reaction mixtures 
were incubated for 2 hours at 37°C and then treated with 20 units RQ1 
RNase-free DNase (Promega) for 20 minutes at 37°C. The products were 
then purified and quantified as described in the 2.1.2.2. section.
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2.2.2. Synthesis of the Synthetic Substrate
2.2.2.1. Linearization of the pCI-Surv Plasmid
In a 1.5 ml tube, 30 |jg of pCI-surv plasmid was mixed with 60 units of Sty/ 
restriction enzyme (Promega), 1x specific digestion buffer (Buffer H) 
(Promega) and distilled water to a final volume of 100 pi. The mixture was 
then incubated at 37°C in a water bath. After 1 hour, the reaction was 
stopped by addition of 5 pi 0.5 M EDTA, pH 8. The linearization of the vector 
template was verified as described in the 1.8.3. section by loading about 
200 ng of digested vector with the same amount of undigested plasmid DNA 
and 500 ng of A-BstEU molecular weight marker. Digestion mixtures were 
then purified as described in the 2.1.2.2. section.
2.2.2.2. In Vitro Transcription of the Synthetic Substrate
In a 0.5 ml tube, 10 pg (6.25 pmoles) of Sfy/-linearised vector was in vitro 
transcribed in a solution containing 260 units recombinant RNAsin 
ribonuclease inhibitor (Promega), 0.25 mM each of ribonucleotide 
triphosphates, 5 mM DTT, 1x transcription buffer (40 mM Tris-HCI, pH 8, 8 
mM MgCI2, 2 mM spermidine), 200 units T7 RNA polymerase (Takara), and 
10 pCi [y-32P]-ATP (800 Ci/mmole) (Amersham). The reaction mixtures were 
incubated for 2 hours at 37°C and then treated with 20 units RQ1 RNase-free 
DNase (Promega) for 20 minutes at 37°C. Labelled DNA was purified and 
recovered as described in the 2.1.2.2. section with some modifications.
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Labelled DNA pellet was washed 4 times with 70% ethanol; the dried DNA 
pellet was dissolved in distilled water (50 pi) and cpm corresponding to 1 pi 
of this DNA solution was evaluated by “Cerenkov counting” at the p-counter 
(Tri-Carb Liquid Scintillation Analyzer; Camberra-Packard Italia, Milan, Italy). 
Assuming a DNA recovery of 50% after purification steps, a solution at a 
concentration of 100 ng/pl with a specific activity of 50,000-100,000 cpm/ng 
was generally obtained.
2.2.3. In Vitro Cleavage Reaction
The synthetic 32P-substrate RNA (10 nM) was mixed with 10-1000 nM Rz 
or with 1000 nM mutRz in 50 mM Tris-HCI, pH 7.5. The mixtures were heated 
for 5 minutes at 90°C, cooled at 37°C, and then incubated in the presence of 
50 mM MgCb. The cleavage reactions were performed at 37°C for 
120 minutes. Reactions were stopped by adding an equal volume of stop 
solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.02% 
xylene cyanol FF). Products were resolved on a 5% polyacrylamide/7 M urea 
gel and the results were quantified by densitometric analysis.
2.3. Transfection of Cells with the Ribozyme Expression Vectors
After harvesting in logarithmic growth phase, JR8 cells were seeded in 6- 
well plates (Corning-Costar) in 2 ml of fresh media at a density yielding 
approximately 50% confluency at the time of transfection. The plates were
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then incubated at 37°C in a 5% CO2 humidified atmosphere in the air 
incubator for 24 hours. In a 0.5 ml tube, 5 pg of pRc/Rz vector (or pRc/mutRz 
vector) were complexed with 30 pg of DOTAP (N-(1-(2,3 dioleoyloxy) propyl)- 
N,N,N-trimethylammoniummethyl sulphate) (Boehringer Mannheim, 
Mannheim, Germany). The reaction mixtures were incubated for 20 minutes 
at 37°C and then added to the wells. Twenty-four hours after transfection the 
culture medium containing the DOTAP/DNA mixture was replaced by a 
selection medium containing G418 to a final concentration of 2 mg/ml. The 
transfected cells were exposed to G418 for 1 month for the selection of 
different cellular clones. Two polyclonal populations, JR8 /Rz and JR8 /mutRz 
cells expressing the active and the mutant ribozymes respectively, were 
selected for the study.
2.4. Transduction of Cells with the Ribozyme Expression Vectors
2.4.1. Transfection of HEK293gp cells
Twenty-four hours prior to transfection, HEK293gp packaging cells 
(constitutively expressing gag and pol genes) [Somia et al, 2000] were 
seeded in 4 ml of fresh media at a density of 2 x 106 cells in 6 -well plates 
(Corning-Costar). Just prior to transfection, the medium was removed and 
the fresh growth medium was gently added. In a 0.5 ml tube, 5 pg of plasmid 
vector (pCLXSN/Rz or pCLXSN/CTR) was complexed with 5 pg of VSV-G- 
encoding plasmid, 36 pi of 2 M CaCb, 300 pi of 2 x HeBS and sterile distilled 
water to a final volume of 600 pi. This solution was then added to the cells
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and the plate was gently swirled to ensure uniform mixing. After 6 hours 
incubation at 37°C in a 5% C02 humidified atmosphere, the transfection 
cocktail was washed out and replaced with fresh medium. The viral particle- 
containing supernatants were collected 24, 48 and 72 hours after transfection 
and filtered through a 0.45-pm filter.
2.4.2. Infection of Prostate Cancer Cells
Twenty-four hours prior to transfection, DU 145 and PC-3 prostate cancer 
cells were seeded in 4 ml of fresh media at a density of 1 x 106 cells in 6-well 
plates (Corning-Costar). Just prior to transfection, the medium was removed 
and replaced with 1 ml of viral particle-containing supernatants, 1 ml of fresh 
complete media and polybrene (8 pg/ml). The cells were cultured for 
72 hours in the presence of the virus and then maintained in RPMI medium 
supplemented with G418 for 1 month and four polyclonal cell populations, 
two expressing the anti-survivin ribozyme (DU145/Rz and PC-3/Rz) and two 
expressing the control ribozyme (DU145/CTR and PC-3/CTR), were selected 
for the study.
2.5. Reverse Transcriptase-PCR Analysis of Ribozyme Expression
Ribozyme expression in parental (JR8, DU 145 and PC-3), transfected 
(JR8/Rz and JR8/mutRz) and infected (DU145/Rz, PC-3/Rz, DU145/CTR 
and PC-3/CTR) cells was evaluated by RT-PCR analysis.
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2.5.1. Cell Preparation
Cells in logarithmic growth phase were detached from the flasks by means 
of sterile Trypsin-EDTA solution, transferred into a sterile a 15 ml conical 
tube and pelleted by a 5-minute centrifugation at 1,500 rpm at 4°C. Single­
cell suspension was obtained by resuspending cell pellets in 10 ml of sterile 
PBS; the suspension was checked under the microscope, and a small aliquot 
(100-500 pi) was transferred in the isoton solution and counted in the particle 
counter.
An aliquot of cell suspensions containing about 5-10 x 106 cells was then 
transferred in a sterile 1.5 ml tube, cells were pelleted by a 30-second 
centrifugation at 12,000 rpm at 4°C. After removal of PBS, cell pellets were 
washed twice with 1 ml of sterile PBS. At the end of the last wash, PBS was 
removed and total RNA was extracted from the cells.
2.5.2. Total RNA Isolation
All extraction and manipulation steps were performed under sterile 
conditions using Diethylpirocarbonate (DEPC) (Sigma)-treated or 'RNase- 
free' certified chemicals and plastic disposable materials.
Total cellular RNA was obtained from fresh or frozen cell pellets by means 
of the Trizol Reagent (Invitrogen) according to the manufacturer's 
instructions. The amount of extracted RNA was determined 
spectrophotometrically.
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Quality of isolated RNA was checked by gel electrophoresis analysis 
carried out by using a 1% (w/v) agarose mini gel (10 centimetres length/6 
centimetres wide) prepared in 1x TAE buffer. An aliquot corresponding to 
about 1 pg of extracted ribonucleic acid was mixed in a RNase-free 0.5 ml 
tube with an equal volume of sequencing gel loading buffer [95% (v/v) 
Formamide (Sigma), 20 mM EDTA pH 8, 0.05% (w/v) bromophenol blue and 
0.05% (w/v) xylene cyanol (Sigma)], heated at 100°C for 3 minutes (to 
completely destroy possible RNA secondary structures), chilled on ice for 
further 3 minutes and loaded. RNA samples were run at a constant voltage 
of 90 volts for 1 hour at room temperature. The gel was then stained for 
30 minutes at room temperature with gentle shaking in the ethidium bromide 
staining solution (1 pg/ml ethidium bromide prepared in 1x TAE buffer) and 
destained for further 30 minutes at room temperature with gentle shaking in 
1x TAE buffer. RNA was visualised by means of the UV transilluminator and 
photographed on a 667 Polaroid film (Polaroid LtD-St. Albans, United 
Kingdom). The presence of well defined and visible bands corresponding to 
both 28S and 18S ribosomal RNA was indicative of a good RNA preparation.
Total RNA extracted from each cell line was stored at -80°C as 1 pg 
aliquots.
2.5.3. Synthesis of First Strand cDNA by Reverse Transcriptase 
Reaction
Total RNA extracted from each cell line was reverse transcribed by using 
RNA PCR Core Kit (Perkin-Elmer). In a RNase-free 0.5 ml reaction tube
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(Perkin-Elmer), 1 pg of total RNA was mixed with 2.5 pM random hexamers, 
20 units of RNase inhibitor, 2.5 mM MgCI2, 1mM each dNTP, 1x PCR buffer 
(10 mM Tris-HCI pH 8.3, 50 mM KCI), 50 units of MuLV reverse transcriptase 
and RNase-free water to a final volume of 20 pi. Tubes were incubated at 
room temperature for 15 minutes (to allow annealing between random 
hexamers and RNA). First strand cDNA synthesis and MuLV reverse 
transcriptase inactivation were then obtained by a 42°C-incubation for 
30 minutes and a 5-minute heating at 95°C, respectively, in a hot-bonnet 
thermal cycler (MJ Research/M-Medical-Florence, Italy). Samples were 
stored at 4°C until they were used in PCR reactions.
2.5.4. PCR Reactions
To analyze ribozyme expression, the resultant cDNAs were amplified 
using T7 (5-TAA TAC GAC TCA CTA TAG GGA GA-3’) and SP6 (5’-CG 
ATT TAG GTG ACA CTA TAG-3’) or VA1 sense (5’-GGG CAC TCT TCC 
GTG GTC-3’) and VA1 anti-sense (5-AAA GGA GCG CTC CCC CGT TG-3’) 
primers in melanoma and prostate cancer cells, respectively. All primers 
used were synthesised and supplied in lyophilised form by MWG Biotech. For 
each primer, 100 pM stock solution was prepared by dissolving the 
lyophilised primer in an opportune volume of 1x TE pH 8 (10 mM Tris-HCI, 
1 mM EDTA) by extensive vortexing. The successive dilutions were prepared 
in distilled water.
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The vectors pRc/Rz, pRc/mutRz, pCLXSN/Rz and pCLXSN/CTR were 
used as controls for the correct fragment size during PCR amplification.
The PCR amplification was performed using the RNA PCR Core Kit 
(Perkin-Elmer) as follows. In DNase-free 0.5 ml PCR reaction tubes, 125 ng 
of total RNA reverse transcribed in first strand cDNA (or plasmid vector) were 
mixed with 1 pM T7 and SP6 (or VA1 sense and antisense) primers, 
0.625 units of AmpliTaq DNA polymerase, 1x PCR buffer, 2 mM MgCh and 
DNase-free water to a final volume of 25 pi. Tubes were then placed in a hot- 
bonnet thermal cycler and PCR products were obtained performing 1 cycle at 
95°C for 5 minutes followed by 30 cycles each formed by a denaturation step 
of 1 minute at 95°C, an annealing step of 1 minute at 47°C for T7/SP6 
primers (62°C for VA1 sense and antisense) and an extension step of 
1 minute at 72°C followed by a final extension cycle of 5 minutes at 72°C.
It is important to stress that these experimental conditions were selected 
on the basis of preliminary experiments to ensure that the PCR was still in 
the exponential phase when the reaction was stopped.
2.5.5. Gel Electrophoresis and Densitometric Quantification of PCR 
Products
Twenty-five pi PCR solution were mixed with 5 pi 6x gel loading buffer 
(0.25% (w/v) of both bromophenol blue and xylene cyanol, 30% (v/v) glycerol 
in distilled water) and samples were loaded onto 3% (w/v)-1x TAE buffer 
agarose gel. Electrophoretic separation was performed at 90 volts in 1x TAE
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buffer and was stopped when bromophenol blue dye reached the bottom of 
the gel. Agarose gel was then stained for 30 minutes at room temperature 
with gentle shaking in the ethidium bromide-1 x TAE buffer staining solution 
and destained for a further 30 minutes at room temperature with gentle 
shaking in 1x TAE buffer. PCR products were visualised on the UV- 
transilluminator and photographed on a 665 Polaroid film. Negative copy of 
the film was developed by using 18% (w/v) sodium sulphite (Sigma) 
according to the manufacturer's instructions and it was used for densitometric 
quantification of the PCR products by means of a HP ScanJet llcx/t scanner 
(HewlettPackard Italia, Milan, Italy) and IQ software (Molecular Dynamics 
Ltd., Kemsing, United Kingdom).
2.6. Small Interfering RNA Design
Four different siRNAs (siRNA2 [Carvalho et al, 2003], siRNA3, siRNA7 
and siRNAIO) targeting specific consensus sequences (5’-AA(Ni9)UU-3\ 
where N is any nucleotide) within the survivin mRNA were designed by using 
the siRNA target finder tool (http://www.ambion.com/techlib/misc/siRNA_ 
finder) (Figure 26). A blast search (http://www.ncbi.nlm.nih.gov/BLAST) for 
selected siRNA sequences was performed to ensure that only a single gene 
was targeted. A scramble siRNA, made of a sequence with no significant 
homology to any known human mRNA, was used as control (siRNActr) 
throughout the study (Figure 26) [Elbashir et al, 2001].
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survivin pre m RNA
— ™ exon 1 ■ ■ ■ ■ exon 2 ■ ■ ■ ■ exon 3 ■ ■ ■ ■ exon 4
92 112 116 136 243 263 283 303 Position of target
sequences
2 3 7 10
siR N A 2 G G A C C A C C G C A U C U C U A C A d Td T
d Td TC C U G G U G G C G U A G A G A U G U
siR N A 3
G A A C U G G C C C U U C U U G G A G dT dT
d Td TC U U G A C C G G G A A G A A C C U C
siR N A 7
G G C U G G G A G C C A G A U G A C G d T d T
dTd TC C G A C C C U C G G U C U A C U G C
siR N A IO
A G C A U U C G U C C G G U U G C G C d T d T
d T d TU C G U A A G C A G G C C A A C G C G
siR N A ctr C G U A C G C G G A A U A C U U C G A dT dT
d Td TG C A U G C G C C U U A U G A A G C U
Figure 26. Structures of siRNAs.
Schematic representation of the survivin pre-mRNA and location of each target 
sequence in survivin mRNA (GeneBank accession n. NM_001168.1). The scramble 
siRNA (siRNactr) denotes a siRNA that had no significant homology to any known 
human mRNA [Elbashir et al, 2001] and was used to control the specificity of the 
RNAi reaction.
All siRNAs were purchased from MWG Biotech as preformed and purified 
duplexes, made of 19 ribonucleotides with two extra thymidine bases forming 
a 3’ overhang on both strands (Figure 26). Each siRNA was resuspended in 
water and the stock solutions (20 pM) were stored at 4°C until use.
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2.7. Transfection of Prostate Cancer Cells with siRNAs
The day before transfection, prostate cancer cells were seeded at a 
density of 2.5-5.0 x 105 per 25 cm2 flask. A given amount of each siRNA was 
diluted in 50 pi of Opti-MEM® I reduced serum medium (Invitrogen). The 
Lipofectamine2000™ (Lipo2000) was diluted in 50 pi of Opti-MEM® I 
medium and incubated for 5 minutes at room temperature. After the 
incubation, the diluted siRNA was combined with the diluted Lipo2000 (total 
volume is 100 pi) and incubated for 20 minutes at room temperature to allow 
the siRNA:Lipo2000 complexes to form. The mixtures were then applied to 
the cells in a final volume of Opti-MEM® I medium giving a final siRNA 
concentration of 100 nM. After incubation for 8 hours at 37°C, RPMI-1640 
medium supplemented with serum was added. Cells were then cultured for 
an additional 24-48 hours at 37°C before further analysis.
2.8. Expression of Survivin and Apoptosis-Related Proteins
The expression of survivin and some of the most important proteins 
involved in the control of apoptosis was determined by Western blot analysis.
2.8.1. Protein Extract Preparation
Cells in logarithmic growth phase were detached from the flasks by means 
of Trypsin-EDTA solution, transferred in a 15 ml conical tube and pelleted by
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a 5-minute centrifugation at 1,500 rpm at 4°C. To obtain a single-cell 
suspension, cell pellets were dissolved by repeated pipetting in 10 ml of PBS. 
Cell suspension was checked under the microscope, and a small aliquot 
(100 pi) was transferred in the isoton solution and counted in the particle 
counter.
An aliquot of cell suspension containing about 5 x 106 cells was then 
transferred in a 1.5 ml conical tube and cells were pelleted by a 15-second 
centrifugation at 12,000 rpm at 4°C. After removal of PBS, cell pellets were 
again washed twice with PBS. At the end of the last wash, PBS was removed 
and cells were resuspended by gentle pipetting in 50 pi of ice-cold lysis 
buffer [1% Nonidet P-40, 10 mM NaF, 1 mM NaV30 4, 1 mM NaPP04, 10 
pg/ml leupeptin, 10 pg/ml aprotinin, 1 mM AEBSF, 1x PBS]. Cell suspensions 
were incubated on ice for 30 minutes. The homogenates were then 
centrifuged 5 minutes at 12,000 rpm at 4°C and supernatants containing the 
protein extracts were transferred in a clean 0.5 ml conical tubes.
Protein concentration was determined as described in section 1.4, and 
protein extracts were stored at -80°C as 50 pg aliquots.
2.8.2. Immunoprecipitation
For the assessment of the Thr34-phosphorylated form of survivin, 100 pg of 
precleared, detergent-solubilized protein extracts were mixed with 50 pi of a 
20% (v/v) protein A-Sepharose slurry (Amersham) 50:50 protein A slurry 
(Sigma) and immunoprecipitated with the anti-human survivin antibody
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(20 pg/ml). The formation of immune complexes was carried out by a 4°C- 
incubation on a shaking platform. The protein A-Sepharose/anti-survivin 
antibody/survivin ternary immune complexes were then collected to the 
bottom of the tube by a 12,000 rpm-centrifugation for 2 minutes at 4°C. After 
the supernatant phase removal, immune complexes pellets were washed 
twice with 100 pi of lysis buffer.
2.8.3. Western Blot Analysis
Equivalent amounts of cellular extracts were fractionated, blotted onto 
solid support and immunoassayed to qualitatively evaluate the expression of 
survivin protein and apoptosis-related proteins.
2.8.3.1. SDS-Polyacrylamide Gel Electrophoresis
An 12% (w/v) polyacrylamide resolving gel was used to obtain the 
separation of survivin, Bcl-2, Bcl-xL, Bax, caspase-3, caspase-9, Akt and 
cdk6. An aliquot of cellular extracts containing 40 pg of proteins were mixed 
with 20 pi of colour markers for SDS-PAGE and protein transfer spanning a 
molecular weight range of 6.5-205 KDa (Sigma) in a 1.5 conical tube. An 
equal volume of 2x SDS loading buffer (100 mM Tris-HCI pH 6.8, 4% (w/v) 
SDS, 0.2% (w/v) bromophenol blue (Sigma), 20 (v/v) glycerol and 200 mM 
DTT) was then added. Tubes were heated at 100°C for 5 minutes, chilled on
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ice for an additional 5 minutes, centrifuged at 4°C at 12,000 rpm for 
5 seconds and loaded onto the SDS-PAGE system.
Proteins were fractionated running the gel at constant voltage (150 volt) by 
means of a Biorad 200/2.0 power supply (Biorad). The run was stopped 
when the 6.8 KDa band of the colour marker reached the bottom of the gel.
2.8.3.2. Transfer of Fractionated Proteins into Nitrocellulose Filter
Protein blotting was performed in an electrophoresis protein transfer unit 
(Biorad). When the SDS-PAGE was approaching the end of its run, four 
pieces of Whatman 3MM (Whatman International LtD., Maidstone, United 
Kingdom) and one piece of nitrocellulose filter (Hybond ECL, Amersham) to 
the exact size of the resolving gel were cut and soaked for at least 5 minutes 
in transfer buffer [50 mM Tris base, 100 mM Glycine, 0.01% (w/v) SDS, 20% 
(v/v) methanol (Carlo Erba Reagenti), pH 7.5]. At the end of the run, the 
glass plates holding the SDS-polyacrylamide gel were removed from the 
electrophoresis tank, the glass plates were opened and, by means of a 
scalpel, the stacking gel was removed. The resolving gel was placed exactly 
on the top of nitrocellulose filter and then sandwiched between two pairs of 
transfer buffer wetted-Whatman 3MM papers. Possible air bubbles trapped 
were displaced by repeated rolling with a pipette tip. The sandwich was then 
placed between two transfer buffer wetted-porous pads and two plastic 
supports and the entire construction was immersed in the electrophoresis 
transfer tank containing transfer buffer with the nitrocellulose filter placed
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toward the anode. Transfer of the protein from the gel to nitrocellulose 
membrane was carried out at room temperature for 2 hours at 70 volt 
(constant voltage) by means of a Biorad 200/2.0 power supply.
2.8.3.3. Immunological Detection of Nitrocellulose-Immobilised Proteins
At the end of the transfer, the nitrocellulose filter was recovered from the 
sandwich and, in order to verify the correct protein blotting, it was stained for 
5 minutes in a clean tray containing a Ponceau S red dye solution (Sigma) 
with gentle agitation at room temperature. When the bands of proteins were 
visible, the filter was destained with several washes of distilled water at room 
temperature. To completely destain the Ponceau S red dye bound to the 
proteins, nitrocellulose slices were washed three times for 20 minutes at 
room temperature on a shaking platform with blocking solution [5% (w/v) 
dried-nonfat milk (Regilait, Barcelona, Spain), 0.1% (v/v) Tween-20 (Sigma) 
and PBS]; filter slices were then incubated at room temperature on a shaking 
platform in blocking solution to mask potential nonspecific antibodies binding 
sites and, thus, to reduce general background. After 1 hour, blocking solution 
was removed and filters were incubated over night at 4°C on a shaking 
platform with the specific antibody-containing solution. Detection of proteins 
of interest was achieved by using polyclonal antibodies anti-survivin, Bcl-2, 
B c I-x l , Bax, Akt and cdk6 (Abeam Ltd, Cambridge, United Kingdom) or 
monoclonal antibodies anti-caspase-3, caspase-9 and (3-actin (Abeam), 
diluted in blocking solution. At the end of the over night incubation, primary
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antibodies were removed and filter slices were washed 3 times for 
20 minutes with T-PBS wash solution [0.1% (v/v) Tween-20 in PBS] at room 
temperature on a shaking platform. Nitrocellulose filters were then incubated 
at room temperature on a shaking platform with the secondary anti-mouse or 
anti-rabbit Ig horseradish peroxidase-linked whole antibodies (Amersham) 
diluted 1:1000 in blocking solution. After a 1-hour hybridisation, secondary 
antibodies were removed and filter slices were washed three times for 
20 minutes at room temperature on a shaking platform with T-PBS wash 
solution followed by a rapid wash with PBS. Antibodies bound to proteins of 
interest on nitrocellulose slices were detected by means of the enhanced 
chemoluminescence system (ECL) (Amersham) according to the 
manufacturer's instructions using Hyperfilm MP films (Amersham).
2.9. Evaluation of Survivin Gene Expression by RT-PCR Analysis
The expression of survivin gene in cancer cells was quantified by RT-PCR 
analysis.
2.9.1. Cell Preparation
Cells were detached from the flasks by means of sterile Trypsin-EDTA 
solution, transferred into a sterile a 15 ml conical tube and pelleted by a 5- 
minute centrifugation at 1,500 rpm at 4°C. Single-cell suspension was 
obtained by resuspending cell pellets in 10 ml of sterile PBS, the suspension
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was checked under the microscope, and a small aliquot (100 pi) was 
transferred in the isoton solution and counted in the particle counter.
An aliquot of cell suspensions containing about 5-10 x 106 cells was then 
transferred in a sterile 1.5 ml tube, cells were pelleted by a 15-second 
centrifugation at 12,000 rpm at 4°C. After removal of PBS, cell pellets were 
washed twice with 1 ml of sterile PBS. At the end of the last wash, PBS was 
removed and total RNA was extracted from the cells.
2.9.2. Total RNA Extraction
All extraction and manipulation steps were performed under sterile 
conditions using DEPC-treated or RNase-free certified chemicals and plastic 
disposable materials.
Total cellular RNA was obtained from fresh or frozen cell pellets by means 
of the Trizol Reagent (Invitrogen) according to the manufacturer's 
instructions. The amount of extracted RNA was determined 
spectrophotometrically. Quality of isolated RNA was checked by gel 
electrophoresis analysis carried out by using a 1% (w/v) agarose mini gel 
(10 centimetres length/6 centimetres wide) prepared in 1x TAE buffer. An 
aliquot corresponding to about 1 pg of extracted ribonucleic acid was mixed 
in a RNase-free 0.5 ml tube with an equal volume of sequencing gel loading 
buffer [95% (v/v) Formamide (Sigma), 20 mM EDTA pH 8, 0.05% (w/v) 
bromophenol blue and 0.05% (w/v) xylene cyanol (Sigma)], heated at 100°C 
for 3 minutes (in order to completely destroy possible RNA secondary
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structures), chilled on ice for further 3 minutes and loaded. RNA samples 
were run at a constant voltage of 90 volts for 1 hour at room temperature. 
The gel was then stained for 30 minutes at room temperature with gentle 
shaking in the ethidium bromide staining solution (1 pg/ml ethidium bromide 
prepared in 1x TAE buffer) and destained for further 30 minutes at room 
temperature with gentle shaking in 1x TAE buffer. RNA was visualised by 
means of the UV transilluminator and photographed on a 667 Polaroid film. 
The presence of well defined and visible bands corresponding to both 28S 
and 18S ribosomal RNA was indicative of a good RNA preparation.
Total RNA extracted from each cell line was stored at -80°C as 1 pg 
aliquots.
2.9.3. Synthesis of First Strand cDNA by Reverse Transcription 
Reaction
Total RNA extracted from each cell line was reverse transcribed by using 
RNA PCR Core Kit (Perkin-Elmer). In a RNase-free 0.5 ml reaction tube 
(Perkin-Elmer), 1 pg of total RNA was mixed with 2.5 pM random hexamers, 
20 units of RNase inhibitor, 2.5 mM MgCI2, 1 mM each dNTP, 1x PCR buffer 
(10 mM Tris-HCI pH 8.3, 50 mM KCI), 50 units of MuLV reverse transcriptase 
and RNase-free water to a final volume of 20 pi. Tubes were incubated at 
room temperature for 15 minutes (to allow annealing between random 
hexamers and RNA). First strand cDNA synthesis and MuLV reverse 
transcriptase inactivation were then obtained by a 42°C-incubation for 30
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minutes and a 5-minute heating at 95°C, respectively, in a hot-bonnet 
thermal cycler. Samples were stored at 4°C until they were used in PCR 
reactions.
2.9.4. PCR Reactions
Primers used were synthesised and supplied in lyophilised form by MWG 
Biotech:
survivin sense 5’-AGCCCTTTCTCAAGGACCAC-3’ 
survivin antisense 5’-TGACAGATAAGGAACCTGCA-3’
P-actin sense 5’-GGGAATTCAAAACTGGAACGGTGAAGG-3’
P-actin antisense 5’-GGAAGCTTATCAAAGTCCTCGGCCACA-3’
For each primer, 100 pM stock solution was prepared by dissolving the 
lyophilised primer in an opportune volume of 1x TE pH 8 (10 mM Tris-HCI, 
1 mM EDTA) by extensive vortexing. The successive dilutions were prepared 
in distilled water.
Non-competitive quantitative PCR amplification was performed using the 
RNA PCR Core Kit (Perkin-Elmer) as follows. In DNase-free 0.5 ml PCR 
reaction tubes, 125 ng of total RNA reverse transcribed in first strand cDNA 
were mixed with 1 pM sense and antisense survivin primers, 0.1 pM sense 
and antisense p-actin primers, 0.625 units of AmpliTaq DNA polymerase, 
1x PCR buffer, 2 mM MgCb and DNase-free water to a final volume of 25 pi. 
Tubes were then placed in a hot-bonnet thermal cycler and both 864 bp 
survivin and 620 bp p-actin PCR products were obtained performing 1 cycle
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at 95°C for 2 minutes followed by 30 cycles each formed by a denaturation 
step of 1 minute at 95°C, an annealing step of 30 seconds at 62°C and an 
extension step of 30 seconds at 72°C followed by a final extension cycle of 
7 minutes at 72°C.
It is important to stress that these experimental conditions were selected 
on the basis of preliminary experiments to ensure that the PCR was still in 
the exponential phase when the reaction was stopped.
2.9.5. Gel Electrophoresis and Densitometric Quantification of PCR 
Products
Twenty-five pi of PCR solution were mixed with 5 pi of 6x gel loading 
buffer (0.25% (w/v) of both bromophenol blue and xylene cyanol, 30% (v/v) 
glycerol in distilled water) and samples were loaded onto 3% (w/v)-1x TAE 
buffer agarose gel. Electrophoretic separation was performed at 110 volts in 
1x TAE buffer and was stopped when bromophenol blue dye reached the 
bottom of the gel. Agarose gel was then stained for 30 minutes at room 
temperature with gentle shaking in the ethidium bromide-1 x TAE buffer 
staining solution and destained for a further 30 minutes at room temperature 
with gentle shaking in 1x TAE buffer. PCR products were visualised on the 
UV-transilluminator and photographed on a 665 Polaroid film. Negative copy 
of the film was developed by using 18% (w/v) sodium sulphite (Sigma) 
according to the manufacturer's instructions and it was used for densitometric 
quantification of the PCR products by means of a HP ScanJet llcx/t scanner
154
Chapter 3 M ater ia l  & M etho ds
(HewlettPackard) and IQ software (Molecular Dynamics). The relative 
expression level of survivin was normalised to that of p-actin.
2.10. The Cytotoxic Activity of Different Drugs on Cell Lines
2.10.1. Colony Formation Assay
After harvesting in logarithmic growth phase, melanoma cell clones, HeLa, 
OAW42/e and OAW42/Surv cells were plated in plastic dishes (Corning- 
Costar) in 5 ml of fresh media at a different density (ranging from 250 to 2000 
cells/dish) depending on the drug concentration to be used.
Immediately before cell treatment, drug stock solutions were diluted in 
specific growth media and cells were exposed to cisplatin (1.0-20 pg/ml) for 1 
hour, topotecan (1.0-10 ng/ml) for 24 hours, temozolomide (0.1-10 pg/ml) for 
24 hours, or to paclitaxel (1.0-10 nM), NU6140 and purvalanol A (1.0-10 pM), 
singly administrated or in combination. For the paclitaxel and cdk inhibitors 
combination, two schedules were tested: a) a 24-hour paclitaxel treatment 
followed by a 24-hour incubation with NU6140 or purvalanol A; b) a 24-hour 
NU6140 or purvalanol A treatment followed by a 24-hour incubation with 
paclitaxel. Control cells were exposed to 1% (v/v) DMSO. At the end of the 
different treatments, drug-containing medium was removed from each well, 
cells were washed with PBS and incubated at 37°C in a 5% C02 humidified 
atmosphere for 10 days to form colonies.
Colonies consisting of at least 50 cells were stained with crystal violet in 
70% v/v ethanol/water and counted under the microscope. Each
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experimental point was run four times. The colony-forming efficiency was 
calculated from the number of colonies counted and the number of 
morphologically intact single cells seeded.
The in vitro effect of drugs was expressed in terms of IC5 0 , i.e, the 
concentration able to inhibit clonogenic cell survival by 50%. The plating 
efficiency (PE) was calculated from the number of colonies counted and the 
number of cells seeded. The surviving fraction (SF) was calculated as 
follows:
SF = (PE of treated sample)/(PE of control).
2.10.2. Cell Proliferation Assay
After harvesting in logarithmic growth phase, DU 145 and PC-3 cells were 
seeded in 6-well plates (Corning-Costar) in 2 ml of fresh media at 40 x 103 
cells/well. Plates were then incubated at 37°C in a 5% C02 humidified 
atmosphere in the air incubator for 24 hours.
Immediately before cell treatment, cisplatin stock solution was diluted in 
specific growth media and cells were treated with increasing concentrations 
of cisplatin (1.0-20 pg/ml) for 1 hour. At the end of the treatment, drug- 
containing medium was removed from each well, cells were washed with 
PBS and incubated at 37°C in a 5% CO2 humidified atmosphere for 3 days.
To assess siRNA-mediated inhibition of cell proliferation, prostate cancer 
cells were transfected with 100 nM of each siRNA as described in the
2.7 section. In combination experiments, following an 8-hour transfection with
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siRNA2, cells were exposed for 72 hours to different concentrations (from 
5 to 500 ng/ml) of 17-AAG (previously reconstituted in sterile DMSO and then 
diluted with sterile water to the final dose). Cells were then harvested 
immediately at the end of treatment (day 3), or after an additional 4 days in 
drug-free medium (day 7).
At the end of treatments, medium was removed from each well, cells were 
washed three times with PBS (3 ml/well) and detached from the plates by a 
5-minute incubation at 37°C with Trypsin-EDTA solution (1 ml/well). Trypsin 
activity was stopped by addition of a 10% (v/v) FBS-PBS solution (5 ml/well) 
and cells were transferred in the isoton solution. Single-cell suspensions 
were obtained by repeated pipetting, checked under the microscope and 
counted in a particle counter. Cell viability was determined by the Trypan 
blue dye exclusion test. Each experimental sample was run in triplicate and 
the results were expressed as percentage variation in the number of viable 
cells in treated compared to control cells.
2.11. The Cytotoxic Activity of Ionising Radiation on Cell Lines
2.11.1. Irradiation
After harvesting in logarithmic growth phase, melanoma cells were 
irradiated at room temperature using a 137Cs y-irradiator (IBL-437, Oris, 
France) at a dose rate of 7.2 Gy/min. Immediately after irradiation or 
72 hours after irradiation, cells were processed for colony formation or 
apoptosis experiments, respectively, as outlined below.
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2.11.2. Clonogenic Assay
After treatment with 1-10 Gy ionizing radiation, melanoma cells were 
plated at appropriate concentrations in plastic dishes (ranging from 250 to 
2000 cells/dish) and incubated at 37°C in an atmosphere of 5% CO2 and 
95% air for 10 days. Colonies consisting of at least 50 cells were stained with 
crystal violet in 70% v/v ethanol/water and counted under the microscope. 
The colony-forming efficiency was calculated from the number of colonies 
counted and the number of morphologically intact single cells seeded. The 
surviving fractions of treated cells relative to unirradiated cells were 
determined, and the data were fitted to the multitarget single-hit model of cell 
inactivation:
S/SO =1-(1 - e"D/D0)n
where S/SO is the surviving fraction and D is the dose (Gy). The parameters 
n and Do were calculated using ELMAT software (kindly provided by Dr. 
Benassi, Regina Elena Cancer Institute, Rome, Italy). Triplicate 
determinations of each radiation dose were performed and an intra­
experiment average was calculated. The points shown on the clonogenic 
survival curves are the inter-experiment averages (and their relative standard 
deviations) calculated from at least three intra-experiment averages.
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2.12. Cell Cycle Analysis
Fresh cells (1 x 106, 0.5 ml) were fixed by a drop-to drop addition of 
cellular suspension to 4.5 ml of -20°C cold 70% ethanol present in a 5 ml 
Nalgene tube. Fixed cells were stored at -20°C until they were subjected to 
flow cytometric analysis.
Immediately before analysis, fixed cells were collected by a 1,500 rpm- 
centrifugation at 4°C for 5 minutes, transferred into a 1.5 ml tube and washed 
twice with 0.5 ml of PBS. Cell pellets were then resuspended in 0.5 ml of the 
solution A [50 pg/ml propidium iodide (Sigma), 50 mg/ml RNase A and 
0.05% (v/v) Nonidet P-40] and stained at 4°C. After 30 minutes, drug-induced 
cell cycle perturbations were assessed by analysing the stained cellular 
suspension with a FACScan flow cytometer (Becton Dickinson, Sunnyvale, 
CA, USA). At least 30,000 events were read and the percentages of cells in 
Go/i, S and G2/M phases were evaluated on DNA plots by CellFit software 
(Becton Dickinson) according to the SOBR model (Becton Dickinson).
2.13.Apoptosis Analysis
Each experimental sample was split into various aliquots (containing an 
appropriate number of cells) for the different apoptosis assays. Cells aliquots 
destined to be used in assays for which fresh cells were not required were 
collected by a 12,000 rpm-centrifugation at 4°C for 30 seconds and frozen by 
snap freezing in liquid nitrogen and stored at -80°C.
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2.13.1. Evaluation of Apoptotic Morphology by Fluorescent Microscopy
Untreated and treated cells were stained with solution A (1 ml for 1 x 106 
cells) as described in the 3.12 section. An aliquot of 30,000 stained cells was 
cytocentrifuged onto a glass slide for 3 minutes at 500 rpm (Cytospin 3) 
(Shandon Italia, Milan, Italy) at room temperature and, a cover slide was then 
placed on the top of cells and glass slides were observed under fluorescence 
microscopy (excitation wave length = 588 nm, emission wave length = 
610 nm) by using a fluorescence miscroscope. The percentage of apoptotic 
cells was determined by scoring at least 500 cells in each sample.
2.13.2. The Terminal dUTP Nick-End Labeling (TUNEL) Assay
Cells (1 x 106) were washed in cold PBS and centrifuged at 200 g for 
5 minutes and then fixed in 1 ml 4% paraformaldehyde pH 7.4 for 45 minutes 
at room temperature. After rinsing with PBS, cells were permeabilized in a 
solution of 0.1% Triton X-100 in sodium 0.1% citrate for 2 minutes on ice. 
Cell suspension was centrifuged at 200 g for 5 minutes and washed with 
PBS. Cell pellet was resuspended in 50 pi of the TUNEL reaction mixture 
(Boehringer Mannheim) and incubated for 1 hour at 37°C in the dark. After 
rinsing with PBS, the pellet was suspended in PBS and analyzed by a 
FACScan flow cytometer (Becton Dickinson). The results were expressed as 
the percentage of TUNEL-positive cells in the overall cell population.
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2.13.3. Evaluation of Caspase-9 and Caspase-9 Catalytic Activity
Cell pellet (2 x 106) was washed with cold PBS, resuspended in 100 pi of 
chilled lysis buffer (caspase-9/Mch6 or caspase-3/cpp32 fluorometric assay 
kit, MBL, Japan) and incubated on ice for 20 minutes. The pellet was 
centrifuged for 15 minutes at 14,000 rpm at 4°C and the clear supernatant 
was transferred in a 1.5 ml conical tube. One hundred pi of 2x Reaction 
Buffer (MBL) and 10 pi of the specific fluorogenic substrate (leu-glu-his-asp- 
7-amino-4-trifluoromethylcoumarin, LEHD-AFC, for caspase-9 and N-acetyl- 
Asp-Glu-Val-Asp-aldehyde-7-amino-4-methylcoumarin, Ac-DEVD-AMC, for 
caspase-3) were added and incubate at 37°C for 1 hour. At the end of 
incubation, samples were transferred to a 96-well plate and the hydrolysis of 
the specific substrates for caspase-9 and caspase-3 was monitored by 
spectrofluorometry using an excitation wavelength of 400 nm and an 
emission wavelength of 505 nm.
2.14. Detection of Telomerase Activity
2.14.1. Protein Extract Preparation
Cell pellet was resuspended by gentle pipetting in 200 pi of ice cold 
1x CHAPS lysis buffer (Intergen Co., Oxford, United Kingdom) [10 mM Tris- 
HCI, pH 7.5, 1 mM MgCL, 1 mM EGTA, 0.1 mM benzamidine, 0.5% CHAPS, 
5 mM mercaptoethanol, and 10% glycerol], and leaved on ice for 30 minutes. 
The lysate was then centrifuged at 12,000 rpm for 20 minutes at 4°C and
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160 pi of supernatant were collected into a clean eppendorf tube, making 
sure no traces of pellet were withdrawn. Protein concentration was 
determined as described in section 1.4, and protein extracts were stored at - 
80°C as 0.5 pg/pl aliquots.
2.14.2. Labeling of the TS Primer
In RNase-free 0.5 ml PCR reaction tubes, 10 pi of the TS primer 
oligonicleotide (5’-AATCCGTCGAGCACAGAGTT-3’) were mixed with 25 pCi 
[y-32P]-ATP, 5 units of T4 polynucleotide kinase, 1x kinase buffer, RNase- 
free water to a final volume of 20 pi. Tubes were then placed in a hot-bonnet 
thermal cycler for 20 minutes at 37°C followed by 5 minutes at 85°C.
2.14.3. The Telomere Repeat Amplification Protocol (TRAP) Assay
One pg (2 pi) of protein extract was used to assess telomerase activity by 
the polymerase chain reaction (PCR)-based telomeric repeats amplification 
protocol (TRAP) assay by means of the TRAPeze kit (Intergen). Specifically, 
the master mix was prepared by mixing 1x TRAP reaction buffer, 1x dNATs 
mix, 2 pi 32P-TS primer, 1 pi TRAP primer mix, 2 units Taq polymerase and 
RNase-free water to a final volume of 48 pi. Two pi of the protein extract (or 
control sample) were mixed with 48 pi of the master mix and the tubes were 
incubated for 30 minutes at 30°C.
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The enzyme activity products were amplified by PCR performing 1 cycle at 
94°C for 2 minutes followed by 30 cycles each formed by the first step of 
10 seconds at 94°C, the second step of 25 seconds at 50°C and the last step 
of 30 seconds at 72°C, followed by a final cycle of the first step of 
15 seconds to 94°C, the second step of 25 seconds to 50°C and the last step 
of 1 minute to 72°C.
Each reaction product was amplified in the presence of a 36-bp internal 
TRAP assay standard. A TSR8 quantiation standard (which serves as a 
standard to estimate the amount of product extended by telomerase in a 
given extract) was included for each set of TRAP assays.
2.14.4. Polyacrylamide Gel Electrophoresis
The enzyme activity products were resolved in 10% (w/v) polyacrylamide- 
0.5x TBE buffered non-denaturing gel, prepared as described in the
1.7 section.
Ten pi of loading 6x gel loading buffer were then added to each 50 pl- 
reaction mixture and 30 pi of the samples were loaded onto the gel. 
Electrophoretic run was performed at a constant voltage of 180 volts for 
45 minutes then at 300 volts for 1 hour and 45 minutes. When the xylene 
cyanol runs 75% of the gel length, electrophoresis was stopped and the 
polyacrylamide gel was detached from the glass plates by means of 
Whatman 3MM papers. After that a sheet of Saran Wrap was placed on the 
top, the gel was dried at 80°C for 20 minutes, placed in a Hypercassette with
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intensifying screens and autoradiographed by exposure to X-ray film over 
night at -80°C.
2.14.5. Quantification of Telomerase Activity
Quantitative analysis was performed with the Image-QuanT software 
(Molecular Dynamics), which allowed densitometric evaluation of the digitized 
image. Telomerase activity was quantified by measuring the signal of 
telomerase ladder bands, and the relative telomerase activity was calculated 
as the ratio to the internal standard using the following formula:
[(X-Xo)/C]x[(R-Ro)/C iT1
where X is the untreated sample, X0 is the RNase-treated sample, C is the 
internal control of untreated samples, Cr is the internal control of TSR8, R is 
the TSR8 quantitation control and Ro is the negative control.
2.15. In Vivo Studies
All procedures requiring the use of animals were carried out according to 
the United Kingdom Coordinating Committee on Cancer Research 
Guidelines [Workman et al, 1998] and approved by the Ethics Committee for 
Animal Experimentation of the Istituto Nazionale per lo Studio e la Cura dei 
Tumori (Milan, Italy). Male and female athymic Swiss nude mice supplied 
from Charles River Laboratories (Calco, Italy) were randomly distributed into
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treatment groups and housed in groups of four to five in polypropylene cages 
with stainless steel wire lids and heat treated chips (Cellu-Dri; Shepherd 
Specialty Papers, Kalamazoo, USA), with access to food (Lab Rodent Diet 
5001; PMI Nutrition International Inc., St. Louis, USA) and water ad libitum. 
The animal rooms were maintained on a 12-hours light.dark cycle (6 a.m. to 
6 p.m.) at 23 ± 1°C with 30-50% relative humidity.
2.15.1. Tumour Injection
Cells from in vitro cultures of JR8, JR8/mutRz or JR8/Rz were 
intramuscularly injected into the right hind leg of female mice 
(107 cells/mouse). For each cell line, half of the group (5-8 mice) was left 
untreated and half was treated with topotecan. Topotecan was dissolved in 
sterile, distilled water and delivered in a volume of 10 ml/kg body weight. The 
drug was administered orally at the dose of 10 mg/kg every seventh day for 
four times (q7dx4), starting the day after cell injection. In a second set of the 
experiments, exponentially growing DU145/CTR and DU145/Rz cells were 
injected subcutaneously (107 cells/mouse) into the right flank of the male 
mice (9 mice/group).
The mice were inspected daily to establish tumour take (i.e. the ratio 
between the number of growing tumours over the total number of tumour- 
injected mice), the time of tumour appearance and the tumour volume. 
Tumour growth was followed by measuring tumour diameters with a Varnier 
caliper.
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Tumour volume was calculated according to the formula:
TV (mm3) = d2 x D/2
where d and D are the shortest and longest diameter, respectively.
2.15.2. Reverse Transcriptase-PCR Analysis of Ribozyme Expression
2.15.2.1. RNA Isolation from Tissues
Animals were sacrified 60 days after tumour cell inoculation with carbon 
dioxide anesthesia followed by cervical dislocation. Tumours were removed, 
fixed in 10% formalin and then stored at -80°C. All extraction and 
manipulation steps were performed under sterile conditions using DEPC- 
treated chemicals and plastic disposable materials.
Frozen tissues were homogenised using Brinkman Tissuemizer (Haereus) 
for 30 to 60 seconds and total RNA was obtained by means of the Trizol 
Reagent (Invitrogen) according to the manufacturer’s instructions. The 
amount of extracted RNA was determined spectrophotometrically. Quality of 
isolated RNA was checked by gel electrophoresis analysis carried out by 
using a 1% (w/v) agarose mini gel prepared in 1x TAE buffer. RNA was 
visualised by means of the UV transilluminator and photographed. Total RNA 
extracted was stored at -80°C as 1 pg aliquots.
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2.15.2.2. RT-PCR Reaction and Gel Electrophoresis
Total RNA extracted from tissues was reverse transcribed by using RNA 
PCR Core Kit (Perkin-Elmer) as described in the 2.5.3 section.
To analyze ribozyme expression, the resultant cDNAs were amplified 
using T7 (5’-TAA TAC GAC TCA CTA TAG GGA GA-3’) and SP6 (5’-CG 
ATT TAG GTG ACA CTA TAG-3’) primers and the PCR amplification was 
performed as described in the 2.5.4. section. PCR products were obtained 
performing 30 cycles of PCR (at 95°C for 1 minute, 47°C for 1 minute, and 
72°C for 1 minute), followed by a 7-minutes extension step at 72°C. PCR 
products were then verified by agarose gel electrophoresis. Vectors pRc/Rz 
and pRc/mutRz were used during PCR amplification as control for the correct 
fragment size.
2.16.Statistical Analysis
Statistical evaluation of data was generally done with two-tailed Student’s 
ftest. The Fisher exact text was used to compare tumour take between 
animal groups. P values <0.05 were considered statistically significant.
The type of interaction between the cytotoxic effects of siRNA2 and 17- 
AAG was analyzed as previously described [Silvestrini et al, 1997]. For the 
evaluation, the agents were assumed to provide independent effects. For a 
given concentration of 17-AAG, we observed a survival fraction of cells 
(SFa); likewise, for siRNA2 transfection, we observed SFb. For the combined
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treatment (siRNA2 transfection followed by 17-AAG exposure) we observed 
SFab. The results obtained were expressed according to the following 
criteria: SFab = SFa x SFb indicates additive effect; SFab < SFa x SFb 
indicates supra-additive effect; SFab > SFa x SFb indicates subadditive 
effect.
The method described by Chou & Talalay [1984] was used to determine 
the nature of the interaction between NU6140 or purvalanol A and paclitaxel. 
Drugs were always combined at a constant ratio of paclitaxel and NU6140 or 
purvalanol A concentrations (i.e. 1:1000). The interaction of drugs was 
quantified by determining a combination index (Cl). Cl values of less than or 
greater than 1 indicated synergy or antagonism, respectively, whereas a Cl 
value of 1 indicates additivity.
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1. R ib o zy m e -m ed ia ted  d o w n -r eg u la tio n  of  su r vivin  expr essio n  sen sit is es
HUMAN MELANOMA CELLS TO DRUG AND RADIATION TREATMENT
Cutaneous melanoma is the most aggressive form of skin tumours and its 
incidence is increasing more rapidly than that of any other cancer [Grossman 
& Altieri, 2001]. In contrast to localized melanoma, which has a good 
prognosis after adequate surgery, disseminated disease is characterized by 
a very poor clinical outcome, which is not modified by conventional 
anticancer treatments [Becker et al, 2000]. Although not yet fully elucidated, 
the basis of melanoma resistance to chemotherapy seems to rely on 
dysregulation of apoptosis [Satyamoorthy et al, 2001; Soengas & Lowe, 
2003]. In fact, it has been shown that cells within melanoma lesions are 
characterized by an inherently low level of spontaneous apoptosis [Mooney 
et al, 1995]. Moreover, defects at multiple levels of the two major apoptotic 
pathways have been found in melanoma cells, including altered death 
receptor signalling [Thomas & Hersey, 1998], increased levels of anti- 
apoptotic proteins belonging to the Bcl-2 family such as Bcl-2, Bcl-xL and 
Mcl-1 [Tang et al, 1998], inactivation of the apoptosis effector Apaf-1 
[Soengas et al, 2001], and overexpression of members of the inhibitors of 
apoptosis protein (IAP) family such as ML-IAP and survivin [Vucic et al, 2000; 
Grossman etal, 1999]. In particular, survivin expression has been detected in 
almost all invasive and metastatic melanomas but not in normal skin 
melanocytes [Grossman etal, 1999].
Considering that apoptosis is the major mode of cell kill by many 
chemotherapeutic agents and radiation, it appears reasonable that the
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inability to undergo programmed cell death is a major mechanism of the 
chemo- and radio-resistance of melanoma. As a consequence, the genes 
that control apoptosis provide interesting new targets for the rational 
development of strategies aimed at increasing the susceptibility of melanoma 
cells to chemical and physical treatments. In this context, it has been 
demonstrated that down-regulation of Bcl-2 and Mcl-1 by antisense 
oligonucleotides sensitised human melanoma to dacarbazine in cell culture 
as well as in SCID mouse xenotransplantation models [Jansen et al, 1998; 
Thallinger et al, 2003]. Moreover, in the clinical setting, sensitisation of 
malignant melanoma to dacarbazine by concomitant Bcl-2 antisense therapy 
was confirmed in a phase l-ll study in patients with Bcl-2-expressing 
advanced melanoma [Jansen et al, 2000]. Again, reduction of Bcl-xL protein 
expression by a specific antisense oligonucleotide significantly increased the 
in vitro sensitivity of melanoma cells to cisplatin [Heere-Ress et al, 2002]. 
Using a different approach dealing with the recovery of Apaf-1 expression by 
treatment with the demethylating agent 5’-aza-2’-deoxycytidine, Soengas et 
al [2001] were able to enhance the in vitro sensitivity of Apaf-1-negative 
melanoma cells to doxorubicin.
The possibility to modulate the chemosensitivity of melanoma and other 
tumour cell types by targeting survivin has been also actively pursued in the 
last years. It has been previously demonstrated by Grossman et al [1999] 
that transfection of melanoma cells with survivin antisense was able to 
increase the fraction of spontaneous apoptosis. The same research group 
reported that the forced expression of a phosphorylation-defective survivin 
mutant (Thr34->Ala) in melanoma cell lines, besides triggering apoptosis,
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enhanced the level of programmed cell death induced by in vitro treatment 
with the chemotherapeutic agent cisplatin [Grossman et al, 2001a]. A number 
of additional studies carried out in experimental models of other tumour types 
showed that targeting of survivin by antisense oligonucleotides or dominant 
negative mutants resulted in an increased sensitivity to anticancer agents 
including taxol [Mesri etal, 2001; O’Connor et al, 2002], etoposide [Olie etal,
2001], doxorubicin [Wall et al, 2003] and 5-fluorouracil [Yamamoto et al,
2002]. Moreover, a possible role of survivin as a molecular determinant of 
radiation response in tumour cells has been recently proposed by Asanuma 
et al [2000], who reported evidence suggesting that this protein acts as a 
constitutive and inducible radio-resistance factor in pancreatic cancer cell 
lines.
In the present study, we proposed to assess the effect of attenuation of 
survivin expression, accomplished through a ribozyme-mediated strategy, in 
the response of human melanoma cells to chemotherapeutic agents and 
ionising radiation.
1.1. In Vitro Catalytic Activity of the Anti-Survivin Ribozyme
The catalytic potential of the Rz ribozyme was assessed as the ability to 
cleave an internally 32P-labeled synthetic RNA substrate obtained by cloning 
a portion of the human survivin mRNA. The size of the substrate was 362- 
nucleotides, and the cleavage reaction (the cleavage site is indicated by the 
arrow in Figure 25) was expected to produce two fragments of 236 and
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126 nucleotides, respectively. Experiments performed by incubating 10 nM of 
labelled RNA substrate with increasing concentrations (from 10 to 1000 nM) 
of the Rz ribozyme for 120 minutes at 37°C (Figure 27) resulted in a 
decrease of the full-length substrate and accumulation of the expected 
cleavage products.
m utR z Rz
Bl 1:102 1:1 1:10 1:102
—  362 nts
—  236 nts
—  126 nts
Figure 27. I n  v i t r o  catalytic activity.
The synthetic 32P-substrate was incubated with 10- 
1000 nM Rz or 100-1000 nM mutRz for 120 minutes 
at 37°C. (BL: 32P-substrate RNA incubated without 
the ribozyme).
The efficiency of cleavage was dependent on the substrate/ribozyme ratio, 
with the cleavage products being detectable at a ratio of 1:10. As expected, 
the mutRz ribozyme, carrying a mutation (i.e., deletion of G12) in the catalytic 
core of the Rz ribozyme, did not induce any cleavage in the synthetic RNA 
(Figure 27).
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1.2. Ribozyme-Mediated Attenuation of Survivin Expression in JR8 
Melanoma Cells
To evaluate the effect of the ribozyme in intact cells, the JR8 human 
melanoma cell line inherently over-expressing survivin was transfected with 
pRc/Rz and pRc/mutRz vectors containing the sequence coding for the 
active Rz ribozyme and the catalytically inactive mutRz ribozyme, 
respectively. The transfectants were treated with G418 for 1 month, and the 
G418-resistant clones were selected and screened for survivin expression by 
Western blotting. To rule out the possibility that attenuation of survivin 
expression was simply due to clonal divergence, we used two polyclonal 
populations of transfectants proven to endogenously express the active 
(JR8/Rz cells) or the mutant (JR8/mutRz cells) ribozyme (Figure 28).
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Figure 28. Ribozyme expression in JR8 melanoma 
cell clones.
Ribozyme expression was detected by RT-PCR in 
JR8 parental cells and cell clones transfected with the 
active ribozymes (JR8/Rz cells) or with the mutant 
ribozyme (JR8/mutRz cells). Lanes pRc/Rz and 
pRc/mutRz indicate plasmids used as controls for the 
size of each fragment during PCR amplification.
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JR8/Rz cells were characterized by a markedly lower survivin protein level 
(-60 ± 8%) than JR8 parental cells, as assessed by Western blot analysis in 
four independent cultures. Conversely, a very modest reduction (-13 ± 7%) in 
survivin expression was observed in mutRz cells (Figure 29). No appreciable 
differences were found among the different melanoma cell lines in the 
expression of other proteins involved in the control of apoptosis, such as Bcl- 
2 and Bax (Figure 29).
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Figure 29. Survivin expression in melanoma cell clones.
(A) A representative Western blotting experiment illustrating the expression of survivin and 
other apoptosis-related proteins in JR8, RZ and mutRZ cells, p-actin was used as control for 
loading. (B) Densitometric quantification of band intensities for survivin. Data represent mean 
values ± sd of three independent experiments.
Attenuation of survivin expression did not appreciably affect the growth 
potential of melanoma cells. In fact, only a modest increase in the doubling 
time of JR8/Rz cells compared to JR8 and JR8/mutRz cells was observed 
(29 ± 3h vs 24 ± 3h and 25 ± 4h, respectively).
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1.3. Survivin Inhibition Sensitises JR8 Melanoma Cells to Drug-Induced 
Apoptosis
To determine whether the level of survivin expression is associated with 
the chemosensitivity of melanoma cells, JR8/Rz and JR8/mutRz cell lines 
were analyzed for their clonogenic cell survival profiles after exposure to 
different concentrations of the topoisomerase-l inhibitor topotecan for 
24 hours (Figure 30). Transfection with the active ribozyme sequence did not 
appreciably modify the plating efficiency of JR8/Rz cells compared to 
JR8/mutRz cells (10.2 ± 1.5% and 13.4 ± 2.1%, respectively).
A dose-dependent reduction in cell survival was observed in both cell lines 
following topotecan exposure. However, JR8/Rz cells showed enhanced 
sensitivity to the drug compared to JR8/mutRz cells. The concentration of the 
drug that inhibited cell proliferation by 50% (IC50) was calculated by 
computer-assisted extrapolation. Specifically, a curve of drug concentration 
versus mean percent inhibition was constructed. Using the formula for the 
slope of the line between the two drug doses that bracketed (above and 
below) 50% inhibition, the IC50 was calculated. A significantly (p<0.01) lower 
topotecan IC50 was observed in JR8/Rz than JR8/mutRz (1.86 ± 0.44 ng/ml 
vs 6.76 ± 0.53 ng/ml) (Table III).
In parallel, we assessed the susceptibility of melanoma cells as a function 
of the level of survivin expression to other DNA-interacting agents currently 
used in the treatment of melanoma patients. Specifically, we observed an 
increased sensitivity of JR8/Rz cells compared to cells expressing the mutant 
ribozyme to a 1-hour cisplatin exposure, as indicated by the significantly
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(p<0.05) lower IC50 (1.36 ± 0.40 pg/ml vs 2.9 ± 0.30 Mg/ml) (Table III). 
Conversely, JR8/Rz and JR8/mutRz cells showed a comparable sensitivity to 
a 24-hours exposure to temozolomide (IC50: 5.81 ± 0.39 pg/ml vs 
6.29 ±0.29 pg/ml) (Table III).
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Figure 30. Clonogenic cell survival curves obtained 
after exposure of melanoma cell clones to topotecan.
JR8/Rz (•) and JR8/mutRz (■) cells were treated with 
topotecan for 24 hours and then incubated at 37°C for 10 days. 
Colonies consisting of at least 50 cells were stained with crystal 
violet and counted under the microscope. Data represent mean 
values ± sd of three independent experiments. (The IC50 values 
were calculated from the dose-response curves by graphical 
extrapolation.)
Table III. Cytotoxic activity of topotecan, cisplatin and temozolomide in melanoma 
cell clones.
Cell line Topotecan Cisplatin Temozolomide
IC 50 (ng/ml) IC 50 (Mg/ml) IC 50 (MQ/ml)
JR8/mutRz 6.76 ±0.53 2.9 ±0.30 6.29 ± 0.29
JR8/Rz 1.86 ± 0.44 1.36 ±0.40 5.81 ± 0.39
Drug activity is expressed in terms of concentration able to inhibit clonogenic cell survival 
by 50% (IC50). Values represent the mean ± sd of three independent experiments.
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To investigate whether the increased cytotoxic activity of cisplatin and 
topotecan observed in JR8/Rz cells was mediated by an enhanced 
susceptibility of cells to undergo programmed cell death as a consequence of 
survivin inhibition, we examined the induction of apoptosis in the two cell 
lines. Specifically, the number of cells with apoptotic nuclei was determined 
by fluorescence microscopy 72 hours after a 1-hour exposure to 10 pg/ml 
cisplatin or 24-hours exposure to 10 ng/ml topotecan (Figures 31). 
Spontaneous apoptosis was observed in a small fraction of cells in both cell 
lines (0.5 ± 0.2% and 1.0 ± 0.2% of the overall cell population in JR8/mutRz 
and JR8/Rz cells, respectively). Conversely, a significantly (p<0.01) higher 
apoptotic response to drugs was appreciable in JR8/Rz than in JR8/mutRz 
cells (27.7 ±2.3% vs 4.8 ± 1.7% for cisplatin; 26.4 ± 2.6% vs 9.8 ± 1.3% for 
topotecan) (Figure 31).
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Figure 31. Induction of apoptosis in melanoma cell clones 
exposed to topotecan and cisplatin.
The percentage of cells with an apoptotic morphology with respect to 
the overall population as assessed by fluorescence microscopy in 
untreated cells (empty column) and in cells exposed to topotecan 
(blue column) or cisplatin (red column). Data represent mean values 
± sd of three independent experiments. *p<0.01, Student’s t test.
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To obtain mechanistic insights into the apoptotic pathway activated by 
lowering survivin expression, we evaluated the in vitro catalytic activity of 
caspase-9 and caspase-3 in the two melanoma cell lines. JR8/Rz and 
JR8/mutRz cells were characterized by a similar basal level of caspase 
activity as assessed by hydrolysis of specific fluorogenic substrates 
(Figure 32).
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Figure 32. Caspase activation in melanoma cell 
clones treated with topotecan and cisplatin.
Caspase-9 (A) and caspase-3 (B) catalytic activity was 
determined by hydrolysis of specific fluorogenic substrates in 
untreated cells (empty column) and in topotecan- (blue 
column) and cisplatin- (red column) treated cells. Data are 
expressed as relative fluorescence units (r.f.u.) and 
represent mean values ± sd of three independent 
experiments. *p<0.05, Student’s t test.
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Treatment with cisplatin and topotecan increased the activation of 
caspase-9 and caspase-3 in both cell lines. However, the catalytic activity of 
both enzymes was significantly (p<0.05) higher (two-fold and three-fold in 
the case of caspase-9 and caspase-3, respectively) in the JR8/Rz than in the 
JR8/mutRz drug-treated cells (Figure 32).
1.4. Survivin Inhibition Enhances the Antitumour Activity of Topotecan 
in Vivo
The effect of survivin inhibition on the antitumour activity of topotecan was 
studied in athymic nude mice after injection of melanoma cells expressing the 
active or the mutant ribozyme. The endogenous presence of the ribozymes in 
tumours grown in the animal was confirmed by RT-PCR (Figure 33).
Figure 33. Ribozyme expression in tumours grown in nude mice.
Ribozyme expression was detected by RT-PCR in tissue samples 
obtained from tumours originating from JR8 cells transfected with the 
active ribozyme (JR8/Rz) or with the mutant ribozyme (JR8/mutRz). 
Lanes pRc/Rz and pRc/mutRz indicate plasmids used as controls for the 
size of each fragment during PCR amplification.
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The drug (10 mg/kg) was administered orally every seventh day for 4 
times (q7dx4), starting from the day after cell injection. Although JR8/Rz cells 
retained a reduced expression of survivin compared to JR8/mutRz cells after 
xenografting in mouse, survivin inhibition did not appreciably modify tumour 
take or growth in untreated animals. Specifically, at day 12 after cell injection, 
tumours were present in 5/7 and 3/8 mice receiving JR8/mutRz and JR8/Rz 
cells, respectively (Table IV), and tumour growth curves of the two groups of 
mice were similar and superimposable to that observed for JR8 parental cells 
(Figure 34; Table V).
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Figure 34. Growth curves of JR8, JR8/mutRz and 
JR8/Rz melanoma cells in athymic nude mice.
Cells were intramuscularly injected into the right hind leg of 
mice (107 cells/mouse) at day 0. JR8 (o ) , JR8/mutRz (• )  and 
JR8/Rz (□) cells.
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Table IV. Effects of oral topotecan on tumorigenicity (tumour take3) of 
JR8/mutRz and JR8/Rz melanoma cells in nude mice.
Days'5 JR8/mutRz JR8/Rz
12 49 12 49 63 104
Controls 5/7 5/7 3/8 5/8 6/8 —
Topotecan 1/5 4/5 0/8
o00o 3/8 4/8
aTumour take, i.e. number of growing tumours/total number of tumour- 
injected mice.
bDay 0: 107 cells were i.m. injected into the right hind leg. Topotecan 
treatment: 10 mg/kg, q7dx4 from day 1. 
cp=0.0128 vs control mice; Fisher exact test.
Table V. Effect of survivin inhibition on the growth3 of melanoma cells in 
nude mice.
Days15 12 15 19 22 26 30 35 43 49 56 63
J R 8
#1 25 50 50 294 648 729
# 2 25 216 750 1224 1690 2475
# 3 25 198 384 908 1527 2156
# 4 28 245 384 700 1352 1690
# 5 50 196 567 1368 2250 2944
# 6 25 196 416 750 1521 1960
# 7 25 216 650 1029 2156 2352
# 8 28 221 56 800 1521 1960
J R 8 / m u t R z
#1 60 198 500 527 698 752 853 988 1420 1520
# 2 288 550 650 1268 1008 1008 1352 1568 1460 1268
# 3 288 408 486 1372 1800 1800 2304 2890 3240 3978
# 4 50 88 256 221 256 300 405 750 1352 3240
# 5
# 6 352 700 726 793 802 844 902 1002 1130 1180
# 7
J R 8 / R Z
#1 _ 405 968 968 1352 2025 1862 2250 2475 2816 2475
# 2 50 221 486 847 1268 1004 1268 1568 2250 2025 3240
# 3 196
# 4
# 5 50 196 787 787 787 908 869 1152 1521 1666 1764
# 6
# 7 — 196 365 446 550 550 1080 1852 2475 1859 2475
# 8 50 288 500 500 1183 1183 1183 1372 1800 1800 2176
Expressed as tumour volume (calculated according to the formula: TV (mm3) = d2 
x D/2, where d and D are the shortest and longest diameter, respectively) in 
individual animals.
bDay 0 :107 cells were i.m. injected into the right hind leg.
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In JR8/mutRz tumours, topotecan treatment initially retarded tumour 
growth (Figure 35; Table IV & VI). In fact, at day 12 the tumour was present 
in only 1/5 mice. However, at later intervals, tumours grew in most of the 
treated mice (4/5), and no difference was evident in tumour take or volume 
between treated and untreated mice. In contrast, topotecan was very 
effective in increasing the latency and reducing the take rate and growth of 
JR8/Rz tumours. In fact, at day 49 after cell injection, tumours had not yet 
appeared in topotecan-treated mice, whereas they were present in 
5/8 control mice (p=0.0128). Again, at day 63, when control mice were 
sacrificed for tumour burden, tumours were present in only 3/8 treated mice. 
Topotecan-treated mice were kept under observation for more than 
100 days, but tumour take did not increase over 50% (4/8 at day 104).
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Figure 35. Effect of ribozyme-mediated survivin inhibition on 
the anti-tumorigenic activity of oral topotecan in melanoma 
xenografts.
Cells were intramuscularly injected into the right hind leg of mice 
(107 cells/mouse) at day 0. Treatment consisted of 10 mg/kg, 
q7dx4 from day 1. Control JR8/mutRz (O), topotecan-treated 
JR8/mutRz (• ) , control JR8/Rz (□) and topotecan-treated JR8/Rz 
cells (■).
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Table VI. Effect of oral topotecan on the growth3 of melanoma cells in nude mice.
Days0 12 15 19 22 26 30 35 43 49 56 63 70 77 86 93 104
JR8/mutRz
#1
# 2
# 3
# 4
# 5
JR8/RZ
#1
# 2
# 3
# 4
# 5
#6
# 7
# 8
Expressed as tumour volume (calculated according to the formula: TV (mm3) = d2 x 
D/2, where d and D are the shortest and longest diameter, respectively) in individual 
animals.
bDay 0: 107 cells were i.m. injected into the right hind leg. Topotecan treatment: 10 
mg/kg, q7dx4 from day 1.
1.5. Ribozyme-Mediated Survivin Inhibition Sensitises JR8 Melanoma
Cells to Ionising Radiation
To determine whether the level of survivin expression is associated with
the radio-sensitivity of melanoma cells, the different cell lines were analyzed
for their clonogenic cell survival profiles after exposure to different doses of y-
irradiation (Figure 36). Transfection with the active ribozyme sequence did
not appreciably modify the plating efficiency of JR8/Rz cells compared to JR8
and JR8/mutRz cells (8.7 ± 0.9% vs 9.8 ± 1.0% and 9.6 ± 1.3%,
respectively).
- - - - - - -  -  -  -  352 1470 1568 2560 3971 4800
- - - - - -  - - - - -  -  50 365 666 1352 1913 2560
- - - - - -  -  -  -  195 486 486 1372 1500 2432 3564
- - - - - - -  -  -  -  -  50 50 50 50 136
-  136 405 390 600 908 1224 1224 1521
-  320 550 600 787 908 1002 1332 1521 2138
50 50 126 88 87 1080 1960 1890 1960
50 75 320 365 162 726 1080 1764 1960 1960
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Figure 36. Clonogenic cell survival curves obtained 
after y-irradiation of melanoma cell clones.
JR8 (O), JR8/Rz (■) and JR8/mutRz ( • )  cells were 
irradiated and then incubated at 37°C for 10 days. 
Colonies consisting of at least 50 cells were stained with 
crystal violet and counted under the microscope. Data 
represent mean values ± sd of three independent 
experiments.
A radiation dose-dependent reduction in cell survival was observed in all 
cell lines (survival curve parameters are reported in Table VII). However, 
cells expressing the active ribozyme showed enhanced radio-sensitivity 
compared to parental cells. Specifically, the surviving fractions of JR8/Rz 
cells were significantly (p<0.01) lower than those observed for JR8 at all 
radiation doses starting from 2 Gy. Such radio-sensitisation seemed to be a 
consequence of the decreased survivin levels in cells expressing the active 
ribozyme rather than non-specific effects of the expression vector itself. In 
fact, the survival curve obtained after irradiation of JR8/mutRz cells
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expressing the catalytically inactive ribozyme was superimposable to that 
obtained for irradiated JR8 parental cells (Figure 36).
Table VII. Survival curve parameters of melanoma cell.
Cell lines Do n SF2
JR8 1.29 ±0.02 4.83 ± 0.45 0.68 ± 0.03
JR8/mutRz 1.27 ±0.02 4.19 ±0.38 0.70 ± 0.08
JR8/Rz 1.15 ± 0.01 2.32 ±0.16 0.36 ± 0.02
The colony-forming efficiency was calculated from the number of 
colonies counted and the number of morphologically intact single 
cells seeded. The parameters n and D0 were calculated using 
ELMAT software. Values represent the mean ± sd of three 
independent experiments.
To investigate whether the increased cytotoxic activity of y-irradiation 
observed in the active ribozyme transfectant cells was mediated by an 
enhanced susceptibility of cells to undergo programmed cell death as a 
consequence of survivin inhibition, we examined the extent of apoptosis 
induction in the different cell lines 48 and 72 hours after exposure to different 
radiation doses. For this purpose the percentage of cells with an apoptotic 
nuclear morphology was determined by fluorescence microscopy after cell 
staining with propidium iodide and calculated in relation to the total cell 
population (Figure 37). Spontaneous apoptosis was observed in a small 
fraction (always <2%) of cells in the different cell lines, and y-irradiation 
consistently induced a dose-dependent increase in the percentage of 
apoptotic cells in the different clones.
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Figure 37. Induction of apoptosis in melanoma cell clones exposed 
to y-irradiation.
The percentage of cells with an apoptotic morphology with respect to the overall 
population was assessed by fluorescence microscopy 48 hours (red column) 
and 72 hours (blue column) after exposure to different radiation doses. Data 
represent mean values ± sd of three independent experiments. *p<0.05, 
**p<0.01, Student’s t test.
However, in cells expressing the active ribozyme, the extent of radiation- 
induced programmed cell death was higher than that observed in JR8/mutRz 
cells and in JR8 parental cells. (Figure 37). Specifically, such a difference 
was statistically significant at 48 hours (p<0.05) and 72 hours (p<0.01) after 
exposure to 10 Gy and at 72 hours after exposure to 6 Gy (p<0.01).
The caspase-3 catalytic activity, as assessed by hydrolysis of the 
fluorogenic substrate Ac-DEVD-AMC, was markedly higher in the JR8/Rz 
than in the JR8/mutRz cells and in JR8 parental cells after 10 Gy exposure 
(Figure 38).
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Figure 38. Caspase activation in melanoma cell clones exposed 
to y-irradiation.
Caspase-3 catalytic activity was determined by hydrolysis of the 
fluorogenic substrate Ac-DEVD-AMC 72 hours after exposure to 10 Gy 
in unirradiated control cells (empty column) and y-irradiated cells (blue 
column). Data are expressed as relative fluorescence units (r.f.u.) and 
represent mean values ± sd of three independent experiments. 
*p<0.05, Student’s t test.
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2 . R ib o z y m e - m e d ia t e d  in h ib it io n  o f  s u r v iv in  e x p r e s s io n  in c r e a s e s
SPONTANEOUS AND DRUG-INDUCED APOPTOSIS AND DECREASES THE
TUMORIGENIC POTENTIAL OF HUMAN PROSTATE CANCER CELLS
Prostate cancer is the most frequently diagnosed tumour and the second 
leading cause of cancer-related death among men in Western countries 
[Dennis & Resnick, 2000]. Whereas more than 80% of tumours are initially 
responsive to androgen ablation, metastatic disease inevitably progresses to 
an androgen-independent state that is largely refractory not only to hormonal 
manipulation but also to chemotherapy and radiotherapy [Daskivich & Oh, 
2006; Swanson, 2006; Sowery et al, 2007]. Accordingly, androgen- 
independent progression is the main obstacle to survival in patients with 
advanced disease, and this emphasizes the need for novel therapeutic 
strategies targeting the molecular determinants of treatment resistance of 
advanced prostate cancer. Several lines of evidence suggested that one of 
the main events associated with the conversion to an androgen-independent 
phenotype is increased resistance to apoptosis [Denmeade et al, 1996; 
Howell, 2000], mainly due to up-regulation of anti-apoptotic genes, including 
Bcl-2, B c I-Xl and Mcl-1 [Krajewska et al, 1996]. Moreover, it has been 
described to be selectively expressed in the most common human 
neoplasms, including prostate cancer [McEleny et al, 2002], and to be 
associated with clinical tumour progression [Altieri, 2001]. As a consequence, 
the identification of points in the apoptotic pathway at which dysregulation 
occurs could open new therapeutic opportunities for this malignancy.
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As an alternative strategy to target the survivin pathway we developed a 
Moloney-based retroviral vector expressing a hammerhead ribozyme 
directed against the 3’ end of the CUAno triplet in survivin mRNA, encoded 
as a chimeric RNA within adenoviral VA1 RNA. Here we assessed the effects 
of the ribozyme-mediated inhibition of survivin expression on the 
spontaneous and drug-induced apoptosis and on the tumorigenic potential of 
androgen-independent human prostate cancer cells.
2.1. Construction of a Retroviral Vector for Targeted Intracellular 
Expression of an Anti-Survivin Ribozyme and Transduction of 
Prostate Cancer Cells
The hammerhead ribozyme coding sequence was cloned as a substitute 
to a portion of the central domain of the adenovirus type 2 VA1 gene, a 
region that does not influence transcription by RNA polymerase III or cellular 
localization of the RNA in the cytoplasm [Cagnon & Rossi, 2000; Mendoza- 
Maldonado et al, 2002]. As a control, we also inserted in the VA1 construct 
an irrelevant ribozyme targeting the feline immunodeficiency virus (FIV) 
primer binding site. To attain high-efficiency expression of the VA1-ribozyme 
cassettes, Moloney-based retroviral vectors were constructed, in which the 
VA1-ribozyme cassette was encoded in the 3’ long terminal repeat (LTR). 
After transduction, a double copy vector was obtained, with the ribozyme- 
expressing cassettes at both LTRs.
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Two androgen-independent human prostate cancer cell lines, DU 145 and 
PC-3, were transduced with the viral vectors and treated in vitro with G418 
for 1 month. G418-resistant clones were selected and screened for survivin 
expression by Western blotting. To rule out the possibility that attenuation of 
survivin expression was simply due to clonal divergence, we used polyclonal 
populations proven to endogenously express the anti-survivin (DU145/Rz 
and PC-3/Rz cells) or control (DU145/CTR and PC-3/CTR cells) ribozyme 
(Figure 39).
Figure 39. Ribozyme expression in prostate cancer cells.
Ribozyme expression was detected by RT-PCR in DU145 and PC-3 
parental cells and cell clones transduced with the anti-survivin 
ribozyme (DU145/Rz and PC-3/Rz) or with the control ribozyme 
(DU145/CTR and PC-3/CTR). pCLXSN/CTR and pCLXSN/Rz 
plasmids were used as controls for the correct size of each fragment 
during PCR amplification.
Specifically, DU145/Rz and PC-3/Rz cells were characterized by a 
markedly lower survivin protein level (-90 ± 8% and -68 ± 5%, respectively) 
than DU145/CTR and PC-3/CTR cells (Figure 40), as assessed in three 
independent western blot experiments.
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Figure 40. Survivin expression in prostate cancer cells.
(A) A representative Western blotting experiment illustrating the expression of 
survivin in DU 145, DU145/CTR, DU145/Rz, PC-3, PC-3/CTR and PC-3/Rz 
cells, p-actin was used as control for loading. (B) Densitometric quantification of 
band intensities for survivin. Data represent mean values ± sd of three 
independent experiments.
Attenuation of survivin protein expression markedly affected the in vitro 
growth potential of DU145/Rz cells, as demonstrated by the significantly 
(p<0.01) longer doubling time than DU145/CTR cells (48 ± 4h vs 26 ± 3h). 
Consistent with the role of survivin in the proper execution of mitosis [Giodini 
et al, 2002], we observed that the almost complete ribozyme-mediated 
inhibition of survivin induced aberrant mitotic progression in DU145/Rz cells 
with the appearance of a fraction of polyploid cells characterized by a more 
than 4N DNA content (Figure 41 A). This finding was consistently observed in 
four cell samples collected at different intervals of growth in culture.
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Conversely, a very modest increase in the doubling time of PC-3/Rz 
compared to PC-3/CTR cells (30 ± 3h vs 24 ± 3h) was observed, and the 
presence of polyploid cells was undetectable in the PC-3/Rz cell population 
(Figure 41B).
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Figure 41. Effect of survivin inhibition on cell cycle progression.
Cell cycle analysis of DU145/CTR and DU145/Rz (A), PC-3/CTR and 
PC-3/Rz (B), was carried out by flow cytometry on cells stained with 
propidium iodide.
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2.2. Ribozyme-Mediated Survivin Inhibition Enhances Spontaneous 
and Drug-Induced Apoptosis in Prostate Cancer Cells
Down-regulation of survivin in ribozyme-expressing prostate cancer cells 
was associated with an increased rate of spontaneous apoptosis in both cell 
lines. Specifically, a more marked DNA fragmentation was observed in cells 
expressing the anti-survivin ribozyme, as indicated by the percentage of 
TUNEL-positive cells, which was 20% in DU145/Rz and 17% in PC-3/Rz 
compared to only 2% and 3% in DU145/CTR and PC-3/CTR cells, 
respectively (Figure 42A). At the molecular level, ribozyme-mediated 
inhibition of survivin expression in DU145/Rz cells resulted in proteolytic 
processing of caspase-9 and caspase-3, which coincided with a significantly 
increased catalytic activity of both enzymes. Specifically, caspase-9 and 
caspase-3 activity, as assessed by in vitro hydrolysis of specific fluorogenic 
substrates (LEMD-AFC for caspase-9 and Ac-DEVD-AMC for caspase-3) 
was 12-fold (p<0.05) and 10-fold (p<0.01) higher, respectively, in DU145/Rz 
than in DU145/CTR cells (Figure 42B). Although to a lower extent, increased 
caspase-9 and caspase-3 catalytic activity (10-fold; p<0.01 and 3-fold; 
p<0.02, respectively) was also observed in PC-3/Rz compared to PC-3/CTR 
cells (Figure 42B).
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Figure 42. Induction of spontaneous apoptosis in prostate cell 
clones.
(A) TUNEL analysis of spontaneous apoptosis in DU145/CTR, 
DU145/Rz, PC-3/CTR and PC-3/Rz cells was carried out by flow 
cytometry. Red lines represent the negative control incubated in 
the absence of terminal transferase; blue lines represent the 
samples incubated with TUNEL reaction mixture. The percentage 
of TUNEL-positive cells in each sample is reported. (B) Caspase-9 
(red column) and caspase-3 (blue column) catalytic activity was 
determined by hydrolysis of the specific fluorogenic substrates. 
Data are expressed as relative fluorescence units (r.f.u.) and 
represent mean values ± sd of three independent experiments. 
*p<0.05, **p<0.02, ***p<0.01, Student’s ttest.
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To evaluate whether or not inhibition of survivin expression influences the 
susceptibility of prostate cancer cells to undergo programmed cell death after 
exposure to anticancer agents, we treated DU145/Rz and DU145/CTR cells 
with increasing concentrations of cisplatin. DU145/Rz cells showed enhanced 
sensitivity to the drug compared to DU145/CTR cells, as indicated by the 
significantly (p<0.05) lower concentration required to inhibit cell proliferation 
by 50% (IC50: 3.17 ± 0.39 pg/ml vs 8.25 ± 0.98 pg/ml).
We then assessed the effect of cisplatin (10 pg/ml) on caspase-3 activity 
72 hours after treatment. Drug exposure enhanced caspase-3 activity in both 
cell clones; however, in DU145/Rz cells expressing the anti-survivin ribozyme 
the enzyme’s catalytic activity was significantly (p<0.01) higher than that in 
DU145/CTR cells (Figure 43).
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Figure 43. Caspase activation in prostate cell clones 
exposed to cisplatin.
Caspase-3 catalytic activity was determined by hydrolysis of 
the fluorogenic substrate Ac-DEVD-AMC in untreated cells 
(empty column) and in cisplatin-treated cells (blue column). 
Data represent mean values ± sd of three independent 
experiments. *p<0.01, Student’s t test.
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2.3. Effect of Survivin Inhibition on Tumorigenic Potential of Prostate 
Cancer Cells
The effect of ribozyme-mediated inhibition of survivin expression on 
tumour growth in vivo was studied in a xenograft prostate cancer model. 
Subcutaneous injection of DU145/CTR cells into athymic nude mice induced 
tumour growth in 9 of 9 xenografted mice. Tumours were measurable after 6 
days from injection (mean size: 87 ± 25 mm3) and increased with time. 
Conversely, when xenografted in athymic mice DU145/Rz cells were unable 
to form growing tumours during the entire observation period (50 days) 
(Figure 44).
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Figure 44. Effect of ribozyme-mediated survivin 
inhibition on the tumorigenic potential of human 
prostate cancer cells.
Exponentially growing DU145/CTR ( o )  and DU145/Rz (• )  
cells were injected subcutaneously (107 cells/mouse) into 
the right flank of male athymic nude mice.
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3. S ilencing  o f  survivin gene by s m a ll in te r fe r in g  RNAs produces
SUPRA-ADDITIVE GROWTH SUPPRESSION IN COMBINATION WITH 17-
a lly la m in o -17 -d em eth o xy -g eld a n a m ycin  in hum an  pr o s ta te  c a n c er
CELLS
It has recently been demonstrated that the association of survivin with the 
heat shock protein 90 (Hsp90) is required for its stability and function 
[Fortugno et al, 2003]. Targeted antibody-mediated disruption of the survivin- 
Hsp90 complex in cancer cells resulted in proteasomal degradation of 
survivin, mitochondrial-dependent apoptosis and mitotic arrest [Fortugno 
etal, 2003]. Hsp90 plays a central role in the cellular stress response, which 
is constitutively up-regulated in cancer cells to enhance adaptation to 
environmental challenges [Isaacs et al, 2003]. Specifically, Hsp90 is involved 
in the stabilization and conformational maturation of a number of proteins 
belonging to signal transduction pathways, which are deregulated in cancers 
and contribute to all major components of the malignant phenotype [Richter & 
Buchner, 2001].
The identification of survivin as a new client protein for Hsp90 links the 
cellular stress response to the dual cell viability/mitotic checkpoint maintained 
by survivin. While the survivin-Hsp90 association may promote proliferation 
of tumour cells by elevating their anti-apoptotic threshold, it may also suggest 
new opportunities for the design of novel anticancer strategies. In this 
context, combined approaches aimed at interfering with different levels of the 
survivin-Hsp90 connection could be particularly useful.
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Here we evaluated the effect of small interfering RNA (siRNA)-mediated 
silencing of survivin on the proliferative potential of human androgen- 
independent prostate cancer cells and their sensitivity to the first-in-class 
Hsp90 inhibitor 17-allylamino-17-demethoxy-geldanamycin (17-AAG).
3.1. Silencing of Survivin Gene by siRNAs in Prostate Cancer Cells
Since strong positional effects on the function of siRNAs have been 
demonstrated [Ryther et al, 2005], we tested the effectiveness of four 21-mer 
siRNAs targeting different portions within exons 1-3 of survivin mRNA 
(Figure 26) to silence survivin gene expression in the DU145 androgen- 
independent prostate cancer cell line. RT-PCR experiments carried out in 
DU 145 cells collected at different intervals after a 8-hours transfection with 
100 nM of each survivin-specific siRNA showed a reduction of survivin 
mRNA as compared to Lipo2000-exposed cells (Figure 45). Such inhibition 
ranged from 39% to 60%, depending on the different siRNAs, at 24 hours 
after transfection and was still appreciable to a similar extent at 48 hours 
(Figure 45). Survivin mRNA down-regulation was paralleled by a reduction in 
survivin protein abundance that ranged from 38% to 75% at 24 hours and 
remained almost constant at 48 hours (Figure 46).
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Figure 45. Survivin mRNA expression in DU145 cells.
(A) A representative RT-PCR experiment illustrating survivin mRNA 
expression in DU 145 cells at 24 hours after transfection with the different 
siRNAs (100 nM). (3-actin was used as control for loading. (B) 
Densitometric of survivin mRNA expression levels at 24 hours (empty 
column) and 48 hours (blue column) after transfection. Data are 
expressed as percentage inhibition of survivin expression compared to 
Lipo2000-exposed cells and represent mean values ± sd of three 
independent experiments.
Transfection of DU 145 cells with 100 nM of a control, unrelated siRNA 
caused modest inhibition (around 10% compared to Lipo2000-exposed cells) 
of survivin mRNA expression at both time points considered (Figure 45). A 
slightly stronger inhibitory effect (around 25%) on survivin protein expression 
was consistently observed in cells transfected with the control siRNA 
(Figure 46).
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Figure 46. Survivin protein expression in DU145 cells.
(A) A representative Western blotting experiment illustrating survivin 
protein expression in DU 145 cells at 24 hours after transfection with the 
different siRNAs (100 nM). (3-actin was used as control for loading. (B) 
Densitometric of survivin protein expression levels at 24 hours (empty 
column) and 48 hours (blue column) after transfection. Data are 
expressed as percentage inhibition of survivin expression compared to 
Lipo2000-exposed cells and represent mean values ± sd of three 
independent experiments.
Transfection of DU 145 cells with a survivin-specific siRNA, siRNA2, failed 
to appreciably affect the expression of other anti-apoptotic proteins including 
XIAP and Bcl-xL (Figure 47). As already reported [Chaudary et al, 2001], no 
Bcl-2 expression was observed in these cells (Figure 47).
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Figure 47. Effect of siRNA-mediated silencing 
of survivin on the expression of the other anti- 
apoptotic proteins.
A representative Western blot experiment 
illustrating the expression of other anti-apoptotic 
proteins in DU145 cells at 24 hours after 
transfection with 100 nM siRNA2.
3.2. siRNA-Mediated Silencing of Survivin Gene Causes Cell 
Proliferation Decline and Apoptosis Induction in Prostate Cancer 
Cells
Transfection with the three survivin-specific siRNAs (siRNA2, 3 and 10) 
able to induce the greatest inhibition of survivin expression also resulted in 
significant (p<0.01) and time-dependent decline of DU145 cell proliferation 
compared to Lipo2000-exposed cells, which was appreciable starting from 
24 hours after transfection (ranging from 47% to 55% with respect to 
Lipo2000-exposed cells) and increased at 48 hours (ranging from 65% 
to 73%) (Figure 48). Conversely, transfection with the control, unrelated 
siRNA only induced a modest inhibitory effect on cell proliferation (Figure 48).
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Figure 48. Effects of siRNA-mediated survivin down-regulation 
on i n  v i t r o  growth of DU145 cells.
Data are expressed as percentage values of cell growth in DU 145 cells at 
24 (empty column) and 48 hours (blue column) after transfection with 100 
nM control siRNA or survivin-specific siRNAs (siRNA2, 3 and 10), as 
compared to that of control cells exposed to lipofectamine alone. Data 
represent mean values ± sd of three independent experiments. * p<0.01, 
Student’s t test.
To test whether the cytotoxic effect consequent to survivin down- 
regulation was due to the induction of apoptosis, we assessed by flow 
cytometry the presence of an apoptotic sub-G0/i peak 48h after transfection 
of DU 145 with the different siRNAs. No sub-Go/i peak was observed in 
Lipo2000-exposed cells, whereas a peak accounting for 6.5% of the overall 
cell population was present in DU 145 cells transfected with the control siRNA 
(Figure 49). However, the extent of sub-G0/i peaks was markedly increased 
in cells transfected with the survivin-specific siRNAs 2, 3 and 10, and ranged 
from 25% to 40% of the overall cell population (Figure 49).
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Figure 49. Effects of siRNA-mediated survivin down-regulation on the 
apoptotic rate of DU145 cells.
Flow cytometric analysis of DU 145 cells at 48 hours after transfection with different 
siRNAs. The percentage of the sub-G0/i population is reported in each histogram.
At the molecular level, siRNA-mediated inhibition of survivin expression in 
DU145 cells coincided with a significantly (p<0.01) increased catalytic activity 
of caspase-9. Specifically, the enzyme’s activity was three-four-fold higher in 
DU 145 cells transfected with survivin-specific siRNAs than in those exposed 
to Lipo2000. Conversely, transfection of cells with the control, unrelated 
siRNA did not appreciably modify the extent of caspase-9 activity (Figure 50).
204
Chapter 4 RESULTS
Figure 50. Effects of siRNA-mediated survivin 
down-regulation on the apoptotic rate of DU145 cells.
Caspase-9 catalytic activity as determined by hydrolysis of 
the fluorogenic substrate LEHD-AFC in Lipo2000-exposed 
cells and in cells transfected with different siRNAs. Data 
are expressed as relative fluorescence units (r.f.u) and 
represent the mean values ± sd of three independent 
experiments. * p<0.01, Student’s t test.
3.3. siRNA-Mediated Silencing of the Survivin Gene Increases the 
Sensitivity of Prostate Cancer Cells to 17-Allylamino-17- 
Demethoxy-Geldanamycin
To test whether the basal level of survivin in the tumour cell population 
plays a role in determining the in vitro response to Hsp90 inhibitors, we 
examined the effect of siRNA-mediated survivin down-regulation on cell 
sensitivity to 17-AAG in DU145 cells. A 72-hours exposure to different drug
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concentrations (from 5 to 50 ng/ml) induced a dose-dependent decline of 
DU145 cell proliferation (Figure 51) as well as a decrease in the 
expression/activity of Hsp90 client proteins including Akt, cdk6 (Figure52A) 
and telomerase (Figure 52B). The extent of the 17-AAG cytotoxic activity was 
enhanced in cells transfected with siRNA2. Specifically, at all drug 
concentrations tested, the sequential treatment (8-hours siRNA2 transfection 
followed by 72-hours 17-AAG exposure) induced an inhibitory effect on cell 
proliferation greater than that expected by simple additivity of the effects of 
the two agents, which was appreciable both at the end of treatment and at 
7 days (Figure 51).
17-AAG (ng/ml)
Figure 51. Dose-response survival curves of DU145 cells 
exposed to siRNA in combination with 17-AAG.
Dose-response survival curves of DU 145 cells exposed to 17-AAG 
alone for 72 hours (■) or to combined treatment (8-hours transfection 
with 100 nM siRNA2 followed by 72-hours exposure to 17-AAG) (•) 
and obtained at the end of treatment (3 days; top) or at 7 days 
(bottom). Mean plots ± sd of three independent experiments are 
reported. The dashed line indicates the expected curve for an 
additive effect of the two agents in combination.
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Figure 52. Effects of siRNA-mediated survivin down-regulation 
combined with 17-AAG treatment on the expression/activity of Hsp90 
client proteins.
Representative Western blot (A) and TRAP assay (B) experiments illustrating 
the expression of Akt and cdk6 proteins and telomerase catalytic activity in 
DU 145 cells after a 72-hours exposure to 17-AAG.
Exposure of cells to 17-AAG alone did not appreciably affect survivin 
expression up to 100 ng/ml, whereas a marked and dose-dependent 
inhibition of protein expression was observed at the two highest drug 
concentrations (500 and 1000 ng/ml) (Figure 53). Sequential treatment with 
siRNA2 and 17-AAG consistently caused a strong decrease of survivin 
expression, which was almost superimposable to that observed after 
transfection of cells with siRNA2 alone (Figure 53). However, it was not 
possible to evaluate the cytotoxic effect of the sequential treatment at 17- 
AAG concentrations able to down-regulate survivin, since an almost 
complete inhibition of cell proliferation (around 99%) was found after a 3-days 
exposure to 500 ng/ml of drug. The cytotoxic effect of 17-AAG in DU 145 cells 
transfected with the control siRNA was superimposable to that observed in 
cells exposed to 17-AAG alone.
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Figure 53. Survivin protein expression in DU145 cells after 
exposure to siRNA and 17-AAG.
Representative Western blot experiments illustrating the 
expression of survivin in DU 145 cells after exposure to siRNA2 
and 17-AAG, singly administered (top) or in sequence (bottom).
To gain insight into the molecular basis responsible for the increased 
sensitivity to 17-AAG observed in siRNA2-transfected DU 145 cells, we 
evaluated the in vitro catalytic activity of caspase-9 following single and 
combined treatments (Figure 54). Exposure to 17-AAG increased the 
enzyme’s activation compared to that observed in control (no-drug) cells. 
However, the caspase-9 catalytic activity was consistently and significantly 
(p<0.02) higher in cells exposed to the combined treatment (8-hours siRNA2 
transfection followed by 72-hours 17-AAG exposure) than in those treated 
with the drug alone, and such enhancement was greatest (2.8-fold) at the 
highest 17-AAG concentration (Figure 54).
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Figure 54. Caspase activation in DU145 cells after exposure to 
siRNA and 17-AAG.
Caspase-9 catalytic activity was determined by hydrolysis of the 
fluorogenic substrate Ac-DEVD-AMC in DU 145 cells exposed to 17-AAG 
alone (empty column) or to the combined treatment (blue column). Data 
represent the mean values ± sd of three independent experiments. * 
p<0.02; ** p<0.01; Student’s t test.
To evaluate the effect of survivin down-regulation on 17-AAG sensitivity in 
a second prostate cancer cell line, we transfected PC-3 cells with 100 nM 
siRNA2. Such transfection induced a marked inhibition of survivin protein 
expression as compared to Lipo2000-exposed cells, which was appreciable 
starting from 24 hours after transfection and remained stable at 48 hours 
(Figure 55). Moreover, the extent of inhibition (around 70-80%) was 
comparable to that obtained in DU 145 cells after transfection with the same 
survivin-specific siRNA. Transfection of PC-3 cells with siRNA2 failed to 
appreciably modify the expression of other anti-apoptotic proteins such as 
XIAP, Bcl-2 and Bcl-xL (Figure 55).
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Figure 55. Survivin protein expression in PC-3 cells.
Representative Western blot experiments illustrating the 
expression of survivin and other anti-apoptotic proteins in 
PC-3 cells at 24 hours after transfection with siRNA2 
(100 nM).
PC-3 cells were considerably more resistant to 72-hours exposure to 17- 
AAG than DU 145 cells (Figure 56), as indicated by the 13-fold higher 
IC5o value (410 ± 20 ng/ml vs 31 ± 2 ng/ml, respectively). However, 17-AAG 
cytotoxic activity was enhanced in cells transfected with siRNA2 and, in 
accord with that observed in DU 145 cells, the sequential treatment induced 
an inhibitory effect on cell proliferation (appreciable at the end of treatment 
and at 7 days) greater than that expected by simple additivity of the effects of 
the two agents when the drug was used at concentrations ranging from 100to 
500 ng/ml. Conversely, no potentiating effect was observed when the highest 
17-AAG concentration (1000 ng/ml) was used in sequence with siRNA2 
(Figure 56). 17-AAG alone induced an appreciable inhibition of survivin 
expression only when used at 1000 ng/ml, whereas a markedly decreased
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survivin abundance was consistently observed in cells exposed to siRNA2- 
17AAG sequential treatment independently of drug concentration (Figure 57).
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Figure 56. Dose-response survival curves of PC-3 cells exposed 
to siRNA in combination with 17-AAG.
Dose-response survival curves of PC-3 cells exposed to 17-AAG 
alone for 72 hours (■) or to combined treatment (8-hours transfection 
with 100 nM siRNA2 followed by 72-hours exposure to 17- AAG) (•) 
and obtained at the end of treatment (3 days; top) or at 7 days 
(bottom). Mean plots ± sd of three independent experiments are 
reported. The dashed line indicates the expected curve for an additive 
effect of the two agents in combination.
siRNA2 - + - - - siRNA2
17-AAG (n g /m l) - - 1000 500 250 17-AAG (n g /m l)
+ + + +
- 1000 500 250
P-actin P-actin
survivin survivin
Figure 57. Survivin protein expression in PC-3 cells after exposure to siRNA and 17- 
AAG.
A representative Western blot experiment illustrating the expression of survivin in PC-3 cells 
after exposure to siRNA2 and 17-AAG, singly administered (left) or in sequence (right).
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4. Po ten tia tio n  of  p a c lita xel - in d u ced  a po p to sis  by  th e  n o ve l  c y c lin -
DEPENDENT KINASE INHIBITOR NU6140: A POSSIBLE ROLE FOR SURVIVIN
DOWN-REGULATION
Cell progression through the cell cycle is controlled by serine/threonine 
cyclin-dependent kinases (cdk) that form complexes with cyclins and operate 
in distinct phases of the cell cycle [Sherr, 1996; Morgan, 1997]. Aberrant 
control of cdks is a central feature of the molecular pathology of cancer 
[Kamb, 1995; Vogt & Reed, 1998; Pavletich, 1999]; hence cdks and their 
related pathways represent attractive targets in the development of 
anticancer therapeutics. Small molecule cdk inhibitors, including flavopiridol, 
roscovitine, UCN-01 and purvalanol A (Figure 58), which act by competing 
with ATP for binding at the catalytic site of the kinases, have been generated 
[Senderowicz, 2003]. In addition to arresting cell-cycle progression through 
the inhibition of multiple cdks [Senderowicz, 2003], some of these inhibitors 
exhibit a variety of activities, including induction of apoptosis [Meijer et a/, 
1997], promotion of cell differentiation [Lee et al, 1999], interference with 
transcription [Rickert et al, 1996; Chao et al, 2000] and anti-angiogenic 
effects [Melillo et al, 1999]. Furthermore, the possibility of enhancing the 
activity of conventional chemotherapeutic agents and radiation by 
combination with cdk inhibitors has also been shown [Schwartz et al, 1997; 
Motwani et al, 1999; Shah & Schwartz, 2000; Schwartz et al, 2001; Shapiro 
et al, 2001; Jung et al, 2003]. The purine-based cdk inhibitor NU6140 (4-(6- 
cyclohexylmethoxy-9H-purin-2-ylamino)-A/,A/-diethyl-benzamide) (Figure 58) 
was derived from NU6102 (6-cyclohexylmethoxy-2-(4’-
212
Chapter 4 RESULTS
sulfamoylanilino)purine), a potent and selective CDK2 inhibitor developed 
using structure-based drug design [Davies et al, 2002], as a cdk inhibitor with 
greater cellular potency.
HN
HO
purvalanol ANU6140
Figure 58. Chemical structure of NU6140 and purvalanol A.
Survivin is expressed in a cell cycle-dependent manner and during mitosis 
it localizes to various components of the mitotic apparatus and associates 
with microtubules of the mitotic spindle [Giodini et al, 2002]. Its expression is 
controlled at transcriptional [Li & Altieri, 1999] and post-translational 
[O’Connor et al, 2000] levels. In this context, it has been demonstrated that 
cdkl-mediated phosphorylation of survivin on Thr34 is essential for the 
cytoprotective function of the protein [O’Connor et al, 2000]. Moreover, 
previous evidence indicated that targeting survivin by means of Purvalanol A, 
resulted in an increased sensitivity to paclitaxel in HeLa cells [O’Connor 
et al, 2002].
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In this study we investigated the cellular effects of the novel cdk inhibitor 
NU6140 in relation to inhibition of cell proliferation and cell cycle progression, 
and ability to potentiate the apoptotic response to paclitaxel, in HeLa cells, in 
comparison to purvalanol A.
4.1. Effect of Cdk Inhibitors, Alone or in Combination with Paclitaxel, 
on Tumour Cell Growth
Clonogenic survival assays were performed to assess the anti-proliferative 
activity of NU6140 and purvalanol A, alone or in combination with paclitaxel. 
In a preliminary set of experiments, HeLa cervical carcinoma cells were 
treated with increasing concentrations of each cdk inhibitor alone. A 
concentration-dependent decline in cell survival was observed after treatment 
with both compounds, although NU6140 was somewhat more potent than 
purvalanol A as indicated by the three-fold lower concentration required to kill 
50% of cells (IC5o values: 2.3 ± 0.2 pM vs 8.7 ± 0.4 pM, respectively) 
(Figure 59; Table VIII).
We further assessed the cytotoxic effects of the cdk inhibitors in 
combination with paclitaxel. HeLa cells were treated with paclitaxel for 
24 hours followed by a 24 hours-exposure to NU6140 or purvalanol A, and 
the opposite sequence was also tested. Both cdk inhibitors cooperated with 
paclitaxel to inhibit clonogenic cell survival (Table VIII). Specifically, 
sequential treatment with paclitaxel followed by each cdk inhibitor was more 
effective than the reverse treatment sequence, and induced an inhibitory
214
Chapter 4 RESULTS
effect on surviving fraction greater than that expected by simple additivity of 
the effects of the two drugs (Table VIII). However, the most marked effect 
was obtained with the paclitaxel-NU6140 combination.
O)
Figure 59. Clonogenic cell survival curves obtained 
after exposure of HeLa cells to cdk inhibitors.
HeLa cells were treated with NU6140 (•) and purvalanol A (T )  
for 24 hours and then incubated at 37°C for 10 days. Colonies 
consisting of at least 50 cells were stained with crystal violet 
and counted under the microscope. Data represent mean 
values ± sd of three independent experiments.
A marked effect of the paclitaxel-NU6140 combination on the surviving 
fraction was also confirmed in OAW42/e ovarian cancer cells. Conversely, a 
subadditive effect of the paclitaxel-NU6140 combined treatment was found in 
OAW42/Surv cells ectopically expressing survivin (Table IX).
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Table VIII. Cytotoxic effect of NU6140 and purvalanol A against HeLa cells as 
single agents and in combination with paclitaxel.
Agent/Combination Concentration Surviving Surviving E/O C .l.c r
fraction fraction ratio b
Observed (O) Expected3 (E)
Paclitaxel (nM) 1
2.5
5
0.76
0.34
0.12
NU6140 (pM) 1
2.5
5
0.70
0.47
0.14
Purvalanol A (pM) 1
2.5
5
0.97
0.89
0.75
Paclitaxel (nM) 1
+ NU6140 (pM) 1
2.5
0.50 0.53 1.06 1.14 0.96
2.5 0.05 0.16 3.2 0.47 0.77
5
5 0.002 0.02 10 0.29 0.71
Paclitaxel (nM) 1
+ Purvalanol A (pM) 1
2.5
0.62 0.74 1.19 0.90 0.80
2.5 0.18 0.30 1.7 0.60 0.80
5
5 0.02 0.09 4.5 0.44 0.93
NU6140 (pM) 1
+ Paclitaxel (nM) 1
2.5
0.64 0.53 0.87 1.51 1.43
2.5 0.09 0.16 1.78 0.76 0.84
5
5 0.012 0.02 1.67 0.45 0.97
Purvalanol A (pM) 1
+ Paclitaxel (nM) 1
2.5
0.66 0.74 1.12 0.95 0.92
2.5 0.18 0.30 1.67 0.70 0.83
5
5 0.03 0.09 3.00 0.53 1.09
a calculated as the product of the surviving fractions observed for individual drugs; 
b (surviving fraction observed) / (surviving fraction expected) 
c Combination index according to Chou & Talalay [1984] 
d Isobologram analysis according to Berenbaum [Berenbaum, 1989]
216
Chapter 4 RESULTS
Table IX. Cytotoxic effect of NU6140 against OAW42/e and OAW42/Surv cells 
as single agent and in combination with paclitaxel.
Agent/Combination Concentration Surviving Surviving 
fraction fraction 
Observed (0) Expected3 (E)
E/O C .I.c 
ratio b
OAW42/e
Paclitaxel (nM) 1 0.81
2.5 0.56
5 0.14
NU6140 (pM) 1 0.83
2.5 0.29
5 0.17
Paclitaxel (nM) 1
+ NU6140 (pM) 1 0.82 0.67 2.09 1.33
2.5
2.5 0.08 0.16 2.00 0.57
5
5 0.0023 0.023 10 0.36
NU6140 (pM) 1
+ Paclitaxel (nM) 1 0.43 0.67 1.55 0.95
2.5
2.5 0.13 0.16 1.23 0.74
5
5 0.014 0.023 1.64 0.60
OAW42/Surv
Paclitaxel (nM) 1 0.99
2.5 0.90
5 0.75
NU6140 (pM) 1 0.89
2.5 0.30
5 0.18
Paclitaxel (nM) 1
+ NU6140 (pM) 1 0.85 0.88 1.03 1.19
2.5
2.5 0.30 0.27 0.90 1.28
5
5 0.16 0.13 0.81 1.34
NU6140 (pM) 1
+ Paclitaxel (nM) 1 0.87 0.88 1.01 1.25
2.5
2.5 0.32 0.27 0.84 1.33
5
5 0.18 0.13 0.72 1.40
a calculated as the product of the surviving fractions observed for individual drugs; 
b (surviving fraction observed) / (surviving fraction expected) 
c Combination index according to Chou & Talalay [1984].
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4.2. Effects of Cdk Inhibitors on Cell Cycle Progression and Apoptosis
Flow cytometric analysis of propidium iodide-stained HeLa cells showed 
that a 24-hours treatment with NU6140 and purvalanol A resulted in a 
concentration dependent decrease in the number of cells in the Gi phase, 
and a concomitant increase in the sub-Gi apoptotic cell population 
(Figure 60A). Moreover, chromatin condensation and DNA fragmentation, 
which are common features of apoptosis, were detected by fluorescence 
microscopy after staining with propidium iodide of HeLa cells treated with 
NU6140 and purvalanol A. The percentage of cells with an apoptotic nuclear 
morphology, as determined on the overall cell population, increased in a 
concentration-dependent fashion after treatment with both inhibitors 
(Figure 60B).
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Figure 60. Effect of NU6140 and purvalanol A on cell cycle and apoptosis.
HeLa cells were exposed to 1% (v/v) DMSO (control cells) or 1, 10, 100 pM NU6140 and 
purvalanol A. (A) Cell cycle distribution was assessed by flow cytometry on cells stained with 
propidium iodide. The percentage of cells in sub-Gi (grey column), Gi (empty column), S 
(hatched column) and G2/M phase (blue column) are shown. Data represents the means of 
the three independent experiments; sd were always within 5%. (B) The percentage of cells 
with an apoptotic morphology was assessed by fluorescence microscopy. Data represent 
mean values ± sd of three independent experiments.
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At the molecular level, treatment with NU6140 and purvalanol A resulted in 
a concentration-dependent increase in the catalytic activity of capase-9 and 
capase-3, as assessed by the in vitro hydrolysis of specific fluorogenic 
substrates (Figure 61).
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Figure 61. Caspase activation in HeLa cells after exposure to NU6140 and 
purvalanol A.
Caspase-9 (blue column) and caspase-3 (red column) catalytic activity was determined 
by hydrolysis of the fluorogenic substrate LEHD-AFC and Ac-DEVD-AMC AMC 
respectively, in cells exposed to 1% (v/v) DMSO (control cells) or treated with 1, 10, 100 
pM of NU6140 and purvalanol A for 24 hours. Data are expressed as relative 
fluorescence units (r.f.u.) and represent mean values ± sd of three independent 
experiments.
4.3. Effects of Cdk Inhibitors on Survivin Expression
To investigate the mechanisms by which NU6140 and purvalanol A 
induced apoptosis, we evaluated the expression of the anti-apoptotic gene 
survivin in cancer cells after drug exposure. Treatment of HeLa cells with 
NU6140 or purvalanol A induced a concentration-dependent decrease in the 
levels of survivin protein (Figure 62). A NU6140-induced inhibition of survivin
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expression was also seen in OAW42/e and OAW42/Surv cells. However, in 
OAW42/Surv cells, which displayed a 2.5-fold higher basal level of survivin 
protein compared to OAW42/e cells, the protein abundance was consistently 
higher than in parental cells also after exposure to different NU6140 
concentrations (Figure 62). Conversely, exposure to NU6140 failed to 
modulate the expression of other anti-apoptotic proteins, such as Bcl-2 and 
B c I- x l ,  in all three cell lines (Figure 62).
HeLa 0A W 42/e 0A W 42/S urv
(3-actin
survivin
Bcl-2
Bcl-xL
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Figure 62. Down-regulation of survivin protein by cdk inhibitor treatment.
Tumour cells were exposed to 1% (v/v) DMSO (control cells) or treated with 1, 10, 100 pM of 
NU6140 and purvalanol A for 24 hours. Survivin, Bcl-2 and Bcl-xL protein expression was 
assessed by Western blot. P-actin was used as a control for loading.
Furthermore, RT-PCR analysis in HeLa cells demonstrated that survivin 
mRNA levels were reduced by both cdk inhibitors (Figure 63), suggesting 
that NU6140 and purvalanol A modulate survivin expression at the 
transcriptional level.
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Figure 63. Down-regulation of survivin mRNA by cdk inhibitor treatment.
Tumour cells were exposed to 1% (v/v) DMSO (control cells) or treated with 1,10, 
100 pM of NU6140 and purvalanol A for 24 hours. Survivin mRNA expression was 
assessed by RT-PCR. (3-actin was used as a control for amplification.
The possibility that NU6140 and purvalanol A inhibit survivin activation by 
interfering with cdkl, a kinase which is known to activate survivin through 
phosphorylation of its Thr34 residue [O’Connor et al, 2002] was also studied. 
Results from immunoblotting experiments using a phospho-specific antibody 
indicated that the levels of the active, Thr34-phosphorylated form of survivin 
were reduced in a concentration-dependent fashion following treatment of 
HeLa cells with NU6140 and purvalanol A (Figure 64).
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Figure 64. Effect of cdk inhibitor treatment on survivin phosphorylation.
Survivin phosphorylation on Thr34 as evaluated by Western blot. Survivin was 
immunoprecipitated using the anti-human survivin antibody and analysed with the 
antibody to phosphorylated Thr34.
4.4. Effects of Combined Treatment with Paclitaxel and Cdk Inhibitors 
on Cell Cycle Phase Distribution and Apoptosis
Next, we examined cell cycle perturbations induced by paclitaxel alone or 
paclitaxel followed by the cdk inhibitors (Figure 65). HeLa cells treated with 
paclitaxel alone for 24 hours accumulated in the G2/M phase, and a fraction 
of sub-Gi apoptotic cells, corresponding to 19 ± 1.2% of the overall cell 
population, was observed. When cells were treated sequentially with 
paclitaxel and NU6140, a reduction in G2/M arrested was observed, and 
86 ±11% of cells underwent apoptosis. Such an apoptosis rate was 
significantly (p<0.01) higher than that observed after sequential treatment of 
cells with paclitaxel and purvalanol A (37 ± 8%) (Figure 65). However, it must 
be stressed that results of cell cycle analysis of cells undergoing apoptosis
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have to be considered with some caution, since partial loss of DNA during 
the apoptotic process can make it difficult to distinguish between S-phase 
and G2/M-phase cells.
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Figure 65. Effect of combined treatment with paclitaxel followed by 
cdk inhibitors on cell cycle progression and apoptosis.
(A) HeLa cells were incubated with paclitaxel (50 nM), NU6140 (10 pM) or 
purvalanol A (10 pM) alone for 24 hours, or with paclitaxel (50 nM) for 24 hours 
followed by a 24 hours-exposure to cdk inhibitors (10 pM). Following treatment 
cells were analysed by flow cytometry. (B) Quantification of s u b ^  apoptotic 
cells. Data represent mean values ± sd of three independent experiments. 
*p<0.01, Student’s t test.
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We then assessed whether the increases apoptotic response induced by 
combined treatments was sustained by caspase activation in HeLa cells. 
Immunoblotting results indicated that treatment with paclitaxel and 
purvalanol A, singly administered or in combination, did not induce any 
proteolytic processing of the enzymes. Caspase-9 cleavage was detected 
only after the sequential treatment of cells with paclitaxel and NU6140 
(Figure 66). Moreover, in response to NU6140, the 32 kDa pro-caspase-3 
was partially cleaved to a 20 kDa intermediated form, whereas a complete 
activation of caspase-3 was observed after sequential treatment with 
paclitaxel followed by NU6140, as indicated by the presence of both the 
20 and 17 kDa active cleaved products (Figure 66).
caspase-9 46 kDa
32 kDa
caspase-3
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Figure 66. Proteolytic processing of caspase-9 and caspase-3 by 
combined treatment of tumour cells with paclitaxel followed by cdk 
inhibitors.
Cells were incubated with paclitaxel (50 nM), NU6140 (10 pM) or purvalanol 
A (10 pM) alone for 24 hours, or with paclitaxel (50 nM) for 24 hours followed 
by a 24 hours-exposure to cdk inhibitors (10 pM). The proteolytic processing 
of caspase-9 and caspase-3 was assessed by Western blot.
Lane 1, ctr; lane 2, paclitaxel; lane 3, NU6140; lane 4 paclitaxel + NU6140; 
lane 5, purvalanol A; lane 6, paclitaxel + purvalanol A.
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The proteolytic processing of caspase-9 and caspase-3 coincided with an 
increased catalytic activity of both enzymes. Specifically, caspase-9 and 
caspase-3 activity, was about 3-fold (p<0.001) and 4-fold (p<0.01) higher, 
respectively, in HeLa cells treated with paclitaxel followed by NU6140 than in 
cells exposed to single agents or paclitaxel-purvalanol A combination 
(Figure 67).
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Figure 67. Activation of caspases by combined treatment of 
HeLa cells with paclitaxel followed by cdk inhibitors.
Cells were incubated with paclitaxel (50 nM), NU6140 (10 pM) or 
purvalanol A (10 pM) alone for 24 hours, or with paclitaxel (50 nM) 
for 24 hours followed by a 24 hours-exposure to cdk inhibitors 
(10 pM). Caspase-9 (empty column) and caspase-3 (blue column) 
catalytic activity as determined by hydrolysis of the fluorogenic 
substrate LEHD-AFC and Ac-DEVD-AMC AMC, respectively. Data 
are expressed as relative fluorescence units (r.f.u.) and represent 
mean values ± sd of three independent experiments. *p<0.01, 
**p<0.001, Student’s t test.
Similarly, a 3-fold increase (p<0.001) in caspase-9 and caspase-3 catalytic 
activity was observed in OAW42/e cells exposed to paclitaxel followed by 
NU6140 compared to cells treated with individual agents (Figure 68). 
Conversely, a modest and non statistically significant increase in caspase
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catalytic activities was found in OAW42/Surv cells treated with paclitaxel- 
NU6140 combination (Figure 68).
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Figure 68. Activation of caspases by combined treatment of OAW42/e and 
OAW42/Surv cells with paclitaxel followed by cdk inhibitors.
Cells were incubated with paclitaxel (50 nM), NU6140 (10 pM) or purvalanol A (10 pM) alone 
for 24 hours, or with paclitaxel (50 nM) for 24 hours followed by a 24 hours-exposure to cdk 
inhibitors (10 pM). Caspase-9 (A) and caspase-3 (B) catalytic activity as determined by 
hydrolysis of the fluorogenic substrate LEHD-AFC and Ac-DEVD-AMC AMC, respectively, in 
OAW42/e (empty column) and OAW42/Surv (blue column) cells. Data are expressed as 
relative fluorescence units (r.f.u.) and represent mean values ± sd of three independent 
experiments. *p<0.001, Student’s t test.
4.5. Effects of Combined Treatment with Paclitaxel and Cdk Inhibitors 
on Survivin Activation
Finally, the effects of paclitaxel, alone or in combination with NU6140 and 
purvalanol A, on survivin activation, as indicated by the level of the Thr34- 
phosphorylated form of the protein, was assayed by immunoblotting. As 
expected, treatment with paclitaxel alone increased the level of phospho- 
survivin, whereas combined treatment with paclitaxel and cdk inhibitors
226
Chapter 4 RESULTS
appreciably inhibited survivin phosphorylation, which was almost completely 
abrogated in cells exposed to the paclitaxel-NU6140 combination (Figure 69).
IP: survivin 
WB: survivin-Thr34
Figure 69. Effect of combined treatment of HeLa cells with paclitaxel followed by 
cdk inhibitors on survivin phosphorylation.
The phosphorylation of survivin on Thr34 residue was evaluated on HeLa cells treated 
with paclitaxel (50 nM), NU6140 (10 pM) or purvalanol A (10 pM) alone for 24 hours, or 
with paclitaxel (50 nM) for 24 hours followed by a 24 hours-exposure to cdk inhibitors 
(10 pM). Survivin was immunoprecipitated using the anti-human survivin antibody and 
analysed by Western blot with the antibody to phosphorylated Thr34.
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Apoptosis is an attractive and well controlled cell suicide program that is 
evolutionary conserved among all animals [Steller, 1995; Nagata, 1997; 
Hengartner, 2000]. Deregulation of the apoptotic pathway is implicated in the 
pathogenesis of a variety of human diseases, including cancer [Reed, 1999; 
Yuan et al, 2003]. Many cancer cells circumvent normal apoptotic 
mechanisms to prevent their self-destruction, which may be of fundamental 
significance in the development of malignancy [Kerr, 1994; Hale et al, 1996]. 
In addition to the Bcl-2 family, a second anti-apoptotic gene family IAP has 
been identified [Deveraux & Reed, 1999; Hay, 2000; Salvesen & Duckett, 
2002]. Among the lAPs, survivin plays an important role in inhibiting 
apoptosis and regulating mitotic progression [Altieri & Marchisio,1999]. 
Considering that apoptotic cell death is the major mode by which chemical 
and physical anticancer agents kill tumour cells, it appears reasonable that 
the inability to undergo programmed cell death is a major mechanism of the 
chemoresistance of tumour cells. As a consequence, the genes that control 
apoptosis provide interesting new targets for the rational development of 
strategies aimed at increasing the susceptibility of tumour cells to chemical 
and radiation treatment. In this context, the marked expression of survivin in 
cancer versus normal tissues [Altieri, 2003a] and its association with 
unfavourable disease outcome [Altieri, 2003a] have made survivin a 
promising therapeutic target for novel anticancer therapies [Altieri, 2003b].
To validate survivin as a potential therapeutic target in cancer cells, we 
evaluated the effects of the inhibition of survivin expression/activity on the 
proliferative potential, ability to undergo spontaneous apoptosis, and 
sensitivity to drug- and radiation-treatment of different tumour cell lines.
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We first chose an approach based on the use of a hammerhead ribozyme 
since, due to its specific endoribonuclease activity, this small RNA molecule 
is able not only to specifically recognize its target RNA through 
complementary base pairing but also to cleave the substrate leading to its 
degradation and permanent inactivation [Sun et al, 2000]. These catalytic 
RNA motifs have received much attention in view of their potential usefulness 
for gene therapy due to their inherent simplicity, small size and ability to be 
incorporated into a variety of flanking sequence motifs without changing site- 
specific cleavage capacities. Moreover, the typical catalytic cycle of a 
ribozyme offers a considerable advantage with respect to the action 
mechanism of conventional antisense oligonucleotides [Sun et al, 2000]. 
Specifically, one molecule of hammerhead ribozyme can cleave several RNA 
target molecules, which implies that, theoretically, very low concentrations 
are required to obtain a significant biological effect. In fact, the efficacy of the 
ribozyme-mediated approach in inhibiting the expression of several cancer- 
related genes has been clearly demonstrated in a number of studies carried 
out on experimental human tumour models [Lewin & Hauswirth, 2001].
In the first part of the study we demonstrated the possibility to markedly 
attenuate the expression of the anti-apoptotic factor survivin in the JR8 
human melanoma cell line, which inherently over-expresses the anti- 
apoptotic protein, by the use of a hammerhead ribozyme targeting a 
consensus sequence in exon 1 within survivin mRNA. This inhibitory effect 
was lost after inactivation of the catalytic core of the ribozyme (in JR8/mutRz 
cells), which strongly suggests specific cleavage activity of the anti-survivin 
ribozyme not only in the cell-free-system but also in intact cells. Active-
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ribozyme transfectant cells showed enhanced sensitivity to topotecan and 
cisplatin with respect to cells transfected with the mutant ribozyme, as 
demonstrated by a reduced clonogenic cell survival and a lower IC50 value. 
Such an increased susceptibility to drug treatment as a consequence of 
survivin down-regulation was not observed for all DNA-interacting agents 
tested. Although the molecular basis for this putative selectivity is presently 
unknown, it is plausible that different signals are activated in response to 
DNA damage, depending on the type of genotoxic lesion, with a variable 
impact on the survivin pathway.
Ribozyme-transfectant melanoma cells also showed increased sensitivity 
to y-irradiation with respect to parental cells and cells transfected with the 
mutant ribozyme, as demonstrated by a significantly reduced clonogenic cell 
survival. Specifically, cells expressing the active ribozyme were characterized 
by a survival curve with a reduced shoulder. Such a finding would suggest 
that, in the clinical setting, survivin inhibition could improve tumour sensitivity 
to fractionated therapy with multiple low radiation doses. Our results are in 
accord with previous evidence obtained in pancreatic carcinoma cell lines 
showing a direct relationship between the extent of survivin expression and 
the degree of in vitro radioresistance [Asanuma et al, 2000]. The same 
authors also showed that transduction of a dominant-negative mutant 
survivin gene into the radioresistant PANC-1 pancreatic cancer cells 
increased their radiation response [Asanuma et al, 2002]. Taken together 
these results support the hypothesis that survivin is a molecular determinant 
of radiation resistance.
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In vitro sensitisation to drugs and radiation was paralleled by restoration of 
the susceptibility of JR8 cells expressing the active ribozyme to programmed 
cell death induced by the treatment. Such an enhanced apoptotic response 
was mediated by an increased activation of caspase-9 and caspase-3, which 
is consistent with the recognized function of survivin to counteract 
mitochondrial-death pathway [Altieri, 2003c; Beltrami et al, 2004]. However, it 
is still unclear whether survivin inhibits caspases through direct binding or 
indirectly, thereby requiring intermediate proteins [Reed, 2001]. Specifically, 
a possible direct interaction of survivin with caspase-9 has been reported by 
O’Connor et al [2000], whereas, more recently, Song et al [2003] suggested 
an alternative model for indirect inhibition of caspases by survivin based on 
its ability to physically interact with SMAC/Diablo. This mitochondrial factor, 
which is released into the cytosol in response to apoptotic stimuli, is known to 
bind to some lAPs (including XIAP, cIAPi,CIAP2 and livin), thus preventing 
them to inhibit caspases [Du et al, 2000; Vucic et al, 2002]. Accordingly to 
Song’s model, the capability of survivin to sequester SMAC would allow other 
lAPs to block caspases without being antagonized. However, the possibility 
that survivin down-regulation also results in caspase-independent apoptosis 
was suggested by Liu et al [1998]. Specifically, they found the earliest pro- 
apoptotic event in melanoma cells transfected with a survivin dominant- 
negative mutant was nuclear translocation of mitochondrial apoptosis- 
inducing factor (AIF), known to trigger both apoptotic mitochondrial events 
and caspase-9 independent DNA fragmentation.
When tested in a human melanoma xenograft, ribozyme-mediated 
inhibition of survivin expression resulted in increased antitumorigenic activity
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of topotecan, as demonstrated by the significantly delayed tumour 
establishment. Based on our in vitro findings indicating an enhanced 
susceptibility to topotecan-induced apoptosis of JR8 cells expressing the 
active ribozyme, it is conceivable to hypothesize that such an increased 
apoptotic response also occurred in vivo. The delayed growth in nude mice of 
tumour cells containing the active ribozyme after topotecan treatment 
reflected the survival of a limited number of cells that escaped drug-induced 
apoptosis, presumably as a consequence of a heterogeneous expression of 
survivin. Our findings corroborate and extend previous results indicating the 
possibility to target survivin pathway to obtain an improved response to 
apoptosis-inducing anticancer drugs in in vivo tumour models [Olie et al, 
2000; O’Connor et al, 2002; Wall et al, 2003]. In this context, Yamamoto et al 
[2002] showed that down-regulation of survivin by forced expression of its 
natural antisense, the effector cell protease receptor-1 [Altieri, 1995], resulted 
in enhanced sensitivity to cisplatin and 5-fluorouracil of the HT29 colon 
adenocarcinoma cell line transplanted into nude mice. O’Connor et al [2002] 
observed that sequential inhibition of p34cdc2 by purvalanol A (that blocks 
p3 4 cdc2 phosphorylation on Thr34, which seems to be essential for the 
cytoprotective function of survivin [Altieri, 2003d]) enhanced the antitumour 
activity of taxol in an MCF-7 breast cancer xenograft.
In contrast to that reported in the aferomentioned and other studies [Olie 
et al, 2000; Grossman et al, 2001; Mesri et al, 2001; Yamamoto et al, 2002], 
we did not observe any effect of survivin inhibition on proliferative potential, 
induction of spontaneous apoptosis and tumorigenicity of melanoma cells in 
the absence of other stimuli. It could be hypothesized that the concomitant
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overexpression of other anti-apoptotic factors, such as Bcl-2 and Bcl-xL, and 
cell survival factors in JR8 cells might produce a cytoprotective effect and 
contribute to prevent programmed cell death in this tumour model. When JR8 
cells previously exposed for 48 hours to 3 pM of the Bcl-2 antisense 
oligonucleotide G3139 (which reduced by 50% the endogenous expression 
of the Bcl-2 protein) were y-irradiated, however, no significant variation in 
their radio-sensitivity profile was observed. Such a finding would indicate that 
this anti-apoptotic factor does not play a major role in determining radiation 
response of these cells [Folini M, unpublished data].
However, it should be stressed that in JR8/Rz cells, survivin expression 
was attenuated but not completely abrogated. Possibly inhibition below a 
certain threshold is insufficient to abrogate the anti-apoptotic effect as well as 
to efficiently interfere with the major survivin function of preserving the mitotic 
apparatus and allowing normal cell cycle progression, as indicated by the 
lack of spontaneous apoptosis observed in JR8/Rz, which were also 
characterized by an in vitro proliferative potential similar to that of parental 
cells. Interestingly, and in keeping with this hypothesis, when we transduced 
two human androgen-independent prostate cancer cell lines with a Moloney- 
based retroviral vector carrying the catalytic sequence of the ribozyme Rz, 
we were able to select polyclonal cell populations characterized by a 
significant reduction of survivin expression compared to control cultures 
expressing the catalytically inactive ribozyme.
To obtain a high level of expression of the ribozyme within tumour cells 
and to target it to the same cellular compartment as its target mRNA 
substrate, we embedded the ribozyme sequence in the context of the
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adenoviral VA1 gene and delivered it to cells through a retroviral vector. The 
gene is actively transcribed by RNA polymerase III in a variety of cell types, 
and the resulting transcript is characterized by a cytoplasmic localization 
[Prislei et al, 1997]. Moreover, it has been demonstrated that embedding a 
ribozyme in the context of this exogenous RNA molecule provides 
appropriate conformation for catalytic activity and stability [Cagnon & Rossi,
2000].
As expected, ribozyme-mediated down-regulation of survivin expression in 
polyclonal cell populations obtained from both DU 145 and PC-3 cell lines 
resulted in a significant increase in the rate of spontaneous apoptosis, which 
was accompanied by the proteolytic activation of caspase-9 and caspase-3 
and a significant increase in their in vitro catalytic activity. Inhibition of 
survivin expression also caused an increased apoptotic response of 
DU145/Rz cells to the anticancer drug cisplatin. Consistent with a major role 
of survivin in preserving the mitotic apparatus and allowing normal mitotic 
progression [Giodini et ai, 2002], we found the appearance of a polyploid cell 
subpopulation in the DU145/Rz cell line as a possible consequence of the 
almost complete inhibition of survivin expression. The lack of evidence of 
polyploid cells in the PC-3/Rz cell line, in which a larger fraction of residual 
survivin protein was still present, further supports the hypothesis that 
inhibition below a certain threshold might be insufficient to abrogate survivin 
function in the control of mitotic progression. Moreover, a significant 
reduction of the in vitro proliferative potential, as indicated by a markedly 
increased doubling time, was only appreciable in DU145/Rz cells.
235
Chapter 5 D iscu ssio n
As regards the effect of survivin inhibition on the tumorigenic potential of 
prostate cancer cells, we found that DU 145 cells were unable to grow when 
xenografted in athymic mice. Based on the results obtained in DU145/Rz 
cells as well as on previous evidence derived from in vivo studies (in which 
down-regulation of survivin through the use of survivin Thr34-Ala mutant 
suppressed de novo tumour formation and inhibited the growth of established 
tumours in immunodeficient mice) [Grossman et al, 2001; Mesri et al, 2001], 
it could be assumed that the decreased tumorigenic potential of DU145/Rz 
was due an enhanced spontaneous apoptosis and reduced proliferative 
potential as a consequence of survivin inhibition.
The discovery that synthetic 21-23 nucleotide RNA duplexes (siRNAs) can 
trigger an RNAi response in mammalian cells and induce strong inhibition of 
specific gene expression [Elbashir et al, 2001] has opened the door to the 
therapeutic use of siRNAs. Specifically, several studies on experimental 
human tumour models have demonstrated the feasibility of this approach for 
the inhibition of a variety of cancer-related genes [Izquierdo, 2005]. 
Therefore, we used this interference approach to markedly reduce the 
expression of the cytoprotective factor survivin in human androgen- 
independent prostate cancer cells. Since it appears that target specificity can 
be attained depending on the position and sequence of a given siRNA 
[Ryther et al, 2005] in this study we used four 21-mer double-stranded 
siRNAs targeting different regions within survivin mRNA. A marked, though 
variable, extent of survivin inhibition in terms of mRNA and protein 
expression was observed with the different siRNAs, indicating the specificity 
of the inhibitory approach, which was also confirmed by the lack of an effect
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on the expression of other anti-apoptotic proteins. However, the evidence of 
a modest but definite degree of survivin inhibition, mainly appreciable at the 
protein level, following transfection of cells with a control, unrelated siRNA 
suggests the occurrence of minor off-target effects induced by siRNAs. In this 
context microarray experiments aimed at evaluating whether global gene 
expression patterns change in the presence or absence of siRNAs already 
suggested that a small number of nontarget transcripts may also be affected 
[Semizarov et al, 2003].
As expected by our previous results indicating that interference with 
survivin function by the use of the hammerhead ribozyme led to increased 
apoptotic cell death in human androgen-independent prostate cancer cells, 
siRNA-mediated down-regulation of survivin expression in DU 145 cells 
resulted in a significant decline of cell proliferation and an increase in the rate 
of spontaneous apoptosis, with a significant enhancement of in vitro 
caspase-9 catalytic activity in DU 145 cells transfected with survivin-specific 
siRNAs. The possibility to restore the susceptibility to programmed cell death 
as a consequence of survivin gene silencing appears particularly relevant in 
human androgen-independent prostate cancer cells. In fact, one of the main 
events associated with the conversion to an androgen-independent 
phenotype and the concomitant loss of susceptibility not only to hormonal 
manipulation but also to chemotherapy and radiotherapy is an increased 
resistance to apoptosis due to dysregulation of the apoptotic pathways 
[Howell, 2000]. Specifically, a role for survivin in mediating resistance of 
prostate cancer cells to anti-androgen therapy with flutamide has been 
recently reported [Zhang etal, 2005].
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Several in vitro and in vivo studies indicated that survivin down-regulation 
was able to sensitise human tumour cells of different histological origin to 
conventional chemotherapeutic drugs including taxol, doxorubicin, etoposide 
and cisplatin [Olie et al, 2000; Hayashi et al, 2005; Zhang et al, 2005] as well 
as to ionizing radiation [Lu et al, 2004; Kami et al, 2005]. However, thus far, 
no data are available concerning the effect of survivin down-regulation on the 
activity of ansamycin antibiotics, such as geldanamycin and 17-AAG, which 
inhibit Hsp90’s chaperone function by targeting its ATPase activity [Schulte & 
Neckers, 1998]. Hsp90 inhibition results in proteasomal degradation of client 
proteins, leading to potent antitumour activity in experimental models 
[Kelland et al, 1999; Hostein et al, 2001]. In fact, although Hsp90 is highly 
expressed in most cells, Hsp90 inhibitors selectively kill cancer cells 
compared to normal cells. The molecular mechanism of such tumour 
selectivity is the result of an activated, high-affinity conformation of Hsp90 in 
tumour cells [Kamal et al, 2003]. Hsp90 inhibitors have been used as probes 
to definine the biological function of the chaperone at the molecular level and 
to validate it as a novel target for cancer therapy. One of these inhibitors, 17- 
AAG, has entered clinical trials, which served as proof of principle that Hsp90 
function can be modulated pharmacologically without undue toxicity in 
humans [Workman, 2003]. The search for second-generation analogues with 
potential preferential pharmacological features is actively pursued. However, 
the best way to use Hsp90 inhibitors as anticancer agents remains to be 
defined, also because of the limited knowledge of the determinants of cellular 
sensitivity to these compounds.
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We showed that the level of survivin expression influences the in vitro 
response of DU 145 human prostate cancer cells to 17-AAG as suggested by 
the supra-additive cytotoxic effect observed after sequential treatment with a 
survivin-specific siRNA and the Hsp90 inhibitor, which was accompanied by 
a significantly increased caspase-9-dependent apoptotic response. This 
chemosensitising effect seems to be independent of the inherent 
susceptibility to 17-AAG of the tumour cell system, since it was also observed 
in PC-3 cell, which are considerably more resistant to the Hsp90 inhibitor 
than DU 145 cells. Moreover, since 17-AAG itself induces an inhibition in 
survivin expression only when used at high concentrations (500 and 
1000ng/ml), it is unlikely that the supra-additive cytotoxic effects we 
observed with the survivin siRNA2-17-AAG sequential treatment at lower 
drug concentrations were due to a cooperative effect of the two agents in 
inducing survivin depletion. Our findings indicate that 17-AAG is more 
effective in cancer cells expressing reduced levels of survivin and suggest 
the opportunity to design combined treatments including survivin inhibitors 
and 17-AAG and test their antitumour potential against androgen- 
independent prostate cancer.
It has been previously reported that 17-AAG treatment reduced the 
expression of the androgen receptor (AR) in human prostate cancer 
xenografts and inhibited their growth in the animal [Solit et al, 2002]. 
Specifically, 17-AAG induced degradation of both wild-type and mutant AR, 
thus suggesting that this drug may be particularly effective in the treatment of 
androgen-independent prostate cancer. In fact, in a subset of patients treated 
with AR agonists, clinical progression is associated with AR gene
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amplification or mutation [Cabrespine et al, 2004], which may result in 
sufficient AR pathway activation to allow tumour growth at low levels of 
testosterone or following constitutive ligand-independent activation of the 
receptor.
The specific inhibition of survivin levels combined with the collapse of 
Hsp90 function by ansamycin antibiotics would be expected to exert a strong 
antitumour effect by disabling multiple signalling networks required for 
prostate cancer cell maintenance. Moreover, we recently demonstrated that a 
peptidomimetic antagonist of the survivin-Hsp90 complex structurally 
different from 17-AAG, shepherdin, inhibited the chaperone activity and 
exhibited potent and selective anticancer activity in preclinical models 
[Plescia et al, 2005].
There is a widely diffused opinion that RNAi provides a powerful tool for 
targeted inhibition of gene expression, with respect to conventional antisense 
strategies (i.e. ribozymes), presumably because it relies on a natural 
process. Despite the unique assumed potential of RNAi, limitations in the use 
of this approach, such as the possibility that some mammalian cells may not 
be susceptible to RNAi, have been described. Cellular uptake and co 
localization to the specific target site within cells represent the main hurdles 
that have to be overcome for an efficient inhibition of gene expression. 
Although there are still no means to improve co-localization to the target site 
and to increase the efficacy of siRNAs in the presence of hardly accessible 
target RNA, a number of specific strategies have been demonstrated to be 
effective in inducing a sequence-directed colocalization of ribozymes and to 
improve their efficacy at the target site [Lee et al, 1999].
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Ribozymes as well as siRNAs can lead to nonsequence specific effects 
(off-target effects) that are strongly dependent on the concentration of 
oligomers. However, it should be stressed that the double-stranded siRNAs 
may result in two single stranded oligomers which yield more pronounced off- 
target effects than those obtained with an equal molar amount of ribozymes 
[Scherer & Rossi, 2003]. However, lack of a study aimed to comparatively 
evaluate the efficacy of ribozymes and siRNAs in inhibiting the expression of 
the same gene on the same experimental systems makes it difficult to predict 
which is the better approach to be exploited for therapeutic purposes.
Whether selective inhibition of survivin can be used as a therapeutic 
modality aimed to inhibit the growth and enhance the sensitivity to specific 
anticancer drugs of melanoma and androgen-independent prostate cancer is 
an interesting issue that deserves further investigation. However, since 
multiple molecular pathways seem to play a role in mediating treatment 
resistance in these malignancies [Howell et al, 2000; Satyamoorthy et al,
2001], inhibition of a single target could be insufficient to adequately control 
tumour growth. In this context, exploration of additive or synergistic effects of 
combinations of selective inhibitors targeting different cellular pathways in 
preclinical models of melanoma and androgen-independent prostate cancer 
could provide the rational basis for the design of new multi-target clinical 
therapies.
Finally, since most human malignancies show aberrations in cell cycle 
control, the pharmacological modulation of cdks may be an important 
approach for the therapy of cancer. In this context, we evaluated the cellular 
effects of the purine derivative NU6140, a novel cdk inhibitor, in comparison
241
Chapter 5 D iscussio n
to purvalanol A, in HeLa cervical carcinoma, and OAW42/e and OAW42/Surv 
ovarian cancer cell lines. Both cdk inhibitors induced an impairment of cell 
cycle progression with a concentration-dependent accumulation of cells in 
the Gi compartment, which was accompanied by a decline of cell growth and 
the induction of an apoptotic response. Treatment with NU6140 and 
purvalanol A also inhibited the expression of survivin by negatively interfering 
with the transcription of the gene. Moreover, NU6140- and purvalanol A- 
treated cells exhibited a lower abundance of the Thr34-phosphorylated form 
of survivin, possibly as a consequence of drug-induced inhibition of cdkl 
catalytic activity. It has been shown that during mitosis survivin physically 
associates with cdk l, and that phosphorylation on its Thr34 residue by cdkl is 
a requirement for survivin-mediated cytoprotection [O’Connor et al, 2000]. 
Moreover, one of the mechanisms by which cdkl-mediated phosphorylation 
regulates survivin seems to be by increasing its stability at mitosis [O’Connor 
et al, 2002]. No appreciable interference with the expression of other anti- 
apoptotic proteins, such as Bcl-2 and B c I-x l , was observed after exposure of 
tumour cells to NU6140.
Taking into account the ability of NU6140 and purvalanol A to 
downregulate survivin, we tested the ability of the inhibitors to increase 
paclitaxel cytotoxicity. Results from preclinical studies as well as clinical data 
suggest a direct link between survivin expression and tumour cell 
susceptibility to paclitaxel. Initial reports showed that the forced expression 
of survivin was able to counteract apoptosis induced by paclitaxel in NIH3T3 
fibroblasts [Liu et al, 2004]. We previously demonstrated that stable 
transfection of human ovarian carcinoma cells with survivin cDNA caused a
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four- to six-fold increase in resistance to paclitaxel with a concomitant 
reduction in the apoptotic response of the cells to the drug [Zaffaroni et al,
2002]. The increased resistance of ovarian cancer cells ectopically 
expressing survivin to paclitaxel was also confirmed in the present study. 
These findings were indirectly supported by similar observations obtained 
analysing clinical tumour material where high levels of survivin protein 
expression, as detected by immunohistochemistry in advanced ovarian 
carcinomas, were significantly associated with clinical resistance to a 
paclitaxel/platinum-based regimen. Specifically, in these patients survivin 
overexpression correlated with a lower clinical or pathologic complete 
remission rate than absent/low protein expression [Zaffaroni et al, 2002].
The current results demonstrates that combination treatment of HeLa cells 
with paclitaxel and cdk inhibitors produced a sequence-dependent synergistic 
effect. Specifically, exposure of paclitaxel treated cells to NU6140 or 
purvalanol A strongly decreased clonogenic cell survival and increased 
caspase-9-mediated apoptotic response. However, such an enhancement 
was significantly greater for NU6140 than for purvalanol A. A synergistic 
effect of the paclitaxel-NU6140 combination, which was accompanied by a 
significantly enhanced caspase-9 and caspase-3 mediated apoptotic 
response was also observed in OAW42/e ovarian cancer cells. Conversely, a 
subadditive effect of the paclitaxel-NU6140 combined treatment and a lack of 
significant caspase activation was found in OAW42/Surv cells, which 
ectopically expressed survivin and showed a considerably higher level of 
survivin protein expression compared to OAW42 parental cells. Sequential 
treatment of HeLa cells with cdk inhibitors greatly reduced (or almost
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completely abrogated, in the case of NU6140) the expression of the Thr34- 
phosphorylated form of survivin, which, conversely, was significantly 
increased after treatment with paclitaxel alone. These data are consistent 
with a recently proposed model according to which microtubule stabilization 
by poisons such as paclitaxel engages a survival pathway that depends on 
elevated activity of cdkl kinase activity and increased phosphorylation and 
expression of survivin [O’Connor et al, 2002]. These authors demonstrated 
that sequence-specific inhibition of cdkl kinase with purvalanol A after 
paclitaxel treatment in HeLa cells removed this survival checkpoint and 
promoted strong antitumour activity in vitro an in vivo. As shown in the 
studies described here, NU6140 induces greater potentiation of paclitaxel 
cytotoxicity than purvalanol A, despite the generally lower potency of NU6140 
as an inhibitor of cdks in purified enzyme inhibition assays. Studies with 
NU6140 in the SKUT1B uterine tumour cell line have shown that following 
exposure to an extracellular concentration of 10 pM NU6140 for 4 hours, 
cellular levels can exceed 200 pmole/106 cells, i.e. approximately 200 pM 
[Thomas H & Newell DR, unpublished results]. Hence the greater 
potentiation of paclitaxel cytotoxicity induced by NU6140 could in part be due 
to the preferential cellular accumulation of the compound by, as yet, 
undefined mechanisms. Moreover, although it has not been formally 
investigated in this study, the possibility that NU6140 inhibits the 
phosphorylation of the carboxyl-terminal domain of RNA polymerase II and 
interferes with DNA transcription and RNA processing, as already 
demonstrated for the cdk inhibitor flavopiridol [Li et al, 1998], cannot be 
excluded.
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Results from our study indicate that NU6140 can potentiate the apoptotic 
effect of paclitaxel in cancer cells, and supports the hypothesis that inhibition 
of survivin phosphorylation, with the consequent disruption of the cdkl- 
mediated survival checkpoint, is a major mechanism. This may provide a 
rational approach to enhance the therapeutic efficacy of paclitaxel in the 
clinical setting. In fact, based on the evidence derived from preclinical 
studies, which demonstrate the concept of cell cycle-mediated drug 
resistance, the combination of cdk inhibitors with standard cytotoxic agents is 
now emerging as a promising approach to cancer therapy.
Overall, our results obtained from different studies aimed at targeting 
survivin expression/activity by means of different approaches demonstrated 
that inhibition of this cytoprotective factor was able to promote spontaneous 
apoptosis in tumour cells and to enhance the efficacy of several types of 
conventional treatments including chemotherapy and radiotherapy. 
Understanding how chemotherapeutic agents induces apoptosis is critical to 
design better anticancer treatments. To this purpose, results from our studies 
could have pharmacological implications for the improvement of antitumour 
therapy and are expected to provide a rational basis for the design of new 
therapeutic interventions based on the integration of different approaches.
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As previously assessed, the genes that control apoptosis provide 
interesting new targets for the rational development of strategies aimed at 
increasing the susceptibility of tumour cells to chemical treatment. 
Considering the multitude of events involved in the response to drug-induced 
damage, it is reasonable to presume that approaches based on the 
simultaneous targeting of different genes would have a greater impact on the 
final outcome of the drug exposure in tumour cells than the modulation of a 
single factor. In this context, in order to enhance the susceptibility of cancer 
cells to apoptosis-inducing chemotherapeutic agents, we propose to develop 
strategies for the simultaneous inhibition of different anti-apoptotic factors in 
tumour cells.
Specifically, we propose to assess the effects of the down-regulation of 
survivin with the contemporary inhibition of the:
S expression of Apollon/BRUCE, through the use of chemically 
synthesised siRNAs;
S activity of XIAP, through the use of synthetic peptides.
Development of siRNAs targeting Apollon/BRUCE
Apollon/BRUCE is a recently identified member of the IAP family with 
unusual properties [Hauser et al, 1998]. It is a very large membrane- 
associated protein that contains the BIR and the ubiquitin-conjugating 
enzyme domains at amino- and carboxy-terminals, respectively [Hauser et al, 
1998; Chen etal, 1999]. This protein is overexpressed in some drug-resistant 
cancer cells [Chen et al, 1999; Hao et al, 2004]. Unlike other mammalian
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lAPs Apollon/BRUCE is essential for viability of various cell lines [Qiu et 
al, 2004] and the knockout of Apollon/BRUCE in mice causes embryonic or 
neonatal lethality [Hao et al, 2004]. It has been shown that Apollon/BRUCE is 
essential to inhibit apoptosis by promoting ubiquitination and proteasomal 
degradation of precursor and mature forms of Smac/DIABLO and caspase-9, 
but not the effector caspase-3 [Hao et al, 2004; Qiu & Goldberg, 2005]. 
Because it is important in inhibiting apoptosis under normal conditions, 
degradation of Apollon/BRUCE must be a important step in the initiation of 
the apoptotic process. We propose to use chemically synthesised siRNAs 
directed against Apollon/BRUCE, alone or in association with siRNA 
targeting survivin, to improve the chemosensitivity profiles of human tumour 
cells overexpressing this factor.
Development of Smac peptides able to interact with XIAP
It has been demonstrated that during the process of apoptosis, the 
inhibitory function of XIAP (a ubiquitous lAP-family member) can be 
antagonized by Smac/DIABLO, which is also released from mitochondria as 
cytochrome c [Thomadaki & Scorilas, 2006]. Smac/DIABLO is a dimeric 
protein and is post-translationally processed in mitochondria [Du et al, 2000; 
Verhagen et al, 2000]. The amino terminus of processed Smac/DIABLO, 
starting with the residues AVPI, has been shown to be necessary and 
sufficient for removal of inhibition of caspase-9 by XIAP [Chai et al, 2000]. 
Structural studies demonstrated that the four hydrophobic amino acids, Ala- 
Val-Pro-lle (AVPI) residues at the amino terminus of mature Smac/DIABLO
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interact specifically and tightly with a conserved groove within the XIAP BIR3 
domain, and neutralise XIAP inhibition of caspase-9 by competing for the 
same specific binding site of XIAP with caspase-9 [Chai et al, 2000; Wu et al, 
2000]. We propose to use peptides derived from the amino terminus of 
Smac/DIABLO to inhibit the anti-apoptotic function of XIAP in human cancer 
cell lines. To favour cellular uptake, Smac/DIABLO peptides will be 
conjugated with internalization peptides such as Antennapedia or HIV-Tat. 
The chemosensitivity effect of these peptides, single administered or in 
combination with siRNA targeting survivin, will be evaluated in different 
human tumour cell lines.
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Appendix
ABBREVIATIONS
This appendix contains a key of the most common acronyms and 
abbreviations used in this thesis.
17-AAG = 17-allylamino-17-demethoxy-geldanamycin
Ac-DEVD-AMC = N-acetyl-Asp-Glu-Val-Asp-aldehyde-7-amino-4-
methylcoumarin 
Apaf-1 = Apoptotic protease activating factor-1
APS = Ammonium persulfate
ATCC = American Type Culture Collection
BIR = Baculoviral IAP Repeat
BSA = Bovine Serum Albumin
CARD = Caspase Recruitment Domain
cdk = Cyclin-Dependent Kinase
DD = Death Domain
DED = Death Effector Domain
DEPC = Diethylpirocarbonate
DISC = Death-Inducing Signalling Complex
DMSO = Dimethyl Sulfoxide
DOTAP = N-(1-(2,3 dioleoyloxy) propyl)-N,N,N-trimethylammoniummethyl
sulphate
EDTA = Ethylenediaminetetraacetic Acid
FADD = Fas-Associated protein with Death Domain
Fas = Fibroblast-Associated protein
FBS = Fetal Bovine Serum
Flip = FADD-like interleukin-1-converting enzyme-inhibitory protein
Hsp90 = Heat Shock Protein 90
IAP = Inhibitor of Apoptosis Proteins
LB = Loading Buffer
LB medium = Luria-Bertani medium
LEHD-AFC = leu-glu-his-asp-7-amino-4-trifluoromethylcoumarin 
PBS = Phosphate-Buffered Saline
RIP = Receptor-Interacting Protein
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SDS = Sodium Dodecyl Sulfate
TAE = TRIS-Acetate-EDTA
TBE = Tris-Borate-EDTA
TGS buffer = Tris-Glycine-SDS buffer
TNF = Tumour Necrosis Factor
TNF-R = Tumour Necrosis Factor Receptor
TRADD = TNF Receptor-Associated protein with Death Domain
TRAIL-R = TNF-Related Apoptosis-lnducing Ligand Receptor
TRAP = Telomere Repeat Amplification Protocol
TUNEL = Terminal dUTP Nick-End Labeling
